AU2020355837A1 - AZA-quinoline compounds and uses thereof - Google Patents
AZA-quinoline compounds and uses thereof Download PDFInfo
- Publication number
- AU2020355837A1 AU2020355837A1 AU2020355837A AU2020355837A AU2020355837A1 AU 2020355837 A1 AU2020355837 A1 AU 2020355837A1 AU 2020355837 A AU2020355837 A AU 2020355837A AU 2020355837 A AU2020355837 A AU 2020355837A AU 2020355837 A1 AU2020355837 A1 AU 2020355837A1
- Authority
- AU
- Australia
- Prior art keywords
- amino
- methyl
- cyclohexyl
- trans
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 266
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 claims abstract description 73
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 claims abstract description 73
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 230000001404 mediated effect Effects 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 13
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 claims abstract 10
- -1 (8-chloro-1, 7-naphthyridin-2-yl) amino Chemical group 0.000 claims description 415
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 400
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 362
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 298
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 244
- 239000000203 mixture Substances 0.000 claims description 169
- 150000003839 salts Chemical class 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 62
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 claims description 27
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 25
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- DNACGYGXUFTEHO-UHFFFAOYSA-N pyrimidine-2,5-diamine Chemical compound NC1=CN=C(N)N=C1 DNACGYGXUFTEHO-UHFFFAOYSA-N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 12
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 12
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 claims description 11
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- JQTMGOLZSBTZMS-UHFFFAOYSA-N 4-methylpiperazine-1-carbaldehyde Chemical compound CN1CCN(C=O)CC1 JQTMGOLZSBTZMS-UHFFFAOYSA-N 0.000 claims description 8
- UDFMEDPKVIXHCH-UHFFFAOYSA-N CC1(NC=CC=2C=CC(=NC1=2)N)N Chemical compound CC1(NC=CC=2C=CC(=NC1=2)N)N UDFMEDPKVIXHCH-UHFFFAOYSA-N 0.000 claims description 8
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- KKCWBKUOPJMUQV-UHFFFAOYSA-N azetidine-2-carboxamide Chemical compound NC(=O)C1CCN1 KKCWBKUOPJMUQV-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 229940121354 immunomodulator Drugs 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 201000003444 follicular lymphoma Diseases 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 5
- 239000000043 antiallergic agent Substances 0.000 claims description 5
- 230000001120 cytoprotective effect Effects 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- NJYYWQHQUOODDL-UHFFFAOYSA-N oxetane-3-carboxamide Chemical compound NC(=O)C1COC1 NJYYWQHQUOODDL-UHFFFAOYSA-N 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010033963 Parathyroid tumour Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000001062 anti-nausea Effects 0.000 claims description 3
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 210000000013 bile duct Anatomy 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 201000001531 bladder carcinoma Diseases 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 125000003566 oxetanyl group Chemical group 0.000 claims description 3
- 229940124641 pain reliever Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 206010042863 synovial sarcoma Diseases 0.000 claims description 3
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 3
- 208000025421 tumor of uterus Diseases 0.000 claims description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 133
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 108
- 238000005160 1H NMR spectroscopy Methods 0.000 description 89
- 239000000243 solution Substances 0.000 description 86
- 235000019439 ethyl acetate Nutrition 0.000 description 65
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000000460 chlorine Substances 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
- 239000012043 crude product Substances 0.000 description 43
- 239000011541 reaction mixture Substances 0.000 description 41
- 238000002953 preparative HPLC Methods 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 238000004440 column chromatography Methods 0.000 description 26
- 239000003208 petroleum Substances 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000011734 sodium Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 229910052805 deuterium Inorganic materials 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 101000866766 Homo sapiens Polycomb protein EED Proteins 0.000 description 9
- 102100031338 Polycomb protein EED Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 229940127084 other anti-cancer agent Drugs 0.000 description 9
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 8
- 229960001570 ademetionine Drugs 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- OKBQYKAHDSGBEE-UHFFFAOYSA-N 3-(oxetan-3-ylamino)propanenitrile Chemical compound N#CCCNC1COC1 OKBQYKAHDSGBEE-UHFFFAOYSA-N 0.000 description 7
- 102100037164 Histone-lysine N-methyltransferase EZH1 Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 108010033040 Histones Proteins 0.000 description 6
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 description 6
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
- 229960005141 piperazine Drugs 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000004808 supercritical fluid chromatography Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NCADHSLPNSTDMJ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(C(O)=O)C1 NCADHSLPNSTDMJ-UHFFFAOYSA-N 0.000 description 4
- OFCBNMYNAHUDGE-UHFFFAOYSA-N 2-chloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1 OFCBNMYNAHUDGE-UHFFFAOYSA-N 0.000 description 4
- NPNSDEDMKCBDTH-UHFFFAOYSA-N 6-chloro-3-methylpyridine-2-carboxamide Chemical compound ClC1=CC=C(C(=N1)C(N)=O)C NPNSDEDMKCBDTH-UHFFFAOYSA-N 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000006947 Histones Human genes 0.000 description 4
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000002111 antiemetic agent Substances 0.000 description 4
- 229940125683 antiemetic agent Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 description 3
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- SYYBDNPGDKKJDU-ZDUSSCGKSA-N 1-[5-bromo-4-methyl-2-[[(2S)-2-morpholinyl]methoxy]phenyl]-3-(5-methyl-2-pyrazinyl)urea Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC(Br)=C(C)C=C1OC[C@H]1OCCNC1 SYYBDNPGDKKJDU-ZDUSSCGKSA-N 0.000 description 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 3
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 3
- WSZRCNZXKKTLQE-UHFFFAOYSA-N 2-chloro-5-iodopyrimidine Chemical compound ClC1=NC=C(I)C=N1 WSZRCNZXKKTLQE-UHFFFAOYSA-N 0.000 description 3
- QCOKYYIIWNBHRM-UHFFFAOYSA-N 2-chloro-7h-1,7-naphthyridin-8-one Chemical compound C1=CNC(=O)C2=NC(Cl)=CC=C21 QCOKYYIIWNBHRM-UHFFFAOYSA-N 0.000 description 3
- QVNRPWUMXYHGNX-UHFFFAOYSA-N 2-chloro-8-(difluoromethoxy)-1,7-naphthyridine Chemical compound ClC1=NC2=C(N=CC=C2C=C1)OC(F)F QVNRPWUMXYHGNX-UHFFFAOYSA-N 0.000 description 3
- ZGBGPEDJXCYQPH-UHFFFAOYSA-N 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxo-6-quinazolinyl)amino]phenyl]benzamide Chemical compound C1=C(NC=2C=C3C(=O)N(C)C=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(C)(C)C#N)=C1 ZGBGPEDJXCYQPH-UHFFFAOYSA-N 0.000 description 3
- IAYGCINLNONXHY-LBPRGKRZSA-N 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide Chemical compound NC(=O)NC=1C=C(C=2C=C(F)C=CC=2)SC=1C(=O)N[C@H]1CCCNC1 IAYGCINLNONXHY-LBPRGKRZSA-N 0.000 description 3
- PYEFPDQFAZNXLI-UHFFFAOYSA-N 3-(dimethylamino)-N-[3-[[(4-hydroxyphenyl)-oxomethyl]amino]-4-methylphenyl]benzamide Chemical compound CN(C)C1=CC=CC(C(=O)NC=2C=C(NC(=O)C=3C=CC(O)=CC=3)C(C)=CC=2)=C1 PYEFPDQFAZNXLI-UHFFFAOYSA-N 0.000 description 3
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 3
- OTXYVTPSEMLVLS-UHFFFAOYSA-N 3-methyl-1-oxidopyridin-1-ium-2-carbonitrile Chemical compound CC1=CC=C[N+]([O-])=C1C#N OTXYVTPSEMLVLS-UHFFFAOYSA-N 0.000 description 3
- WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 description 3
- MOVBBVMDHIRCTG-LJQANCHMSA-N 4-[(3s)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1h-benzimidazol-2-yl)-6-chloroquinolin-2(1h)-one Chemical compound C([N@](CC1)C2)C[C@@H]1[C@@H]2NC1=C(C=2NC3=CC=CC=C3N=2)C(=O)NC2=CC=C(Cl)C=C21 MOVBBVMDHIRCTG-LJQANCHMSA-N 0.000 description 3
- RZIDZIGAXXNODG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CCC1(N)CC1=CC=C(Cl)C=C1 RZIDZIGAXXNODG-UHFFFAOYSA-N 0.000 description 3
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 3
- BYWWNRBKPCPJMG-UHFFFAOYSA-N 4-dodecyl-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(CCCCCCCCCCCC)=CC=C1S(=O)(=O)NC1=NN=CS1 BYWWNRBKPCPJMG-UHFFFAOYSA-N 0.000 description 3
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 description 3
- GRLXSZKHRDKVTE-UHFFFAOYSA-N 6-chloro-3-methylpyridine-2-carbonitrile Chemical compound CC1=CC=C(Cl)N=C1C#N GRLXSZKHRDKVTE-UHFFFAOYSA-N 0.000 description 3
- YEAHTLOYHVWAKW-UHFFFAOYSA-N 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC2=C1C1=CC=C(C(C)O)C=C1C(=O)O2 YEAHTLOYHVWAKW-UHFFFAOYSA-N 0.000 description 3
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZSLBQQQGKZICAI-UHFFFAOYSA-N ClC1=NC=C(C=N1)C(C(=O)OCC)(F)F Chemical compound ClC1=NC=C(C=N1)C(C(=O)OCC)(F)F ZSLBQQQGKZICAI-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- OTPNDVKVEAIXTI-UHFFFAOYSA-N LSM-1274 Chemical compound C12=C3C4=C5C=CC=C[C]5N3C(O3)CCC3N2C2=CC=C[CH]C2=C1C1=C4C(=O)NC1=O OTPNDVKVEAIXTI-UHFFFAOYSA-N 0.000 description 3
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 3
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 3
- GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 description 3
- BCBKGDPBEBWKNU-UHFFFAOYSA-N N1=C(C2=C(C=C1)C=CC(Cl)=N2)OC Chemical compound N1=C(C2=C(C=C1)C=CC(Cl)=N2)OC BCBKGDPBEBWKNU-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229950010817 alvocidib Drugs 0.000 description 3
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 229940126546 immune checkpoint molecule Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- WPOXAFXHRJYEIC-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CN=2)=C1 WPOXAFXHRJYEIC-UHFFFAOYSA-N 0.000 description 3
- 229950004847 navitoclax Drugs 0.000 description 3
- UMFWNFVHKAJOSE-UHFFFAOYSA-N oxetan-3-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1COC1 UMFWNFVHKAJOSE-UHFFFAOYSA-N 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 3
- NFKXXURQUMEXDJ-UHFFFAOYSA-N pyrimidine-5-carbonyl chloride Chemical compound ClC(=O)C1=CN=CN=C1 NFKXXURQUMEXDJ-UHFFFAOYSA-N 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- 108010091666 romidepsin Proteins 0.000 description 3
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 description 2
- BPNUQXPIQBZCMR-IBGZPJMESA-N (2s)-1-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}-3-phenylpropan-2-amine Chemical compound C([C@H](N)COC=1C=NC=C(C=1)C1=CC=C2NN=C(C2=C1)C)C1=CC=CC=C1 BPNUQXPIQBZCMR-IBGZPJMESA-N 0.000 description 2
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- JWJVSDZKYYXDDN-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC1C(O)=O JWJVSDZKYYXDDN-UHFFFAOYSA-N 0.000 description 2
- 238000004293 19F NMR spectroscopy Methods 0.000 description 2
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 2
- QLUYMIVVAYRECT-OCCSQVGLSA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O QLUYMIVVAYRECT-OCCSQVGLSA-N 0.000 description 2
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 2
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 2
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
- FXQSUQZXESNFNH-UHFFFAOYSA-N 2-chloropyrimidine-5-carbonitrile Chemical group ClC1=NC=C(C#N)C=N1 FXQSUQZXESNFNH-UHFFFAOYSA-N 0.000 description 2
- 150000005716 2-chloropyrimidines Chemical class 0.000 description 2
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- NQVWMPOQWBDSAI-UHFFFAOYSA-N 3-methyloxetan-3-amine Chemical compound CC1(N)COC1 NQVWMPOQWBDSAI-UHFFFAOYSA-N 0.000 description 2
- WBXZCDIZXWDPBL-UHFFFAOYSA-N 3-methylpyridine-2-carbonitrile Chemical compound CC1=CC=CN=C1C#N WBXZCDIZXWDPBL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 2
- LZMOSYUFVYJEPY-UHFFFAOYSA-N AT7867 Chemical compound C1=CC(Cl)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 LZMOSYUFVYJEPY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- BMMXYEBLEBULND-UHFFFAOYSA-N BGT226 free base Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 BMMXYEBLEBULND-UHFFFAOYSA-N 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZFHGGKFFXBIJKB-WUXMJOGZSA-N ClC1=CC=C(C(=N1)C(=O)/N=C/N(C)C)C Chemical compound ClC1=CC=C(C(=N1)C(=O)/N=C/N(C)C)C ZFHGGKFFXBIJKB-WUXMJOGZSA-N 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
- MEKASOQEXYKAKM-UHFFFAOYSA-N N-[[5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine Chemical compound CCNCC1=CN=CC(C=2C=C3C(C=4NC5=CC(F)=CC(F)=C5N=4)=NNC3=CC=2)=C1C MEKASOQEXYKAKM-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- IBXPAFBDJCXCDW-MHFPCNPESA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O IBXPAFBDJCXCDW-MHFPCNPESA-A 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- HHNFORCFJOVQNF-UHFFFAOYSA-N cyl-1 Chemical compound N1C(=O)C(CCCCCC(=O)C2OC2)NC(=O)C2CCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(OC)C=C1 HHNFORCFJOVQNF-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229940052372 daunorubicin citrate liposome Drugs 0.000 description 2
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
- IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- WXUJAQBSBZLVEV-UHFFFAOYSA-N isogranulatimide Chemical compound N1C2=CC=CC=C2C2=C1N1C=NC=C1C1=C2C(=O)NC1=O WXUJAQBSBZLVEV-UHFFFAOYSA-N 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229960000435 oblimersen Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 229950009919 saracatinib Drugs 0.000 description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 description 1
- WFAZBZVIPFZPJD-CCPARQTGSA-N (2R,3R,4S,5R)-2-(5-amino-3-methyl-3,5,7,8,10-pentazatricyclo[7.2.1.01,6]dodeca-7,9(12)-dien-10-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1N(C)CN(N)C2N=NC3=CC21CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WFAZBZVIPFZPJD-CCPARQTGSA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GNYCTMYOHGBSBI-SVZOTFJBSA-N (3s,6r,9s,12r)-6,9-dimethyl-3-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@H](C)C(=O)N1)=O)C)CCCCC(=O)[C@@H]1CO1 GNYCTMYOHGBSBI-SVZOTFJBSA-N 0.000 description 1
- SGYJGGKDGBXCNY-QXUYBEEESA-N (3s,9s,12r)-3-benzyl-6,6-dimethyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@@H]2C(=O)N1)=O)(C)C)CCCCC(=O)[C@@H]1CO1 SGYJGGKDGBXCNY-QXUYBEEESA-N 0.000 description 1
- GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 description 1
- DQGPYIDMOHQZSY-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;n-(4-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC DQGPYIDMOHQZSY-RNWHKREASA-N 0.000 description 1
- JYRJOQGKGMHTOO-VURMDHGXSA-N (4z)-4-(2-amino-4-oxo-1h-imidazol-5-ylidene)-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one Chemical compound N1C(N)=NC(=O)\C1=C/1C(C=CN2)=C2C(=O)NCC\1 JYRJOQGKGMHTOO-VURMDHGXSA-N 0.000 description 1
- WANLLPADDCXPGO-WMKJBNATSA-N (6r,9s,12s)-3-[(2s)-butan-2-yl]-6-[(4-methoxyphenyl)methyl]-9-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound C([C@@H]1C(=O)NC(C(N2CCCC[C@H]2C(=O)N[C@@H](CCCCCC(=O)C2OC2)C(=O)N1)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 WANLLPADDCXPGO-WMKJBNATSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- SUVMJBTUFCVSAD-SNVBAGLBSA-N (R)-sulforaphane Chemical compound C[S@@](=O)CCCCN=C=S SUVMJBTUFCVSAD-SNVBAGLBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical group CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- ZZAKLGGGMWORRT-UHFFFAOYSA-N 1-methylsulfonylpiperazine Chemical compound CS(=O)(=O)N1CCNCC1 ZZAKLGGGMWORRT-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- DVEXZJFMOKTQEZ-UHFFFAOYSA-N 2,3-bis[amino-[(2-aminophenyl)thio]methylidene]butanedinitrile Chemical compound C=1C=CC=C(N)C=1SC(N)=C(C#N)C(C#N)=C(N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-UHFFFAOYSA-N 0.000 description 1
- IWWLVWWEZSOTJH-UHFFFAOYSA-N 2,3-dihydroxy-4-(4-methylbenzoyl)oxy-4-oxobutanoic acid Chemical compound CC1=CC=C(C(=O)OC(=O)C(O)C(O)C(O)=O)C=C1 IWWLVWWEZSOTJH-UHFFFAOYSA-N 0.000 description 1
- OOVTUOCTLAERQD-OJMBIDBESA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride Chemical compound Cl.OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O OOVTUOCTLAERQD-OJMBIDBESA-N 0.000 description 1
- SFRDXVJWXWOTEW-UHFFFAOYSA-N 2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)CO SFRDXVJWXWOTEW-UHFFFAOYSA-N 0.000 description 1
- OQCWLAMXJVEQDQ-UHFFFAOYSA-N 2-(oxetan-3-ylamino)ethanol Chemical group OCCNC1COC1 OQCWLAMXJVEQDQ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- UPTIDSXFMRSSBW-UHFFFAOYSA-N 2-[(2-chloropyrimidin-5-yl)methyl]isoindole-1,3-dione Chemical compound ClC1=NC=C(C=N1)CN1C(C2=CC=CC=C2C1=O)=O UPTIDSXFMRSSBW-UHFFFAOYSA-N 0.000 description 1
- PIMQWRZWLQKKBJ-SFHVURJKSA-N 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol Chemical compound C=1C(N2[C@@H](CCCC2)CCO)=NC2=C(CC)C=NN2C=1NCC1=CC=C[N+]([O-])=C1 PIMQWRZWLQKKBJ-SFHVURJKSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-butanol Substances CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- RUVUQOOKKGVDNN-UHFFFAOYSA-N 3-(ethylamino)propanenitrile Chemical group CCNCCC#N RUVUQOOKKGVDNN-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- REUOCJLVDZPJEK-UHFFFAOYSA-N 3-chlorocinnoline Chemical compound C1=CC=C2N=NC(Cl)=CC2=C1 REUOCJLVDZPJEK-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- ZHXCTIMNNKVMJM-JSPLCZCHSA-N 4-[(2r,3s,4r,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]-8-ethenyl-1-hydroxy-10,12-dimethoxynaphtho[1,2-c]isochromen-6-one Chemical compound C1=CC(O)=C2C(OC)=CC(C3=C(OC)C=C(C=C)C=C3C(=O)O3)=C3C2=C1[C@H]1O[C@H](C)[C@@H](O)[C@@H](N(C)C)[C@@H]1O ZHXCTIMNNKVMJM-JSPLCZCHSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-M 4-phenylbutyrate Chemical compound [O-]C(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-M 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- JGZVUTYDEVUNMK-UHFFFAOYSA-N 5-carboxy-2',7'-dichlorofluorescein Chemical compound C12=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 JGZVUTYDEVUNMK-UHFFFAOYSA-N 0.000 description 1
- BVUBLIHUYSRSFE-LBPRGKRZSA-N 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N1=CN=C2NC=NC2=C1N[C@@H](C)C1=NC2=CC=CC(=C2C(N1C1=CC=CC=C1)=O)F BVUBLIHUYSRSFE-LBPRGKRZSA-N 0.000 description 1
- DEZJGRPRBZSAKI-KMGSDFBDSA-N 565434-85-7 Chemical compound C([C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CO)C(=O)N[C@H](CC=1C(=C(F)C(F)=C(F)C=1F)F)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 DEZJGRPRBZSAKI-KMGSDFBDSA-N 0.000 description 1
- ODSPBBWQVLWOPG-UHFFFAOYSA-N 6-chloro-3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=C(Cl)N=C1C(O)=O ODSPBBWQVLWOPG-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-UWKORSIYSA-N 6-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1C(C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-UWKORSIYSA-N 0.000 description 1
- PRIGRJPRGZCFAS-UHFFFAOYSA-N 6-phenyl[5h]pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(CCCC)=C1C1=CC=C(O)C=C1 PRIGRJPRGZCFAS-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100026024 Acyl-coenzyme A synthetase ACSM3, mitochondrial Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930182536 Antimycin Natural products 0.000 description 1
- 101100452478 Arabidopsis thaliana DHAD gene Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 108010079882 Bax protein (53-86) Proteins 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KAJYHKRSEVHEGX-HCQSHQBASA-N C1[C@@]([N+]([O-])=O)(C)[C@@H](NC(=O)OC)[C@@H](C)O[C@H]1O[C@@H]1C(/C)=C/[C@@H]2[C@@H](O)CC(C=O)=CC2(C2=O)OC(O)=C2C(=O)[C@@]2(C)[C@@H]3[C@@H](C)C[C@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](OC(C)=O)[C@H](O[C@@H]5O[C@@H](C)[C@H](O[C@@H]6O[C@@H](C)[C@H](O[C@@H]7O[C@@H](C)[C@H](O)CC7)[C@H](O)C6)CC5)C4)[C@H]3C=C[C@H]2\C(C)=C/C1 Chemical compound C1[C@@]([N+]([O-])=O)(C)[C@@H](NC(=O)OC)[C@@H](C)O[C@H]1O[C@@H]1C(/C)=C/[C@@H]2[C@@H](O)CC(C=O)=CC2(C2=O)OC(O)=C2C(=O)[C@@]2(C)[C@@H]3[C@@H](C)C[C@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](OC(C)=O)[C@H](O[C@@H]5O[C@@H](C)[C@H](O[C@@H]6O[C@@H](C)[C@H](O[C@@H]7O[C@@H](C)[C@H](O)CC7)[C@H](O)C6)CC5)C4)[C@H]3C=C[C@H]2\C(C)=C/C1 KAJYHKRSEVHEGX-HCQSHQBASA-N 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101100441844 Caenorhabditis elegans cyl-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010089388 Cdc25C phosphatase (211-221) Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- SGYJGGKDGBXCNY-UHFFFAOYSA-N Chlamydocin Natural products N1C(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(C)(C)NC(=O)C1CCCCCC(=O)C1CO1 SGYJGGKDGBXCNY-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010063406 Cyl-2 Proteins 0.000 description 1
- WANLLPADDCXPGO-UHFFFAOYSA-N Cyl-2 Natural products N1C(=O)C(CCCCCC(=O)C2OC2)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(OC)C=C1 WANLLPADDCXPGO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
- JYRJOQGKGMHTOO-UHFFFAOYSA-N Debromohymenialdisine hydrochloride Natural products N1C(N)=NC(=O)C1=C1C(C=CN2)=C2C(=O)NCC1 JYRJOQGKGMHTOO-UHFFFAOYSA-N 0.000 description 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- QYZRTBKYBJRGJB-PCMHIUKPSA-N Granisetron hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-PCMHIUKPSA-N 0.000 description 1
- 108010051041 HC toxin Proteins 0.000 description 1
- 108050001949 Histone-lysine N-methyltransferase EZH1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100382953 Mus musculus Ccnd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- GHLIFBNIGXVDHM-UHFFFAOYSA-N Ravidomycin Natural products COC1=CC(C=C)=CC(C(OC2=C34)=O)=C1C2=CC(OC)=C3C(O)=CC=C4C1OC(C)C(OC(C)=O)C(N(C)C)C1O GHLIFBNIGXVDHM-UHFFFAOYSA-N 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 description 1
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIOHNDKHQHVLKA-UHFFFAOYSA-N acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound CC(O)=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 NIOHNDKHQHVLKA-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940111214 busulfan injection Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 description 1
- 229960003778 casopitant Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 108700023145 chlamydocin Proteins 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- RYJIRNNXCHOUTQ-OJJGEMKLSA-L cortisol sodium phosphate Chemical compound [Na+].[Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 RYJIRNNXCHOUTQ-OJJGEMKLSA-L 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940077926 cytarabine liposome injection Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 229940041983 daunorubicin liposomal Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000006010 dichloroethoxy group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N gamma-phenylbutyric acid Natural products OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- GNYCTMYOHGBSBI-UHFFFAOYSA-N helminthsporium carbonum toxin Natural products N1C(=O)C(C)NC(=O)C(C)NC(=O)C2CCCN2C(=O)C1CCCCCC(=O)C1CO1 GNYCTMYOHGBSBI-UHFFFAOYSA-N 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 229930193320 herbimycin Natural products 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960002293 leucovorin calcium Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000006216 lysine-methylation Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RDSACQWTXKSHJT-UHFFFAOYSA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide Chemical compound C1CC1(CC(O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-UHFFFAOYSA-N 0.000 description 1
- RDSACQWTXKSHJT-LLVKDONJSA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2r)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-LLVKDONJSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- RBOKLZGCVRXGEP-XTQSDGFTSA-N n-[[5-[(3e)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine Chemical compound CCNCC1=CN=CC(C=2C=C3C(=C/4N=C5C(F)=CC(F)=CC5=N\4)/NNC3=CC=2)=C1C RBOKLZGCVRXGEP-XTQSDGFTSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JUIXJPRSYHSLHK-UHFFFAOYSA-N n-methyloxetan-3-amine Chemical group CNC1COC1 JUIXJPRSYHSLHK-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QMLWSAXEQSBAAQ-UHFFFAOYSA-N oxetan-3-ol Chemical compound OC1COC1 QMLWSAXEQSBAAQ-UHFFFAOYSA-N 0.000 description 1
- SWYHWLFHDVMLHO-UHFFFAOYSA-N oxetan-3-ylmethanol Chemical group OCC1COC1 SWYHWLFHDVMLHO-UHFFFAOYSA-N 0.000 description 1
- UWOTZNQZPLAURK-UHFFFAOYSA-N oxetane-3-carboxylic acid Chemical group OC(=O)C1COC1 UWOTZNQZPLAURK-UHFFFAOYSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005374 oxymorphone hydrochloride Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229940098901 polifeprosan 20 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- JCWLEWKPXYZHGQ-UHFFFAOYSA-N propan-2-yl 2-bromoacetate Chemical group CC(C)OC(=O)CBr JCWLEWKPXYZHGQ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- LXHKBFMMWHZQBY-UHFFFAOYSA-N pyrimidine;hydrofluoride Chemical compound F.C1=CN=CN=C1 LXHKBFMMWHZQBY-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- GHLIFBNIGXVDHM-VQXSZRIGSA-N ravidomycin Chemical compound COC1=CC(C=C)=CC(C(OC2=C34)=O)=C1C2=CC(OC)=C3C(O)=CC=C4C1O[C@H](C)[C@H](OC(C)=O)[C@H](N(C)C)[C@H]1O GHLIFBNIGXVDHM-VQXSZRIGSA-N 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- XFLBOEMFLGLWFF-HDXRNPEWSA-N spiruchostatin Chemical compound C1SSCC\C=C\[C@H]2OC(=O)C[C@H](O)[C@@H](C(C)C)NC(=O)[C@@H]1NC(=O)[C@@H](C)NC(=O)C2 XFLBOEMFLGLWFF-HDXRNPEWSA-N 0.000 description 1
- 108010021003 spiruchostatin A Proteins 0.000 description 1
- XFLBOEMFLGLWFF-UHFFFAOYSA-N spiruchostatin A Natural products C1SSCCC=CC2OC(=O)CC(O)C(C(C)C)NC(=O)C1NC(=O)C(C)NC(=O)C2 XFLBOEMFLGLWFF-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229950003999 tafluposide Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- CVAWKJKISIPBOD-UHFFFAOYSA-N tert-butyl 2-bromopropanoate Chemical group CC(Br)C(=O)OC(C)(C)C CVAWKJKISIPBOD-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960002190 topotecan hydrochloride Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 229950000185 tozasertib Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 description 1
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 108010060596 trapoxin B Proteins 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 1
- 229960004664 xaliproden Drugs 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of PCT/CN2019/108296 filed 26 September 2019, which is incorporated by reference herein in its entirety.
The present invention relates to compounds, compositions and methods for inhibiting Enhancer of Zeste Homolog (EZH2) , Polycomb Repressive Complex 2 (PRC2) , or a combination thereof.
The site specific lysine methylation on histones is one of the important epigenetic mechanisms in controlling and mediating many fundamental biological processes. The Polycomb Repressive Complex 2 (PRC2) methylates the histone H3 lysine 27 (H3K27) at the genomic region of target genes, and thereby represses gene transcription. PRC2 requires minimally three core subunits including SUZ12 (suppressor of zeste 12) , EED (embryonic ectoderm development) and the catalytic subunit EZH1 or EZH2 (enhancer of zeste homolog 1/2) . EZH1 and EZH2 are homolog proteins and can both be integrated into PRC2 respectively, although with different tissue-and temporal distribution. In PRC2, EZH2 can directly bind the cofactor S-adenosyl methionine (SAM) and transfer the methyl group to histone H3K27 site to form mono-, di-, and tri-methylated lysine (H3K27me1, H3K27me2 and H3K27me3) , which repress gene transcription. PRC2-EZH2 has higher activity than PRC2-EZH1, which predominantly catalyzes formation of H3K27me1 and some H3K27me2. EED may bind H3K27me2/3 and allosterically activate enzyme activity of PRC2 to promote spreading of the repressive marks.
EZH2 plays a critical function in development and adult tissue homeostasis, and is closely associated with many diseases. EZH2, SUZ12 and EED are overexpressed in many cancers, including but not limited to breast cancer, prostate cancer and hepatocellular carcinoma. EZH2 activating mutations, which lead to increased H3K27me3, have been identified in DLBCL (diffuse large B cell lymphoma) , FL (follicular lymphoma) , melanoma, and parathyroid adenocarcinoma patients. Inhibition of PRC2 methyltransferase activity by compounds competing with the cofactor SAM or binding directly to EED in DLBCL reverses high H3K27me3 state, re-activates expression of target genes and inhibits tumor growth/proliferation. Furthermore, EZH2 inhibitors may release the repression of Th1 chemokines in tumor cells and enhance T cell infiltration in ovarian and colorectal cancers.
Therefore, EZH2 provides a pharmacological target for DLBCL and other cancers. In addition, EZH2 also plays important roles in auto-immune diseases and other disorders. Together, there is a high need for small molecules that inhibit the activity of EZH2.
SUMMARY OF THE INVENTION
The present invention provides compounds that inhibit EZH2; and compositions and methods for treating or preventing a disease or condition mediated by EZH2, PRC2, or a combination thereof.
In one aspect, the present invention provides a compound of Formula (I) , or a stereoisomer, enantiomer, enantiomeric mixture or pharmaceutically acceptable salt thereof:
wherein:
Y is N or CR
4;
R
1, R
3 and R
4 are independently H, halogen or -C
1-C
4 alkyl;
R
2 is -CN, -C
1-C
6 alkyl, -hydroxyC
1-C
4 alkylene, -C
1-C
6 alkyl substituted with -N (C
1-C
4 alkyl)
2; -C
1-C
4 alkoxy, -C
2-C
4 alkoxy substituted with 1-2 hydroxyl or cyano; -NH
2, -NR
11C (=O) R
15, -C (=O) NH
2, - (CH
2)
nR
15, -R
15, -NHC (=O) R
11, -NR
12C (=O) OR
11, -C (=O) NR
11R
12, - (CH
2)
nC (=O) NR
11R
12, - (CH
2)
nNR
11R
15, - (CH
2)
nC (=O) NR
11R
15, -C (=O) NR
11R
15, -CR
13R
14C (=O) NR
11R
15, -OCR
11R
12R
13, - (CH
2)
nC (=O) R
15, -C (=O) R
15, -CR
13R
14C (=O) R
15, - (CH
2)
nNR
11C (=O) R
15, - (CH
2)
nNR
11 (CH
2)
2C (=O) R
15, -NR
12C (=O) (CH
2)
2C (=O) R
15, - (CH
2)
nOR
15, - (CH
2)
nNR
11C (=O) OCH
2R
15, -NR
11C (=O) OCH
2R
15, - (CH
2)
nNR
11 (CH
2)
nR
15,
or a 5-to 6-membered heteroaryl having 1 to 4 ring members independently selected from O, S, N and -NR
c;
R
5a, R
5b, R
5c, R
5d and R
c are independently H or -C
1-C
4 alkyl;
R
6, R
7, R
8 and R
9 are independently H, halogen or -C
1-C
4 alkyl;
R
10 is H, halogen, -C
1-C
4 alkyl, -C
1-C
4 alkoxy, -C
1-C
4 haloalkoxy or -NH (C
1-C
4 alkyl) ;
R
11 is H, -C
1-C
4 alkyl, -SO
2 (C
1-C
4 alkyl) , -hydroxyC
1-C
4 alkylene, -cyanoC
1-C
4 alkylene or -C
1-C
4 alkyl substituted with -C
1-C
4 alkoxy;
R
12 is H or -C
1-C
4 alkyl;
R
13 is H, halogen, -CN, -OH, -C
1-C
4 alkyl or –hydroxyC
1-C
4 alkylene;
R
14 is H, halogen or -C
1-C
4 alkyl;
R
15 is
-C
3-C
6cycloalkyl, or a 4-to 6-membered heterocycoalkyl having 1-2 ring members independently selected from O, S, S (=O)
2, N and -NR
11; wherein said -C
3-C
6cycloalkyl and 4-to 6-membered heterocycloalkyl are independently unsubstituted or substituted with 1-2 substituents selected from -OH, -C
1-C
4 alkyl, -hydroxyC
1-C
4 alkylene, -C
1-C
4 alkoxy and -N (C
1-C
4 alkyl)
2;
R
16, if present, is halogen, -CN, -OH, -C
1-C
4 alkyl or -hydroxyC
1-C
4 alkylene;
m is 0, 1 or 2;
each n is independently selected from 1 and 2; and
provided that the compound of Formula (I) is not (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (4-methylpiperazin-1-yl) methanone.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of Formula (I) or sub-formulae thereof, or a stereoisomer, enantiomer, enantiomeric mixture or pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers.
In yet another aspect, the invention provides a combination, in particular a pharmaceutical combination, comprising a compound of Formula (I) or sub-formulae thereof, or a stereoisomer, enantiomer, enantiomeric mixture or pharmaceutically acceptable salt thereof; and one or more therapeutically active agent (s) .
The compounds of the invention, alone or in combination with one or more therapeutically active agent (s) , can be used for treating or preventing a disease or condition mediated by EZH2, PRC2 or a combination thereof.
The present invention provides compositions and methods for treating or preventing a disease or condition mediated by EZH2, PRC2 or a combination thereof.
Definitions
For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.
As used herein, the term “-C
1-C
6 alkyl” or “-C
1-6 alkyl” refer to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to six carbon atoms, and which is attached to the rest of the molecule by a single bond. The term “-C
1-C
4 alkyl” or “-C
1-4 alkyl” are to be construed accordingly. Examples of -C
1-C
6 alkyl include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl) , n-butyl, n-pentyl and 1, 1-dimethylethyl (t-butyl) .
As used herein, the term "-C
1-C
4 alkoxy" refers to a radical of the formula -OR
a where R
a is a C
1-4alkyl radical as generally defined above. Examples of C
1-6alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, and hexoxy.
The term “cycloalkyl, ” as used herein, refers to a saturated, monocyclic, fused bicyclic, fused tricyclic or bridged polycyclic ring system. Non-limiting examples of fused bicyclic or bridged polycyclic ring systems include bicyclo [1.1.1] pentane, bicyclo [2.1.1] hexane, bicyclo [2.2.1] heptane, bicyclo [3.1.1] heptane, bicyclo [3.2.1] octane, bicyclo [2.2.2] octane and adamantanyl. As used herein, the term "C
3-C
6cycloalkyl” , refers to a saturated monocyclic group having at least 3, and at most 6, carbon atoms. Non-limiting examples of such “C
3-C
6cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
"Halo" or “halogen” refer to bromo, chloro, fluoro or iodo.
As used herein, the term "-hydroxyC
1-4alkylene” refers to a -C
1-4alkyl radical as defined above, wherein one or more hydrogen atoms of the C
1-4alkyl radical is replaced by OH. Examples of hydroxyC
1-4alkyl include, but are not limited to, ethan-1-olyl, 2-methylpropan-1-olyl, hydroxy-methyl, 2-hydroxy-ethyl, 2-hydroxy-propyl and 3-hydroxy-propyl.
As used herein, the term “-cyanoC
1-4 alkylene” refers to a -C
1-4alkyl radical as defined above, wherein one of the hydrogen atoms of the -C
1-4alkyl radical is replaced by CN.
The term "haloalkoxy" , as used herein, refers to a haloalkyl linked to an oxygen, which may also be represented as –O-R’, wherein the R’ represents the haloalkyl group. The term "-C
1-C
4 haloalkoxy" is intended to include C
1, C
2, C
3 and C
4 haloalkoxy groups. Examples of haloalkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, pentachloroethoxy, 2, 2, 2-trifluoroethoxy, heptafluoropropoxy, heptachloropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, difluoroethoxy, trifluoroethoxy, difluoropropoxy, dichloroethoxy and dichloropropoxy.
As used herein, the term “heterocyclyl” or “heterocyclic” refers to a stable 4-7 membered non-aromatic monocyclic ring radical comprising 1, 2, or 3, heteroatoms individually selected from nitrogen, oxygen and sulfur. The heterocyclyl radical may be bonded via a carbon atom or heteroatom. The term “5-6 membered heterocyclyl” is to be construed accordingly. Examples of heterocyclyl include, but are not limited to, azetidinyl, oxetanyl, pyrrolinyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl, piperazinyl, tetrahydropyranyl or morpholinyl or perhydroazepinyl.
As used herein, the term "heteroaryl" refers to a 5-9 membered aromatic monocyclic or fused ring radical comprising 1, 2, 3 or 4 heteroatoms individually selected from nitrogen, oxygen and sulfur. The heteroaryl radical may be bonded via a carbon atom or heteroatom. The term “5-6 membered heteroaryl” is to be construed accordingly. Examples of 5-6 membered monocyclic heteroaryls include, but are not limited to, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, pyrimidyl or pyridyl. Examples of fused heteroaryls include but are not limited to 9-membered heteroaryls such as benzofuranyl; 2, 3-dihydrobenzofuranyl, 1, 3-dihydroisobenzofuranyl; benzo [d] [1, 3] dioxol-5-yl; imidazo [1, 2-a] pyridinyl; pyrazolo [1, 5-a] pyridineyl; 1H-indazolyl and 1H-benzo [d] -imidazolyl.
“EZH2” refers to Enhancer of Zeste Homolog 2.
“PRC2” refers to Polycomb Repressive Complex 2.
The term "PRC2-mediated disease or condition” refers to a disease or condition that is directly or indirectly regulated by PRC2. This includes, but is not limited to, any disease or condition which is directly or indirectly regulated by EZH2.
The term “disease or condition mediated by Enhancer of Zeste Homolog (EZH2) , Polycomb Repressive Complex 2 (PRC2) , or a combination of Enhancer of Zeste Homolog 2 (EZH2) and Polycomb Repressive Complex 2 (PRC2) ” or the term “disease or condition mediated by EZH2, PRC2 or EZH2/PRC2” refer to a disease or condition that is directly or indirectly regulated by EZH2, PRC2 or EZH2 and PRC2.
As used herein, the term “subject” refers to mammals, primates (e.g., humans, male or female) , dogs, rabbits, guinea pigs, pigs, rats and mice. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
As used herein, the term “inhibit” , "inhibition" or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term “treat” , “treating" or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof) ; or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient.
As used herein, the term “prevent” , “preventing" or “prevention” of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder
As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
As used herein, the term "a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
As used herein, the term “pharmaceutical composition” refers to a compound of the invention, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, in a form suitable for oral or parenteral administration.
As used herein, the term "pharmaceutically acceptable carrier" refers to a substance useful in the preparation or use of a pharmaceutical composition and includes, for example, suitable diluents, solvents, dispersion media, surfactants, antioxidants, preservatives, isotonic agents, buffering agents, emulsifiers, absorption delaying agents, salts, drug stabilizers, binders, excipients, disintegration agents, lubricants, wetting agents, sweetening agents, flavoring agents, dyes, and combinations thereof, as would be known to those skilled in the art (see, for example, Remington The Science and Practice of Pharmacy, 22
nd Ed. Pharmaceutical Press, 2013, pp. 1049-1070) .
As used herein, the term "a, ” "an, ” "the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
Unless specified otherwise, the term “compounds of the present invention” or “compound of the present invention” refers to compounds of Formula (I) and subformulae thereof, including Formula (II) and subformulae thereof, and exemplified compounds and salts thereof; as well as stereoisomers (including diastereoisomers and enantiomers) , rotamers, tautomers, isotopically labeled compounds (including deuterium substitutions) , and inherently formed moieties. The “compounds of the present invention” further includes N-oxide derivatives of such compounds.
Description of Preferred Embodiments
The present invention provides compounds that inhibit EZH2; and compositions and methods for treating or preventing a condition mediated by EZH2, PRC2 or a combination thereof.
Various enumerated embodiments of the invention are described herein. Features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
Embodiment 1. A compound of Formula (I) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; as described above.
Embodiment 2. A compound of Formula (I) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
R
2 is -CN, -NH
2, -NR
11C (=O) R
15, -C (=O) NH
2, - (CH
2)
nR
15, -R
15, -NHC (=O) R
11, -NR
12C (=O) OR
11, -C (=O) NR
11R
12, - (CH
2)
nC (=O) NR
11R
12, - (CH
2)
nNR
11R
15, - (CH
2)
nC (=O) NR
11R
15, -C (=O) NR
11R
15, -CR
13R
14C (=O) NR
11R
15, -OCR
11R
12R
13, - (CH
2)
nC (=O) R
15, -C (=O) R
15, -CR
13R
14C (=O) R
15, - (CH
2)
nNR
11C (=O) R
15, - (CH
2)
nNR
11 (CH
2)
2C (=O) R
15, -NR
12C (=O) (CH
2)
2C (=O) R
15, - (CH
2)
nOR
15, - (CH
2)
nNR
11C (=O) OCH
2R
15, -NR
11C (=O) OCH
2R
15, - (CH
2)
nNR
11 (CH
2)
nR
15,
-C
1-C
6 alkyl substituted with one R
a, -C
1-C
4 alkoxy substituted with one R
b, or a 5-to 6-membered heteroaryl having 1 to 4 ring members independently selected from O, S, N and NR
c wherein R
c is H or -C
1-C
4 alkyl;
R
11 is H, -C
1-C
4 alkyl, -SO
2 (C
1-C
4 alkyl) or -C
1-C
4 alkyl substituted with one R
b;
each R
13 is independently selected from H, halogen, CN, -OH, and -C
1-C
4 alkyl substituted with 0-1 –OH groups;
R
15 is
C
3-C
6cycloalkyl substituted with 0-1 R
a groups, or a 4-to 6-membered heterocycoalkyl having 1-2 ring members independently selected from O, S, S (=O)
2, N and NR
11, wherein the heterocycloalkyl of R
15 is substituted with 0-1 R
a groups;
R
a is -OH, -CH
2OH, C
1-C
4 alkyl, C
1-C
4 alkoxy, or -N (C
1-C
4 alkyl)
2;
R
b is independently selected from -CN, -OH and C
1-C
4 alkoxy;
m is 0, 1 or 2; and
each n is independently selected from 1 and 2.
Embodiment 3. A compound according to Embodiment 1 or Embodiment 2, wherein said compound is of Formula (I-2) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof:
Embodiment 4. A compound according to Embodiment 1 or Embodiment 2, wherein said compound is of Formula (I-3) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof:
Embodiment 5. A compound according to Embodiment 1 or Embodiment 2, wherein said compound is of Formula (I-4) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof:
Embodiment 6. A compound according to Embodiment 1 or Embodiment 2, wherein said compound is of Formula (I-5) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof:
Embodiment 7. A compound according to Embodiment 1 or Embodiment 2, wherein said compound is of Formula (I-6) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof:
Embodiment 8. A compound according to Embodiment 1 or Embodiment 2, wherein said compound is of Formula (I-7) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof:
Embodiment 9. A compound according to any one of Embodiments 1-8, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is -CN, -NH
2, -C (=O) NH
2, -NHC (=O) R
11, -NR
12C (=O) OR
11, -C (=O) NR
11R
12, - (CH
2)
nC (=O) NR
11R
12, - (CH
2)
nNR
11R
15, - (CH
2)
nC (=O) NR
11R
15, -C (=O) NR
11R
15, -CR
13R
14C (=O) NR
11R
15, -OCR
11R
12R
13, - (CH
2)
nR
15, -NR
12C (=O) (CH
2)
2C (=O) R
15, - (CH
2)
nNR
11C (=O) OCH
2R
15, -NR
11C (=O) OCH
2R
15, - (CH
2)
nNR
11 (CH
2)
nR
15, - (CH
2)
nC (=O) R
15, -C (=O) R
15, -CR
13R
14C (=O) R
15, - (CH
2)
nNR
11C (=O) R
15, -NR
11C (=O) R
15, - (CH
2)
nNR
11 (CH
2)
2C (=O) R
15, - (CH
2)
nOR
15,
-C
1-C
6 alkyl substituted with one R
a, -C
1-C
4 alkoxy substituted with one R
b, or a 5-to 6-membered heteroaryl having 1 to 4 ring members independently selected from N and -NR
c; and
R
a, R
b and R
c are as defined in Embodiment 2.
Embodiment 10. A compound according to any one of Embodiments 1-8, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is -CN, -NH
2, -C (=O) NH
2, -NHC (=O) R
11, -NR
12C (=O) OR
11, -C (=O) NR
11R
12, - (CH
2)
nC (=O) NR
11R
12, - (CH
2)
nNR
11R
15, - (CH
2)
nC (=O) NR
11R
15, -C (=O) NR
11R
15, -CR
13R
14C (=O) NR
11R
15, -OCR
11R
12R
13, - (CH
2)
nR
15, -NR
12C (=O) (CH
2)
2C (=O) R
15, - (CH
2)
nNR
11C (=O) OCH
2R
15, -NR
11C (=O) OCH
2R
15, - (CH
2)
nNR
11 (CH
2)
nR
15, - (CH
2)
nC (=O) R
15, -CR
13R
14C (=O) R
15, - (CH
2)
nNR
11C (=O) R
15, -NR
11C (=O) R
15, - (CH
2)
nNR
11 (CH
2)
2C (=O) R
15, - (CH
2)
nOR
15,
-C
1-C
6 alkyl substituted with one R
a, -C
1-C
4 alkoxy substituted with one R
b, or a 5-to 6-membered heteroaryl having 1 to 4 heteroatoms independently selected from N and -NR
c; and
R
a, R
b and R
c are as defined in Embodiment 2.
Embodiment 11. A compound according to any one of Embodiments 1-8, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is -CN, -NH
2, -C (=O) NH
2, -NHC (=O) R
11, -NR
12C (=O) OR
11, -C (=O) NR
11R
12, -CH
2C (=O) NR
11R
12, triazolyl,
-C
1-C
6 alkyl substituted with one R
a group, or a -C
1-C
4 alkoxy substituted with one R
b group; and
R
a and R
b are as defined in Embodiment 2.
Embodiment 12. A compound according to any one of Embodiments 1-8, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is -CH
2C (=O) NR
11R
12,
or a C
1-C
6 alkyl substituted with one R
a; and
R
a is as defined in Embodiment 2.
Embodiment 13. A compound according to any one of Embodiments 1-2 and 9-12, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
12 is H or -CH
3.
Embodiment 14. A compound according to any one of Embodiments 1-13, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is
R
a is as defined in Embodiment 2.
Embodiment 15. A compound according to any one of Embodiments 2-14, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
a is -OH or -OCH
3.
Embodiment 16. A compound according to any one of Embodiments 1-8, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is - (CH
2)
1-2C (=O) NR
11R
15 or – (CR
13R
14) -C (=O) NR
11R
15.
Embodiment 17. A compound according to Embodiment 16, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
15 is a 4-to 6-membered heterocycoalkyl having 1-2 heteroatoms independently selected from O, S and N; wherein said 4-to 6-membered heterocycloalkyl is unsubstituted or substituted with one substituent selected from -OH, -CH
2OH, -C
1-C
4 alkyl, -C
1-C
4 alkoxy and -N (C
1-C
4 alkyl)
2.
Embodiment 18. A compound according to Embodiment 16, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
15 is
R
16, if present, is halogen, -CN, -OH, -C
1-C
4 alkyl or -hydroxyC
1-C
4 alkylene; and
m is 0, 1 or 2.
Embodiment 19. A compound according to Embodiment 16, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
15 is
Embodiment 20. A compound according to any one of Embodiments 1-19, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is -CN, -NH
2, -C (=O) NH
2, triazolyl,
Embodiment 21. A compound according to any one of Embodiments 1-19, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
2 is
Embodiment 22. A compound according to Embodiment 1, wherein said compound is of Formula (II) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
wherein:
Y is CH or N;
R
1, R
3, R
5a, R
5b, R
5c and R
5d are independently H or -C
1-C
4 alkyl;
R
6, R
7, R
8 and R
9 are independently is H, halogen or -C
1-C
4 alkyl;
R
10 is halogen or –C
1-C
4 alkoxy;
R
11 is H, C
1-C
4 alkyl, -hydroxyC
1-C
4 alkylene or -cyanoC
1-C
4 alkylene;
R
13 is H, halogen, -OH, -C
1-C
4 alkyl or –hydroxyC
1-C
4 alkylene;
R
14 is H, halogen or -C
1-C
4 alkyl;
R
15 is a 4-to 6-membered heterocycloalkyl having 1-2 heteroatoms independently selected from O, S and N; and wherein said 4-to 6-membered heterocycloalkyl is unsubstituted or substituted with 1-2 substituents selected from -OH, -C
1-C
4 alkyl, -hydroxyC
1-C
4 alkylene, -C
1-C
4 alkoxy and -N (C
1-C
4 alkyl)
2.
Embodiment 23. A compound according to Embodiment 22, wherein said compound is of Formula (II-1) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
Embodiment 24. A compound according to Embodiment 22, wherein said compound is of Formula (II-2) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
Embodiment 25. A compound according to Embodiment 22, wherein said compound is of Formula (II-3) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
Embodiment 26. A compound according to any one of Embodiments 1-2, 9-19 and 22-25, or a stereoisomer, enantiomer, enantiomeric mixture of a pharmaceutically acceptable salt thereof; wherein R
11 is H, -C
1-C
4 alkyl or -C
1-C
4 alkyl substituted with one R
b; and R
b is -CN, -OH or -OCH
3.
Embodiment 27. A compound according to any one of Embodiments 1-2, 9-19 and 22-26, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
13 is H, F, -CN, -OH, -CH
3 or -CH
2OH.
Embodiment 28. A compound according to any one of Embodiments 1-2, 9-19 and 22-27, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
14 is H, F or -CH
3.
Embodiment 29. A compound according to any one of Embodiments 1-2, 9-19 and 22-28, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
15 is azetidinyl or oxetanyl, each of which is unsubstituted or substituted with -OH, -C
1-C
4 alkyl or -hydroxyC
1-C
4 alkylene.
Embodiment 30. A compound according to Embodiment 29, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R
15 is
R
16, if present, is -C
1-C
4 alkyl; and m is 0-1. In a particular embodiment, R
15 is
Embodiment 31. A compound according to Embodiment 1, wherein said compound is selected from Examples C1 to C22 and Examples C24 to C77; or a pharmaceutically acceptable salt thereof
Embodiment 32. A compound according to Embodiment 1, wherein said compound is selected from:
N
2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine;
N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) azetidine-3-carboxamide;
N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1-methylazetidine-3-carboxamide;
2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile;
2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide;
N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide;
2-hydroxy-N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide;
(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone;
N- (2-hydroxypropyl) -2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide;
(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone;
(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (4-methylpiperazin-1-yl) methanone;
N- ( (1, 4-trans) -4- ( ( (5- (1H-1, 2, 4-triazol-5-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide;
N
2- ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine;
methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;
2-methoxyethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;
2-hydroxyethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;
oxetan-3-ylmethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;
N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxyacetamide;
N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -4-morpholino-4-oxobutanamide;
2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile;
(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone;
(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone;
2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) -N- (oxetan-3-yl) pyrimidine-5-carboxamide;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-ylamino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( ( (3-methyloxetan-3-yl) amino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
1- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidin-3-ol;
4- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) thiomorpholine 1, 1-dioxide;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( ( (oxetan-3-ylmethyl) amino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( ( (3-methoxycyclobutyl) amino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
3- ( ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) amino) cyclobutan-1-ol;
(2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1, 3-dioxan-5-yl) methanol;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-yloxy) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) acetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) ethan-1-one;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3- (dimethylamino) pyrrolidin-1-yl) ethan-1-one;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (4- (2-hydroxyethyl) piperazin-1-yl) ethan-1-one;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (piperazin-1-yl) ethan-1-one;
2- (6- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyridin-3-yl) -N- (oxetan-3-yl) acetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (4-methylpiperazin-1-yl) ethan-1-one;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-cyclobutylacetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (4- (2-methoxyethyl) piperazin-1-yl) ethan-1-one;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethan-1-ol;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- ( (3-methyloxetan-3-yl) amino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- (oxetan-3-ylamino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N- (oxetan-3-yl) acetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N-ethylacetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-hydroxyethyl) -N- (oxetan-3-yl) acetamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide;
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide;
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide;
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide;
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide;
N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidine-2-carboxamide;
N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) oxetane-3-carboxamide;
2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile;
2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide;
N
2- ( (1, 4-trans) -4- ( ( (5-aminopyrimidin-2-yl) amino) methyl) cyclohexyl) -N
8-methyl-1, 7-naphthyridine-2, 8-diamine;
N- (2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide;
3- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one;
methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate;
N
2- ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine;
N- ( (1, 4-trans) -4- ( ( (5- (4H-1, 2, 4-triazol-3-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine;
2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propan-1-ol;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one;
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one;
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one;
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide;
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide;
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide;
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide;
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide, and
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoro-N- (oxetan-3-yl) acetamide;
or a pharmaceutically acceptable salt thereof.
Embodiment 33. A compound according to Embodiment 1, wherein said compound is selected from Examples C1-C7, C9, C12-C21 and Examples C25-C77; or a pharmaceutically acceptable salt thereof.
Embodiment 34. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is selected from Examples C13, C36-C37, C42, C49, C51-57 and C72-C77; or a pharmaceutically acceptable salt thereof.
Embodiment 35. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is 2- (2- ( ( (4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide; or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof.
Embodiment 36. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide; or a pharmaceutically acceptable salt thereof. The compound is also known as 2- (2- ( ( ( (1r, 4r) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (Example C36) .
Embodiment 37. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is 2- (2- ( ( (4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide; or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof.
Embodiment 38. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide; or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof. The compound is also known as 2- (2- ( ( ( (1r, 4r) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (Example C52) .
Embodiment 39. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is (S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide; or a pharmaceutically acceptable salt thereof. The compound is also known as (S) -2- (2- ( ( ( (1r, 4S) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (Example C53) .
Embodiment 40. A compound according to Embodiment 1 or Embodiment 22, wherein said compound is (R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide; or a pharmaceutically acceptable salt thereof. The compound is also known as (R) -2- (2- ( ( ( (1r, 4R) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (Example C54) .
Embodiment 41. A pharmaceutical composition comprising a compound according to any one of Embodiments 1-40 and one or more pharmaceutically acceptable carrier.
Embodiment 42. A combination comprising a compound according to any one of Embodiments 1-40 and one or more additional therapeutically active agent.
Embodiment 43. The combination according to Embodiment 42, wherein said one or more additional therapeutically active agent is an anti-cancer agent, an analgesic, an anti-inflammatory agent, immunomodulator, or a combination thereof.
Embodiment 44. A compound according to any one of Embodiments 1-40 and optionally in combination with a second therapeutic agent, for use in treating a disease or condition mediated by EZH2, PRC2 or EZH2/PRC2.
Embodiment 45. The compound according to Embodiment 44, wherein said second therapeutic agent is an anti-cancer agent, an analgesic, an anti-inflammatory agent or a combination thereof.
Embodiment 46. Use of a compound according to any one of Embodiments 1-40 and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for a disease or condition mediated by EZH2, PRC2 or EZH2/PRC2.
Embodiment 47. A method for treating a disease or condition mediated by EZH2, PRC2 or EZH2/PRC2, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound according to any one of Embodiments 1-40 and optionally in combination with a second therapeutic agent; thereby treating said disease or condition mediated by EZH2, PRC2 or EZH2/PRC2.
Embodiment 48. A method for treating a disease or condition that benefit from or is treatable by inhibition of EZH2, PRC2 or EZH2/PRC2, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound according to any one of Embodiments 1-40 and optionally in combination with a second therapeutic agent; thereby treating said disease or condition that benefit from or is treatable by inhibition by EZH2, PRC2, or EZH2/PRC2.
Embodiment 49. The use of a compound according to Embodiment 46, or the method according to Embodiment 47 or 48, wherein said disease or condition mediated by EZH2, PRC2 or EZH2/PRC2, or said disease or condition that benefit from or is treatable by inhibition of EZH2, PRC2 or EZH2/PRC2, is diffuse large B cell lymphoma (DLBCL) , follicular lymphoma, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, neuroblastoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, rhabdomyosarcoma, Kaposi sarcoma, synovial sarcoma, osteosarcoma and Ewing’s sarcoma.
Embodiment 50. The use of a compound according to Embodiment 46, or the method according to Embodiment 47 or 48, wherein said disease or condition mediated by EZH2, PRC2 or EZH2/PRC2, or said disease or condition that benefit from or is treatable by inhibition of EZH2, PRC2 or EZH2/PRC2, is diffuse large B cell lymphoma (DLBCL) , follicular lymphoma, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, and hepatocellular carcinoma.
Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible stereoisomers or as mixtures thereof, for example as pure optical isomers, or as stereoisomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. The present invention is meant to include all such possible stereoisomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms. Optically active (R) -and (S) -stereoisomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z) -or trans- (E) -form. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis-or trans-configuration.
Any asymmetric atom (e.g., carbon or the like) of the compound (s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R) -, (S) -or (R, S) - configuration. In certain embodiments, each asymmetric atom has at least 50 %enantiomeric excess, at least 60 %enantiomeric excess, at least 70 %enantiomeric excess, at least 80 %enantiomeric excess, at least 90 %enantiomeric excess, at least 95 %enantiomeric excess, or at least 99 %enantiomeric excess in the (R) -or (S) -configuration.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible stereoisomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) stereoisomers, diastereomers, optical isomers (antipodes) , racemates or mixtures thereof.
Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
Any resulting racemates of compounds of the present invention or of intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O, O'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic compounds of the present invention or racemic intermediates can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. lsotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Isotopes that can be incorporated into compounds of the invention include, for example, isotopes of hydrogen.
Further, incorporation of certain isotopes, particularly deuterium (i.e.,
2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index or tolerability. It is understood that deuterium in this context is regarded as a substituent of a compound of Formula (I) or sub-formulae thereof. The concentration of deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted as being deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5%deuterium incorporation at each designated deuterium atom) , at least 4000 (60%deuterium incorporation) , at least 4500 (67.5%deuterium incorporation) , at least 5000 (75% deuterium incorporation) , at least 5500 (82.5%deuterium incorporation) , at least 6000 (90%deuterium incorporation) , at least 6333.3 (95%deuterium incorporation) , at least 6466.7 (97%deuterium incorporation) , at least 6600 (99%deuterium incorporation) , or at least 6633.3 (99.5%deuterium incorporation) . It should be understood that the term “isotopic enrichment factor” can be applied to any isotope in the same manner as described for deuterium.
Other examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as
3H,
11C,
13C,
14C,
15N,
18F
31P,
32P,
35S,
36Cl,
123I,
124I,
125I respectively. Accordingly it should be understood that the invention includes compounds that incorporate one or more of any of the aforementioned isotopes, including for example, radioactive isotopes, such as
3H and
14C, or those into which non-radioactive isotopes, such as
2H and
13C are present. Such isotopically labelled compounds are useful in metabolic studies (with
14C) , reaction kinetic studies (with, for example
2H or
3H) , detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an
18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of Formula (I) or sub-formulae thereof can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
The compounds of the present invention are either obtained in the free form, as a salt thereof. As used herein, the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the invention. “Salts” include in particular “pharmaceutical acceptable salts” . The term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
In another aspect, the present invention provides compounds of the present invention in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlorotheophyllinate, citrate, ethanedisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate trifenatate, trifluoroacetate or xinafoate salt form.
Pharmacology and Utility
EZH2 is the catalytic subunit in PRC2; the other homolog, EZH1, is redundant with EZH2 in mouse and required for adult progenitor maintenance at EZH2-loss condition. Cofactor SAM-competitive or EED binding PRC2 inhibitors have been identified and represent variable selectivity on EZH2 compared with EZH1. Considering the role of EZH1 in adult tissue homeostasis, targeting EZH2 of PRC2 selectively may offer a novel and unique angle to be advantageous to, or complementary to, directly targeting the SAM competitive or EED mechanisms of PRC2. Therefore, targeting EZH2 selectively represents a highly attractive strategy for the development of a novel therapy for the treatment of cancer.
The compounds of the invention were assessed for their ability to inhibit PRC2 activity in a pentameric complex of EZH2/EZH1, SUZ12, EED, Rbap48 and AEBP in biochemical assays. The ability of compounds of the invention to inhibit cellular activity of PRC2 was assessed by analysing H3K27me3 in human cell lines. The ability of compounds of the invention to inhibit cancers was derived from their ability to modulate proliferation of human cancer cell lines bearing specific dependence to PRC2 activity to maintain cancerous growth. The compounds of the invention selectively target EZH2, with MOI distinct from the SAM-competitive inhibitors and the EED K27me3-pocket binders.
In one aspect, the invention provides compounds of Formula (I) or subformulae thereof, or a pharmaceutically acceptable salt thereof, that are useful for therapy; particularly, for treating or preventing a disease or condition that is mediated by EZH2, PRC2 or a combination thereof, such as cancers that depend on PRC2 activity to maintain cancerous growth.
In another aspect, the invention provides the use of a compound of Formula (I) or subformulae thereof, or a pharmaceutically acceptable salt thereof, for treating a disease or condition that benefit from or is treatable by inhibition of EZH2, PRC2 or a combination thereof; and for the manufacture of a medicament for treating a disease or condition that is treatable by inhibition of EZH2, PRC2 or a combination thereof.
Examples of diseases or conditions that are mediated by EZH2, PRC2 or EZH2/PRC2, or that benefit from or are treatable by inhibition of EZH2, PRC2 or EZH2/PRC2, include but is not limited to diffuse large B cell lymphoma (DLBCL) , follicular lymphoma, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, neuroblastoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, rhabdomyosarcoma, Kaposi sarcoma, synovial sarcoma, osteosarcoma and Ewing’s sarcoma.
Pharmaceutical Compositions, Dosage and Administration
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration (e.g. by injection, infusion, transdermal or topical administration) , and rectal administration. Topical administration may also pertain to inhalation or intranasal application. The pharmaceutical compositions of the present invention can be made up in a solid form (including, without limitation, capsules, tablets, pills, granules, powders or suppositories) , or in a liquid form (including, without limitation, solutions, suspensions or emulsions) . Tablets may be either film coated or enteric coated according to methods known in the art. Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:
a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also
c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired
d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and
e) absorbents, colorants, flavors and sweeteners.
In another aspect, the compounds of the present invention are combined with other therapeutic agents, such as other anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics) , pain relievers, cytoprotective agents, immunomodulator and combinations thereof.
In one embodiment, the other therapeutic agent is an anti-cancer agent or chemotherapeutic agent. General chemotherapeutic agents considered for use in combination therapies include anastrozole
bicalutamide
bleomycin sulfate
busulfan
busulfan injection
capecitabine
N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin
carmustine
chlorambucil
cisplatin
cladribine
cyclophosphamide (
or
) , cytarabine, cytosine arabinoside
cytarabine liposome injection
dacarbazine
dactinomycin (Actinomycin D, Cosmegan) , daunorubicin hydrochloride
daunorubicin citrate liposome injection
dexamethasone, docetaxel
doxorubicin hydrochloride
etoposide
fludarabine phosphate
5-fluorouracil
flutamide
tezacitibine, Gemcitabine (difluorodeoxycitidine) , hydroxyurea
Idarubicin
ifosfamide
irinotecan
L-asparaginase
leucovorin calcium, melphalan
6-mercaptopurine
methotrexate
mitoxantrone
mylotarg, paclitaxel
nab-paclitaxel
phoenix (Yttrium90/MX-DTPA) , pentostatin, polifeprosan 20 with carmustine implant
tamoxifen citrate
teniposide
6-thioguanine, thiotepa, tirapazamine
topotecan hydrochloride for injection
vinblastine
vincristine
and vinorelbine
Anti-cancer agents of particular interest for combinations with the compounds of the invention include:
Cyclin-Dependent Kinase (CDK) inhibitors: (Chen, S. et al., Nat Cell Biol., 12 (11) : 1108-14 (2010) ; Zeng, X. et al., Cell Cycle, 10 (4) : 579-83 (2011) ) Aloisine A; Alvocidib (also known as flavopiridol or HMR-1275, 2- (2-chlorophenyl) -5, 7-dihydroxy-8- [ (3S, 4R) -3-hydroxy-1-methyl-4-piperidinyl] -4-chromenone, and described in US Patent No. 5,621,002) ; Crizotinib (PF-02341066, CAS 877399-52-5) ; 2- (2-Chlorophenyl) -5, 7-dihydroxy-8- [ (2R, 3S) -2- (hydroxymethyl) -1-methyl-3-pyrrolidinyl] -4H-1-benzopyran-4-one, hydrochloride (P276-00, CAS 920113-03-7) ; 1-Methyl-5- [ [2- [5- (trifluoromethyl) -1H-imidazol-2-yl] -4-pyridinyl] oxy] -N- [4- (trifluoromethyl) phenyl] -1H-benzimidazol-2-amine (RAF265, CAS 927880-90-8) ; Indisulam (E7070) ; Roscovitine (CYC202) ; 6-Acetyl-8-cyclopentyl-5-methyl-2- (5-piperazin-1-yl-pyridin-2-ylamino) -8H-pyrido [2, 3-d] pyrimidin-7-one, hydrochloride (PD0332991) ; Dinaciclib (SCH727965) ; N- [5- [ [ (5-tert-Butyloxazol-2-yl) methyl] thio] thiazol-2-yl] piperidine-4-carboxamide (B 387032, CAS 345627-80-7) ; 4- [ [9-Chloro-7- (2, 6-difluorophenyl) -5H-pyrimido [5, 4-d] [2] benzazepin-2-yl] amino] -benzoic acid (MLN8054, CAS 869363-13-3) ; 5- [3- (4, 6-Difluoro-1H-benzimidazol-2-yl) -1H-indazol-5-yl] -N-ethyl-4-methyl-3-pyridinemethanamine (AG-024322, CAS 837364-57-5) ; 4- (2, 6-Dichlorobenzoylamino) -1H-pyrazole-3-carboxylic acid N- (piperidin-4-yl) amide (AT7519, CAS 844442-38-2) ; 4- [2-Methyl-1- (1-methylethyl) -1H-imidazol-5-yl] -N- [4- (methylsulfonyl) phenyl] -2-pyrimidinamine (AZD5438, CAS 602306-29-6) ; Palbociclib (PD-0332991) ; and (2R, 3R) -3- [ [2- [ [3- [ [S (R) ] -S-cyclopropylsulfonimidoyl] -phenyl] amino] -5- (trifluoromethyl) -4-pyrimidinyl] oxy] -2-butanol (BAY 10000394) .
Checkpoint Kinase (CHK) inhibitors: (Wu, Z. et al., Cell Death Differ., 18 (11) : 1771-9 (2011) ) 7-Hydroxystaurosporine (UCN-01) ; 6-Bromo-3- (1-methyl-1H-pyrazol-4-yl) -5- (3R) -3-piperidinyl-pyrazolo [1, 5-a] pyrimidin-7-amine (SCH900776, CAS 891494-63-6) ; 5- (3-Fluorophenyl) -3-ureidothiophene-2-carboxylic acid N- [ (S) -piperidin-3-yl] amide (AZD7762, CAS 860352-01-8) ; 4- [ ( (3S) -1-Azabicyclo [2.2.2] oct-3-yl) amino] -3- (1H-benzimidazol-2-yl) -6-chloroquinolin-2 (1H) -one (CHIR 124, CAS 405168-58-3) ; 7-Aminodactinomycin (7-AAD) , Isogranulatimide, debromohymenialdisine; N- [5-Bromo-4-methyl-2- [ (2S) -2-morpholinylmethoxy] -phenyl] -N'- (5-methyl-2-pyrazinyl) urea (LY2603618, CAS 911222-45-2) ; Sulforaphane (CAS 4478-93-7, 4-Methylsulfinylbutyl isothiocyanate) ; 9, 10, 11, 12-Tetrahydro-9, 12-epoxy-1H-diindolo [1, 2, 3-fg: 3', 2', 1'-kl] pyrrolo [3, 4-i] [1, 6] benzodiazocine-1, 3 (2H) -dione (SB-218078, CAS 135897-06-2) ; and TAT-S216A (YGRKKRRQRRRLYRSPAMPENL) , and CBP501 ( (d-Bpa) sws (d-Phe-F5) (d-Cha) rrrqrr) ; and (αR) -α-amino-N- [5, 6-dihydro-2- (1-methyl-1H-pyrazol-4-yl) -6-oxo-1H-pyrrolo [4, 3, 2-ef] [2, 3] benzodiazepin-8-yl] -Cyclohexaneacetamide (PF-0477736) .
Protein Kinase B (PKB) or AKT inhibitors: (Rojanasakul, Y., Cell Cycle, 12 (2) : 202-3 (2013) ; Chen B. et al., Cell Cycle, 12 (1) : 112-21 (2013) ) 8- [4- (1-Aminocyclobutyl) phenyl] -9-phenyl-1, 2, 4-triazolo [3, 4-f] [1, 6] naphthyridin-3 (2H) -one (MK-2206, CAS 1032349-93-1) ; Perifosine (KRX0401) ; 4-Dodecyl-N-1, 3, 4-thiadiazol-2-yl-benzenesulfonamide (PHT-427, CAS 1191951-57-1) ; 4- [2- (4-Amino-1, 2, 5-oxadiazol-3-yl) -1-ethyl-7- [ (3S) -3-piperidinylmethoxy] -1H-imidazo [4, 5-c] pyridin-4-yl] -2-methyl-3-butyn-2-ol (GSK690693, CAS 937174-76-0) ; 8- (1-Hydroxyethyl) -2-methoxy-3- [ (4-methoxyphenyl) methoxy] -6H-dibenzo [b, d] pyran-6-one (palomid 529, P529, or SG-00529) ; Tricirbine (6-Amino-4-methyl-8- (β-D-ribofuranosyl) -4H, 8H-pyrrolo [4, 3, 2-de] pyrimido [4, 5-c] pyridazine) ; (αS) -α- [ [ [5- (3-Methyl-1H-indazol-5-yl) -3-pyridinyl] oxy] methyl] -benzeneethanamine (A674563, CAS 552325-73-2) ; 4- [ (4-Chlorophenyl) methyl] -1- (7H-pyrrolo [2, 3-d] pyrimidin-4-yl) -4-piperidinamine (CCT128930, CAS 885499-61-6) ; 4- (4-Chlorophenyl) -4- [4- (1H pyrazol-4-yl) phenyl] -piperidine (AT7867, CAS 857531-00-1) ; and Archexin (RX-0201, CAS 663232-27-7) .
C-RAF Inhibitors: (Chang, C. et al., Cancer Cell, 19 (1) : 86-100 (2011) ) Sorafenib
3- (Dimethylamino) -N- [3- [ (4-hydroxybenzoyl) amino] -4-methylphenyl] -benzamide (ZM336372, CAS 208260-29-1) ; and 3- (1-cyano-1-methylethyl) -N- [3- [ (3, 4-dihydro-3-methyl-4-oxo-6-quinazolinyl) amino] -4-methylphenyl] -benzamide (AZ628, CAS 1007871-84-2) .
Phosphoinositide 3-kinase (PI3K) inhibitors: (Gonzalez, M. et al., Cancer Res., 71 (6) : 2360-2370 (2011) ) 4- [2- (1H-Indazol-4-yl) -6- [ [4- (methylsulfonyl) piperazin-1-yl] methyl] thieno [3, 2-d] pyrimidin-4-yl] morpholine (also known as GDC 0941 and described in PCT Publication Nos. WO 09/036082 and WO 09/055730) ; 2-Methyl-2- [4- [3-methyl-2-oxo-8- (quinolin-3-yl) -2, 3-dihydroimidazo [4, 5-c] quinolin-1-yl] phenyl] propionitrile (described in PCT Publication No. WO 06/122806 and also known as dactolisib) ; 4- (trifluoromethyl) -5- (2, 6-dimorpholinopyrimidin-4-yl) pyridin-2-amine (described in PCT Publication No. WO2007/084786 and also known as buparlisib) ; Tozasertib (VX680 or MK-0457, CAS 639089-54-6) ; (5Z) -5- [ [4- (4-Pyridinyl) -6-quinolinyl] methylene] -2, 4-thiazolidinedione (GSK1059615, CAS 958852-01-2) ; (1E, 4S, 4aR, 5R, 6aS, 9aR) -5- (Acetyloxy) -1- [ (di-2-propenylamino) methylene] -4, 4a, 5, 6, 6a, 8, 9, 9a-octahydro-11-hydroxy-4- (methoxymethyl) -4a, 6a-dimethyl-cyclopenta [5, 6] naphtho [1, 2-c] pyran-2, 7, 10 (1H) -trione (PX866, CAS 502632-66-8) ; 8-Phenyl-2- (morpholin-4-yl) -chromen-4-one (LY294002, CAS 154447-36-6) ; 2-Amino-8-ethyl-4-methyl-6- (1H-pyrazol-5-yl) pyrido [2, 3-d] pyrimidin-7 (8H) -one (SAR 245409 or XL 765) ; 1, 3-Dihydro-8- (6-methoxy-3-pyridinyl) -3-methyl-1- [4- (1-piperazinyl) -3- (trifluoromethyl) phenyl] -2H-imidazo [4, 5-c] quinolin-2-one, , (2Z) -2-butenedioate (1: 1) (BGT 226) ; 5-Fluoro-3-phenyl-2- [ (1S) -1- (9H-purin-6-ylamino) ethyl] -4 (3H) -quinazolinone (CAL101) ; 2-Amino-N- [3- [N- [3- [ (2-chloro-5-methoxyphenyl) amino] quinoxalin-2-yl] sulfamoyl] phenyl] -2-methylpropanamide (SAR 245408 or XL 147) ; and (S) -Pyrrolidine-1, 2-dicarboxylic acid 2-amide 1- ( {4-methyl-5- [2- (2, 2, 2-trifluoro-1, 1-dimethyl-ethyl) -pyridin-4-yl] -thiazol-2-yl} -amide) (BYL719) .
BCL-2 inhibitors: (Béguelin, W. et al., Cancer Cell, 23 (5) : 677-92 (2013) ) 4- [4- [ [2- (4-Chlorophenyl) -5, 5-dimethyl-1-cyclohexen-1-yl] methyl] -1-piperazinyl] -N- [ [4- [ [ (1 R) -3- (4-morpholinyl) -1- [ (phenylthio) methyl] propyl] amino] -3- [ (trifluoromethyl) sulfonyl] phenyl] sulfonyl] benzamide (also known as ABT-263 and described in PCT Publication No. WO 09/155386) ; Tetrocarcin A; Antimycin; Gossypol ( (-) BL-193) ; Obatoclax; Ethyl-2-amino-6-cyclopentyl-4- (1-cyano-2-ethoxy-2-oxoethyl) -4Hchromone-3-carboxylate (HA14 –1) ; Oblimersen (G3139,
) ; Bak BH3 peptide; (-) -Gossypol acetic acid (AT-101) ; 4- [4- [ (4'-Chloro [1, 1'-biphenyl] -2-yl) methyl] -1-piperazinyl] -N- [ [4- [ [ (1R) -3- (dimethylamino) -1- [ (phenylthio) methyl] propyl] amino] -3-nitrophenyl] sulfonyl] -benzamide (ABT-737, CAS 852808-04-9) ; and Navitoclax (ABT-263, CAS 923564-51-6) .
Mitogen-activated protein kinase (MEK) inhibitors: (Chang, C.J. et al., Cancer Cell, 19 (1) : 86-100 (2011) ) XL-518 (also known as GDC-0973, Cas No. 1029872-29-4, available from ACC Corp. ) ; Selumetinib (5- [ (4-bromo-2-chlorophenyl) amino] -4-fluoro-N- (2-hydroxyethoxy) -1-methyl-1H-benzimidazole-6-carboxamide, also known as AZD6244 or ARRY 142886, described in PCT Publication No. WO2003077914) ; Benimetinib (6- (4-bromo-2-fluorophenylamino) -7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy) -amide, also known as MEK162, CAS 1073666-70-2, described in PCT Publication No. WO2003077914) ; 2- [ (2-Chloro-4-iodophenyl) amino] -N- (cyclopropylmethoxy) -3, 4-difluoro-benzamide (also known as CI-1040 or PD184352 and described in PCT Publication No. WO2000035436) ; N- [ (2R) -2, 3-Dihydroxypropoxy] -3, 4-difluoro-2- [ (2-fluoro-4-iodophenyl) amino] -benzamide (also known as PD0325901 and described in PCT Publication No. WO2002006213) ; 2, 3-Bis [amino [ (2-aminophenyl) thio] methylene] -butanedinitrile (also known as U0126 and described in US Patent No. 2,779,780) ; N- [3, 4-Difluoro-2- [ (2-fluoro-4-iodophenyl) amino] -6-methoxyphenyl] -1- [ (2R) -2, 3-dihydroxypropyl] -cyclopropanesulfonamide (also known as RDEA119 or BAY869766 and described in PCT Publication No. WO2007014011) ; (3S, 4R, 5Z, 8S, 9S, 11 E) -14- (Ethylamino) -8, 9, 16-trihydroxy-3, 4-dimethyl-3, 4, 9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1, 7 (8H) -dione] (also known as E6201 and described in PCT Publication No. WO2003076424) ; 2’-Amino-3’-methoxyflavone (also known as PD98059 available from Biaffin GmbH &Co., KG, Germany) ; Vemurafenib (PLX-4032, CAS 918504-65-1) ; (R) -3- (2, 3-Dihydroxypropyl) -6-fluoro-5- (2-fluoro-4-iodophenylamino) -8-methylpyrido [2, 3-d] pyrimidine-4, 7 (3H, 8H) -dione (TAK-733, CAS 1035555-63-5) ; Pimasertib (AS-703026, CAS 1204531-26-9) ; Trametinib dimethyl sulfoxide (GSK-1120212, CAS 1204531-25-80) ; 2- (2-Fluoro-4-iodophenylamino) -N- (2-hydroxyethoxy) -1, 5-dimethyl-6-oxo-1, 6-dihydropyridine-3-carboxamide (AZD 8330) ; and 3, 4-Difluoro-2- [ (2-fluoro-4-iodophenyl) amino] -N- (2-hydroxyethoxy) -5- [ (3-oxo- [1, 2] oxazinan-2-yl) methyl] benzamide (CH 4987655 or Ro 4987655) .
Aromatase inhibitors: (Pathiraja, T. et al., Sci. Transl. Med., 6 (229) : 229 ra41 (2014) ) Exemestane
Letrozole
and Anastrozole
Topoisomerase II inhibitors: (Bai, J. et al., Cell Prolif., 47 (3) : 211-8 (2014) ) Etoposide (VP-16 and Etoposide phosphate,
and
) ; Teniposide (VM-26,
) ; and Tafluposide.
SRC inhibitors: (Hebbard, L., Oncogene, 30 (3) : 301-12 (2011) ) Dasatinib
Saracatinib (AZD0530, CAS 379231-04-6) ; Bosutinib (SKI-606, CAS 380843-75-4) ; 5- [4- [2- (4-Morpholinyl) ethoxy] phenyl] -N- (phenylmethyl) -2-pyridineacetamide (KX2-391, CAS 897016-82-9) ; and 4- (2-Chloro-5-methoxyanilino) -6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline (AZM475271, CAS 476159-98-5) .
Histone deacetylase (HDAC) inhibitors: (Yamaguchi, J. et al., Cancer Sci., 101 (2) : 355-62 (2010) ) Voninostat
Romidepsin
Treichostatin A (TSA) ; Oxamflatin; Vorinostat (
Suberoylanilide hydroxamic acid) ; Pyroxamide (syberoyl-3-aminopyridineamide hydroxamic acid) ; Trapoxin A (RF-1023A) ; Trapoxin B (RF-10238) ; Cyclo [ (αS, 2S) -α-amino-η-oxo-2-oxiraneoctanoyl-O-methyl-D-tyrosyl-L-isoleucyl-L-prolyl] (Cyl-1) ; Cyclo [ (αS, 2S) -α-amino-η-oxo-2-oxiraneoctanoyl-O-methyl-D-tyrosyl-L-isoleucyl- (2S) -2-piperidinecarbonyl] (Cyl-2) ; Cyclic [L-alanyl-D-alanyl- (2S) -η-oxo-L-α-aminooxiraneoctanoyl-D-prolyl] (HC-toxin) ; Cyclo [ (αS, 2S) -α-amino-η-oxo-2-oxiraneoctanoyl-D-phenylalanyl-L-leucyl- (2S) -2-piperidinecarbonyl] (WF-3161) ; Chlamydocin ( (S) -Cyclic (2-methylalanyl-L-phenylalanyl-D-prolyl-η-oxo-L-α-aminooxiraneoctanoyl) ; Apicidin (Cyclo (8-oxo-L-2-aminodecanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-D-2-piperidinecarbonyl) ; Romidepsin (
FR-901228) ; 4-Phenylbutyrate; Spiruchostatin A; Mylproin (Valproic acid) ; Entinostat (-275, N- (2-Aminophenyl) -4- [N- (pyridine-3-yl-methoxycarbonyl) -amino-methyl] -benzamide) ; and Depudecin (4, 5: 8, 9-dianhydro-1, 2, 6, 7, 11-pentadeoxy-D-threo-D-ido-Undeca-1, 6-dienitol) .
Anti-tumor antibiotics: (Bai, J. et al., Cell Prolif., 47 (3) : 211-8 (2014) ) Doxorubicin (
and
) ; Bleomycin
Daunorubicin (dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride,
) ; Daunorubicin liposomal (daunorubicin citrate liposome,
) ; Mitoxantrone (DHAD,
) ; Epirubicin (Ellence
TM) ; Idarubicin (
Idamycin
) ; Mitomycin C
Geldanamycin; Herbimycin; Ravidomycin; and Desacetylravidomycin.
Demethylating agents: (Musch, T. et al., PLoS One, (5) : e10726 (2010) ) 5-Azacitidine
and Decitabine
Anti-estrogens: (Bhan, A. et al., J Mol Biol., S0022-2836 (14) 00373-8 (2014) ) Tamoxifen
Toremifene
and Fulvestrant
Immunomodulators of particular interest for combinations with the compounds of the invention include one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule (e.g., one or more inhibitors of PD-1, PD-L1, LAG-3, TIM-3 or CTLA4) or any combination thereof.
In certain embodiments, the immunomodulator is an activator of a costimulatory molecule. In one embodiment, the agonist of the costimulatory molecule is chosen from an agonist (e.g., an agonistic antibody or antigen-binding fragment thereof, or a soluble fusion) of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18) , ICOS (CD278) , 4-1 BB (CD137) , GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand.
In certain embodiments, the immunomodulator is an inhibitor of an immune checkpoint molecule. In one embodiment, the immunomodulator is an inhibitor of PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and/or TGFR beta. In one embodiment, the inhibitor of an immune checkpoint molecule inhibits PD-1, PD-L1, LAG-3, TIM-3 or CTLA4, or any combination thereof. The term “inhibition” or “inhibitor” includes a reduction in a certain parameter, e.g., an activity, of a given molecule, e.g., an immune checkpoint inhibitor. For example, inhibition of an activity, e.g., a PD-1 or PD-L1 activity, of at least 5%, 10%, 20%, 30%, 40%or more is included by this term. Thus, inhibition need not be 100%.
In another aspect, the present invention provides pharmaceutical compositions comprising at least one compound of the present invention (e.g., a compound of Formula (I) or a sub- formulae theref) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier suitable for administration to a human or animal subject, either alone or together with other anti-cancer agents.
In combination therapies, compositions will either be formulated together as a combination therapeutic, or as separate compositions. The compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. The structure of therapeutic agents identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium “The Merck Index” or from databases, e.g. Patents International (e.g. IMS World Publications) . The other therapeutic agents, which can be used in combination with a compound of the present invention, can be prepared and administered as described in the art, such as in the documents cited above.
Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above. The pharmaceutical composition or combination of the present invention may, for example, be in unit dosage of about 0.5 mg to 1000 mg of active ingredient (s) for a subject of about 50-70 kg.
In another aspect, the present invention provides methods of treating human or animal subjects suffering from a cellular proliferative disease, such as cancer, comprising administering to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, either alone or in combination with other anti-cancer agents. In combination therapy, the compound of the present invention and other anti-cancer agent (s) may be administered either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent) ; (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
In one embodiment, the compound of the present invention and the other anti-cancer agent (s) is generally administered sequentially in any order by infusion or orally. The dosing regimen may vary depending upon the stage of the disease, physical fitness of the patient, safety profiles of the individual drugs, and tolerance of the individual drugs, as well as other criteria well-known to the attending physician and medical practitioner (s) administering the combination. The compound of the present invention and other anti-cancer agent (s) may be administered within minutes of each other, hours, days, or even weeks apart depending upon the particular cycle being used for treatment. In addition, the cycle could include administration of one drug more often than the other during the treatment cycle and at different doses per administration of the drug.
In yet another aspect, compounds of the present invention may be combined with other anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics) , pain relievers, cytoprotective agents, and combinations thereof.
In some instances, patients may experience allergic reactions to the compounds of the present invention and/or other anti-cancer agent (s) during or after administration. Therefore, anti-allergic agents may be administered to minimize the risk -of an allergic reaction. Suitable anti-allergic agents include corticosteroids, such as dexamethasone (e.g.,
) , beclomethasone (e.g.,
) , hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate; e.g.,
hydrocortisone phosphate,
HYDROCORT
and
) , prednisolone (e.g.,
and
) , prednisone (e.g.,
LIQUID
and
) , methylprednisolone (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate; e.g.,
and SOLU-
) ; antihistamines, such as diphenhydramine (e.g.,
) , hydroxyzine, and cyproheptadine; and bronchodilators, such as the beta-adrenergic receptor agonists, albuterol (e.g.,
) , and terbutaline
In other instances, patients may experience nausea during and after administration of the compound of the present invention and/or other anti-cancer agent (s) . Therefore, anti-emetics may be administered in preventing nausea (upper stomach) and vomiting. Suitable anti-emetics include aprepitant
ondansetron
granisetron HCl
lorazepam (
dexamethasone
prochlorperazine
casopitant (
and
) , and combinations thereof.
In yet other instances, medication to alleviate the pain experienced during the treatment period is prescribed to make the patient more comfortable. Common over-the-counter analgesics, such
are often used. Opioid analgesic drugs such as hydrocodone/paracetamol or hydrocodone/acetaminophen (e.g.,
) , morphine (e.g.,
or
) , oxycodone (e.g.,
or
) , oxymorphone hydrochloride
and fentanyl (e.g.,
) are also useful for moderate or severe pain.
Furthermore, cytoprotective agents (such as neuroprotectants, free-radical scavengers, cardioprotectors, anthracycline extravasation neutralizers, nutrients and the like) may be used as an adjunct therapy to protect normal cells from treatment toxicity and to limit organ toxicities. Suitable cytoprotective agents include amifostine
glutamine, dimesna
mesna
dexrazoxane (
or
) , xaliproden
and leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid) .
In yet another aspect, a compound of the present invention may be used in combination with known therapeutic processes, for example, with the administration of hormones or in radiation therapy. In certain instances, a compound of the present invention may be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
In yet another aspect, the present invention provides kits comprising one or more compounds of the present invention and another therapeutic agent as described above. Representative kits include (a) compound of Formula (I) or sub-formulae thereof or a pharmaceutically acceptable salt thereof; and (b) at least one other therapeutic agent e.g., as indicated above; whereby such kit may further comprise a package insert or other labeling including directions for administration. The kits of the invention may be used for administering different dosage forms, for example, oral and parenteral; for administering two or more separate pharmaceutical compositions at different dosage intervals; or for titrating the separate compositions against one another; wherein at least one pharmaceutical composition comprises a compound a Formula (I) or sub-formulae thereof.
Processes for Making Compounds of the Invention
The compounds of the invention can be prepared using the methods described below, or by variations thereon as appreciated by one skilled in the art of organic synthesis. Compounds of Formula (I) that possess a chiral center can be made substantially optically pure by using substantially optically pure starting material or by separation chromatography, recrystallization or other separation techniques well-known in the art.
Schemes 1-8 describe potential routes for producing the compounds of the invention, which include compounds of Formula (I-3) :
Compounds of Formula (I) that possess a chiral center can be made substantially optically pure by either using substantially optically pure starting material or by separation chromatography, recrystallization or other separation techniques well-known in the art. For a more detailed description, see the Example section below.
As depicted in Scheme 1, 2-cyano-3-methylpyridine 1 was oxidized with m-CPBA to the corresponding pyridine-N-oxide 2, which was treated with POCl
3 to give the chloro-pyridine 3. Subsequent hydrolysis furnished the picolinamide 4, which could also be prepared via direct amidation of the picolinic acid 1’. Compound 5 was afforded upon treatment of 4 with 1, 1-di-tert-butoxy-N, N-dimethylmethanamine, and was then treated with t-BuOK to give cyclized compound 6. Subsequent O-alkylation with appropriate reagents generated 7, which was reacted with tert-butyl ( ( (1, 4-trans) -4-aminocyclohexyl) methyl) carbamate to give the Boc-protected amines 8. Displacement reactions of the de-protected amines (9) with appropriately substituted 2-chloropyrimidines furnished compounds 10.
As depicted in Scheme 2, removal of O-methyl and NH-Boc group in 8A (where R’ of compound 8 is methyl) with concentrated HCl yielded the amine 11, which upon treatment with POCl
3 furnished the chloro-amine 12. Displacement reactions with appropriately substituted 2- chloropyrimidines furnished compounds 13.
As depicted in Scheme 3, the nitro intermediate 14 (prepared as in scheme 1, where R’ is methyl and R
2 is NO
2) was reacted with POCl
3 to give the chloro-azaquinoline 17, which upon treatment with NH
2CH
3 furnished displacement product 20. Subsequent reduction of the nitro group in intermediates 14, 17 and 20 with hydrogen on palladium/charcoal or NaBH
4 with NiCl
2 hydrate furnished the corresponding amines 15, 18 and 21, which were reacted with appropriate reagents to afford corresponding products 16, 19 and 22.
As depicted in Scheme 4, the ethyl ester 23 (prepared as in scheme 1, where R’ is methyl and R
2 is –C (=O) OEt) was hydrolyzed with KOH to give the acid 24, which was treated with appropriate amines or POCl
3 to give compounds 25 and acyl chloride 26 respectively. Subsequent reaction of the acyl chloride 26 with the appropriate amines furnished compounds 27.
As depicted in Scheme 5, the ethyl ester 28 (prepared as in scheme 2, where R
2 is –C (=O) OEt) was reduced with DIBAL-H to give the alcohol 29, which was oxidized to the aldehyde 30 with MnO
2. Subsequent reductive amination with the appropriate amines furnished compounds 31.
As depicted in Scheme 6, the amine 9A (prepared from scheme 1, where R’ is methyl) was reacted with the appropriate pyridine or pyrimidine fluoride/chloride to give the corresponding bromo or iodo intermediates 32. Subsequent coupling with the appropriate bromides furnished the ester 33, which was demethylated with concentrated HCl to give the hydroxyl azaquinolines 34. Following treatment of 34 with POCl3, the resultant chloro azaquinolines 35 were converted to the acids 36 under acidic or basic conditions. Amide coupling with the appropriate amines furnished compounds 37.
As depicted in Scheme 7 Negishi coupling of 2-chloro-5-iodopyrimidine with the corresponding bromoacetate furnished tert-butyl 2- (2-chloropyrimidin-5-yl) acetate. Subsequent alkylation of tert-butyl 2- (2-chloropyrimidin-5-yl) acetate yielded III. Treatment of acid with the ester II (or III) revealed the acid IV. The preparation of compounds 37A was completed by amide coupling with the acid IV to give V, followed by chloro displacement reaction with the amine 12.
As depicted in Scheme 7, the ester 35A (prepared from scheme 6, where R is isopropyl and R
13 and R
14 are each H) was reduced with DIBAL-H to give the corresponding alcohol 38. Subsequent mesylation and displacement reaction with the appropriate amines furnished compounds 40.
EXAMPLES
Temperatures are given in degrees Celsius. The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21) . Unless otherwise specified, starting materials are generally available from commercial sources.
Purification of intermediates and final products was carried out via either normal or reverse phase chromatography. Normal phase chromatography was carried out using prepacked SiO2 cartridges eluting with either gradients of hexanes and ethyl acetate or DCM and MeOH unless otherwise indicated. Reverse phase preparative HPLC was carried out using C18 columns with UV 214 nm and 254 nm detection or prep LC-eluting with gradients of Solvent A (water with 0.1%TFA) and Solvent B (acetonitrile with 0.1%TFA) , or with gradients of Solvent A (water with 0.05% TFA) and Solvent B (acetonitrile with 0.05%TFA) , or with gradients of Solvent A (water with 0.05%ammonia) and Solvent B (acetonitrile with 0.05%ammonia) .
Nuclear magnetic resonance (NMR) spectra were obtained with Bruker Fourier transform spectrometers operating at frequencies as follows:
1H NMR: 400 MHz (Bruker) .
13C NMR: 100 MHz (Bruker) . Spectra data are reported in the format: chemical shift (multiplicity, number of hydrogens) . Chemical shifts are specified in ppm downfield of a tetramethylsilane internal standard (δ units, tetramethylsilane = 0 ppm) and/or referenced to solvent peaks, which in
1H NMR spectra appear at 2.49 ppm for CD
3SOCD
3, 3.30 ppm for CD
3OD, 1.94 for CD
3CN, and 7.24 ppm for CDCl
3.
The Examples herein merely illuminate the invention and does not limit the scope of the invention otherwise claimed. Further, the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples. Where desired, conventional protecting groups are used to protect reactive functional groups in accordance with standard practice, for example, see T.W. Greene and P.G.M. Wuts in “Protecting Groups in Organic Synthesis” , John Wiley and Sons, 1991.
The compound names provided herein were obtained using ChemDraw Ultra version 14.0
Abbreviations
Abbreviations as used herein, are defined as follows: “1x” for once, “2x” for twice, “3x” for thrice, “℃” for degrees Celsius, “aq” for aqueous, “FCC” for flash column chromatography, “eq” for equivalent or equivalents, “g” for gram or grams, “mg” for milligram or milligrams, “L” for liter or liters, “mL” for milliliter or milliliters, “μL” for microliter or microliters, “N” for normal, “M” for molar, “nM” for nanomolar, “mol” for mole or moles, “mmol” for millimole or millimoles, “min” for minute or minutes, “h” or “hrs” for hour or hours, “RT” for room temperature, “ON” for overnight, “atm” for atmosphere, “psi” for pounds per square inch, “conc. ” for concentrate, “sat” or “sat’d” for saturated, “MW” for molecular weight, “mw” or “μwave” for microwave, “mp” for melting point, “Wt” for weight, “MS” or “Mass Spec” for mass spectrometry, “ESI” for electrospray ionization mass spectroscopy, “HR” for high resolution, “HRMS” for high resolution mass spectrometry, “LCMS” or “LC-MS” for liquid chromatography mass spectrometry, “HPLC” for high pressure liquid chromatography, “RP HPLC” for reverse phase HPLC, “TLC” or “tlc” for thin layer chromatography, “NMR” for nuclear magnetic resonance spectroscopy, “nOe” for nuclear Overhauser effect spectroscopy, “
1H” for proton, “δ” for delta, “s” for singlet, “d” for doublet, “t” for triplet, “q” for quartet, “m” for multiplet, “br” for broad, “Hz” for hertz, “ee” for “enantiomeric excess” and “α” , “β” , “R” , “r” , “S” , “s” , “E” , and “Z” are stereochemical designations familiar to one skilled in the art.
The following abbreviations used herein below have the corresponding meanings:
Example 1
N
2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C1)
Step 1: 2-cyano-3-methylpyridine 1-oxide (1-1)
To a solution of compound 3-methylpicolinonitrile (10 g, 84.6 mmol, 1.0 eq) in CH
2Cl
2 (180 mL) was added m-CPBA (29.2 g, 139.3 mmol, 2.0 eq) . Then the mixture was stirred at 30 ℃ for 12 hours. The mixture was neutralized to pH 7~8 with saturated aqueous Na
2CO
3, and extracted three times with CH
2Cl
2/CH
3OH (5/1, v/v, 200 mL) , the combined organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was triturated with petroleum ether and EtOAc, then filtered to afford 2-cyano-3-methylpyridine 1-oxide (1-1) .
1H-NMR (400 MHz, DMSO-d
6) δ ppm 8.32 (d, J = 6.4 Hz, 1H) , 7.60-7.57 (m, 1H) , 7.41 (d, J = 8.0 Hz, 1H) , 2.45 (s, 3H) .
Step 2: 6-chloro-3-methylpicolinonitrile (1-2)
A mixture of (1-1) (4 g, 29.9 mmol, 1.0 eq) in POCl
3 (30 mL) was stirred at 110 ℃ for 2 hours. The solvent was removed and the residue was neutralized to pH 7~8 with saturated aqueous Na
2CO
3 solution, extracted three times with EtOAc (200 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (petroleum ether/EtOAc = 50/1) to give 6-chloro-3-methylpicolinonitrile (1-2) .
1H-NMR (400 MHz, CDCl
3) δ ppm 7.65 (d, J = 8.4 Hz, 1H) , 7.45 (d, J = 8.0 Hz, 1H) , 2.55 (s, 3H) . MS: [M+H]
+ = 152.8.
Step 3: 6-chloro-3-methylpicolinamide (1-3)
To a solution of (1-2) (1.19 g, 7.9 mmol, 1.0 eq) in DMSO (5 mL) was added a solution of NaOH (0.38 g, 9.44 mmol, 1.2 eq) in water (3 mL) . H
2O
2 (30%in water, 1.78 g, 15.8 mmol, 2.0 eq) was added dropwise to the mixture at 0 ℃. The mixture was stirred at 15 ℃ for 0.5 hour, then poured into water, the resulting white precipitate was collected by filtration to give 6-chloro-3-methylpicolinamide (1-3) .
1H NMR (400 MHz, CD
3OD) δ ppm 7.73 (d, J = 8.4 Hz, 1H) , 7.46 (d, J = 8.0 Hz, 1H) , 2.59 (s, 3H) . MS: [M+H]
+ = 171.0.
Alternatively, to a stirring solution of 6-chloro-3-methylpicolinic acid (23.94 g, 140 mmol, 1.0 eq) and (COCl)
2 (35.28 g, 280 mmol, 2.0 eq) in CH
2Cl
2 (100 mL) was added dropwise dry DMF (2.0 mL) for 30 minutes, then the resulting solution was stirred at 2~5 ℃ for 2 hours, then concentrated. The residue was dissolved in CH
2Cl
2 (200 mL) and the solution was added dropwise to NH
4OH (200 mL) for 30 minutes, then the resulting solution was stirred at 2~5 ℃ for 1 hours. The mixture was extracted with CH
2Cl
2 (200 mL*2) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated to give 6-chloro-3-methylpicolinamide (1-3) .
1H NMR (400 MHz, CD
3OD) : δ ppm 7.73 (d, J = 8.4 Hz, 1H) , 7.46 (d, J = 8.0 Hz, 1H) , 2.59 (s, 3H) . MS: [M+H]
+ = 171.0.
Step 4: (E) -6-chloro-N- ( (dimethylamino) methylene) -3-methylpicolinamide (1-4)
To a solution of (1-3) (2.0 g, 11.7 mmol, 1.0 eq) in THF (400 mL) was added 1, 1-di-tert-butoxy-N, N-dimethylmethanamine (20 mL) under N
2. Then the mixture was stirred at 85 ℃ for 0.5 hour. The resulting solution was used in the next step without further purification. MS: [M+H]
+ = 225.9.
Step 5: 2-chloro-1, 7-naphthyridin-8 (7H) -one (1-5)
To the above solution of (1-4) was added t-BuOK (1.5 M in THF, 11.5 mL, 17.5 mmol, 1.5 eq) . The mixture was stirred at 80 ℃ for 15 minutes. The solvent was removed and ice was added, then the mixture was adjusted to pH 7~8 with 1 N HCl, extracted four times with CH
2Cl
2 /CH
3OH (5/1, 300 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was triturated with petroleum ether and EtOAc, then filtered to afford 2-chloro-1, 7-naphthyridin-8 (7H) -one (1-5) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 11.74 (br s, 1H) , 8.21 (d, J = 8.4 Hz, 1H) , 7.77 (d, J = 8.4 Hz, 1H) , 7.33-7.30 (m, 1H) , 6.59 (d, J = 6.8 Hz, 1H) . MS: [M+H]
+ = 181.1.
Step 6: 2-chloro-8-methoxy-1, 7-naphthyridine (1-6)
To a solution of (1-5) (1.2 g, 6.6 mmol, 1.0 eq) in CH
2Cl
2 (120 mL) was added trimethyloxonium tetrafluoroborate (1.97 g, 13.3 mmol, 2.0 eq) . The mixture was stirred at 65 ℃ for 12 hours. The mixture was added 1N NaOH (40 mL) . After stirring for 20 minutes, the mixture was extracted three times with CH
2Cl
2 (200 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (petroleum ether/EtOAc from 8/1 to 5/1) to give 2-chloro-8-methoxy-1, 7-naphthyridine (1-6) .
1H NMR (400 MHz, CDCl
3) : δ ppm 8.11 (d, J = 5.6 Hz, 1H) , 8.04 (d, J = 8.8 Hz, 1H) , 7.58 (d, J = 8.8 Hz, 1H) , 7.21 (d, J = 5.6 Hz, 1H) , 4.20 (s, 3H) . MS: [M+H]
+ = 194.8.
Step 7: tert-butyl ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) carbamate (1-7)
To a solution of (1-6) (650 mg, 3.35 mmol, 1.0 eq) and tert-butyl ( ( (1, 4-trans) -4-aminocyclohexyl) methyl) carbamate (993 mg, 4.36 mmol, 1.3 eq) in anhydrous THF (50 mL) was added BINAP (625 mg, 1.0 mmol, 0.3 eq) , Pd
2 (dba)
3 (306 mg, 0.34 mmol, 0.1 eq) and t-BuONa (322 mg, 3.35 mmol, 1.0 eq) and the mixture was stirred at 65 ℃ for 1.5 hours. The mixture was filtered and the filtrate was added H
2O (30 mL) , and extracted twice with EtOAc (50 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give the crude product which was purified by silica gel column chromatography (petroleum ether/EtOAc from 4/1 to 3/1) to give tert-butyl ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) carbamate (1-7) .
1H NMR (400 MHz, CDCl
3) : δ ppm 7.79-7.75 (m, 2H) , 7.01 (d, J = 5.6 Hz, 1H) , 6.81 (d, J = 8.8 Hz, 1H) , 5.07 (d, J = 8.0 Hz, 1H) , 4.62 (br s, 1H) , 4.13 (s, 3H) , 3.61-3.54 (m, 1H) , 3.00 (t, J = 6.4 Hz, 2H) , 2.16-2.13 (m, 2H) , 1.85-1.80 (m, 2H) , 1.51-1.39 (m, 10H) , 1.25-1.08 (m, 4H) . MS: [M+H]
+ = 387.2.
Step 8: N- ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (1-8)
To a solution of (1-7) (320 mg, 0.83 mmol, 1.0 eq) in CH
2Cl
2 (5 mL) was added TFA (1 mL) and the mixture was stirred at 25 ℃ for 1.5 hours. The mixture was concentrated to give crude N- ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (1-8) , which was used without further purification. MS: [M+H]
+ = 286.9.
Step 9: 8-methoxy-N- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (1-9)
To a solution of (1-8) (230 mg, 0.8 mmol, 1.0 eq) in acetonitrile (2 mL) and THF (2 mL) was added 2-chloro-5-nitropyrimidine (154 mg, 0.96 mmol, 1.20 eq) and DIPEA (310 mg, 2.4 mmol, 5.0 eq) and the mixture was stirred at room temperature for 0.5 hour. The mixture was concentrated to give the crude product, which was purified by silica gel column chromatography (CH
2Cl
2/CH
3OH = 30/1) to give 8-methoxy-N- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (1-9) .
1H NMR (400 MHz, CDCl
3) : δ ppm 9.11 (d, J = 3.2 Hz, 1H) , 9.03 (d, J = 3.6 Hz, 1H) , 7.83-7.79 (m, 2H) , 7.03 (d, J = 5.6 Hz, 1H) , 6.84 (d, J = 8.8 Hz, 1H) , 6.07 (t, J = 6.0 Hz, 1H) , 5.05 (br s, 1H) , 4.14 (s, 3H) , 3.76-3.58 (m, 1H) , 3.46 (t, J = 6.4 Hz, 2H) , 2.21-2.18 (m, 2H) , 1.94-1.91 (m, 2H) , 1.71-1.67 (m, 1H) , 1.28-1.20 (m, 4H) . MS: [M+H]
+ = 410.1.
Step 10: N
2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (1)
To a solution of (1-9) (230 mg, 0.56 mmol, 1.0 eq) in CH
3OH (15 mL) and EtOAc (15 mL) was added Pd/C (10%, 40 mg) . The suspension was degassed under vacuum and purged with H
2 several times. The mixture was stirred under H
2 balloon at 20 ℃ for 3 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mmx5um, gradient: 20-50%B (A= 0.5%NH
4OH in water, B = acetonitrile) ) to give N
2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C1) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 7.79 (s, 2H) , 7.77 (s, 1H) , 7.68 (d, J = 5.2 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.06 (d, J = 8.0 Hz, 1H) , 6.89 (d, J = 8.8 Hz, 1H) , 6.25 (t, J = 6.0 Hz, 1H) , 4.38 (s, 2H ) , 3.94 (s, 3H) , 3.87 (br s, 1H) , 3.06 (t, J = 6.0 Hz, 2H) , 2.03-2.00 (m, 2H) , 1.82-1.79 (m, 2H) , 1.52 (br s, 1H) , 1.21-1.00 (m, 4H) . MS: [M+H]
+ = 380.2.
Example 2
N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) azetidine-3-carboxamide (C2)
Step 1: tert-butyl 3- ( (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamoyl) azetidine-1-carboxylate (2-1)
To a solution of compound (C1) (200 mg, 0.53 mmol, 1.0 eq) in DMF (5 mL) was added DIEA (204 mg, 1.58 mmol, 3.0 eq) , HATU (603 mg, 1.58 mmol, 3.0 eq) , and 1- (tert-butoxycarbonyl) azetidine-3-carboxylic acid (106 mg, 0.53 mmol, 1.0 eq) . The mixture was stirred at 22 ℃ for 1.0 hour. The mixture was added EtOAc (50 mL) , and washed twice with brine (20 mL) . The organic layer was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (CH
2Cl
2/CH
3OH from 50/1 to 20/1) to give tert-butyl 3- ( (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamoyl) azetidine-1-carboxylate (2-1) .
1H NMR (400 MHz, CDCl
3) : δ ppm 8.41 (s, 2H) , 7.87-7.85 (m, 2H) , 7.40 (br s, 1H) , 7.06 (d, J = 5.6 Hz, 1H) , 6.94 (d, J = 9.2 Hz, 1H) , 5.57 (br s, 1H) , 4.18-4.10 (m, 7H) , 3.63 (br s, 1H) , 3.41-3.33 (m, 1H) , 3.28 (t, J = 6.4 Hz, 2H) , 2.15-2.12 (m, 2H) , 1.92-1.89 (m, 2H) , 1.67-1.60 (m, 1H) , 1.44 (s, 9H) , 1.30-1.10 (m, 4H) . MS: [M+H]
+ = 563.3.
Step 2: N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) azetidine-3-carboxamide (C2)
To a solution of (2-1) (250 mg, 0.44 mmol, 1.0 eq) in CH
2Cl
2 (6.0 mL) was added TFA (1 mL) and the reaction mixture was stirred at 22 ℃ for 1.0 hour. The mixture was concentrated to give the crude product (200 mg) . The crude product (100 mg) was purified by preparative HPLC (column: Phenomenex Gemini C18 250mmx21.2mmx5μm, gradient: 20-50%B (A= water, B = acetonitrile) , flow rate: 25 mL/min) to give N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) azetidine-3-carboxamide (2) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.62 (s, 1H) , 8.39 (s, 2H) , 7.79 (d, J = 9.2 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.15-7.08 (m, 2H) , 7.05 (d, J = 8.0 Hz, 1H) , 6.90 (d, J = 8.8 Hz, 1H) , 3.95 (s, 3H) , 3.88 (br s, 1H) , 3.73-3.71 (m, 1H) , 3.59-3.44 (m, 4H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.06-1.98 (m, 2H) , 1.86-1.76 (m, 2H) , 1.54 (br s, 1H) , 1.24-1.01 (m, 4H) . MS: [M+H]
+ = 463.2.
Example 3
N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1-methylazetidine-3-carboxamide (C3)
A solution of compound (C2) (100 mg, 0.22 mmol, 1.0 eq) in CH
3OH (3.0 mL) was basified to pH 7~8 with DIPEA, then NaBH
3CN (42 mg, 0.66 mmol, 3.0 eq) and (HCHO)
n (32 mg, 1.08 mmol, 5.0 eq) were added. The reaction mixture was stirred at 25 ℃ for 40 minutes. The mixture was quenched with water (20 mL) , and extracted twice with CH
2Cl
2 (50 mL) . The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 250mmx21.2mmx5um, gradient: 20-40%B (A= water, B = acetonitrile) , flow rate: 25 mL/min) to give N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1-methylazetidine-3-carboxamide (C3) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.65 (s, 1H) , 8.39 (s, 2H) , 7.79 (d, J = 9.2 Hz, 1H) , 7.69 (d, J = 5.6 Hz, 1H) , 7.12-7.08 (m, 2H) , 7.05 (d, J = 7.6 Hz, 1H) , 6.90 (d, J = 9.2 Hz, 1H) , 3.95 (s, 3H) , 3.86 (br s, 1H) , 3.40 (t, J = 6.8 Hz, 2H) , 3.27-3.21 (m, 1H) , 3.16-3.10 (m, 4H) , 2.18 (s, 3H) , 2.04-2.01 (m, 2H) , 1.93-1.79 (m, 2H) , 1.55 (br s, 1H) , 1.22-1.03 (m, 4H) . MS: [M+H]
+ = 477.3.
Example 4
2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C4)
The title compound was prepared using a procedure similar to that in Step 9 of Example 1, with 2-chloro-5-nitropyrimidine being replaced with 2-chloropyrimidine-5-carbonitrile and the product purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mmx5μm, gradient: 33-63%B (A= water, B = acetonitrile) ) to give 2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C4) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.71 (d, J = 3.2 Hz, 1H) , 8.63 (d, J = 3.2 Hz, 1H) , 8.41 (t, J = 6.0 Hz, 1H) , 7.79 (d, J = 9.2 Hz, 1H) , 7.68 (d, J = 5.2 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.05 (d, J = 8.0 Hz, 1H) , 6.90 (d, J = 9.2 Hz, 1H) , 3.94 (s, 3H) , 3.87 (br s, 1H) , 3.23 (t, J = 6.4 Hz, 2H) , 2.04-2.01 (m, 2H) , 1.81-1.77 (m, 2H) , 1.58 (br s, 1H) , 1.23-1.05 (m, 4H) . MS: [M+H]
+ = 390.1.
Example 5
2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (C5)
To a solution of compound (C4) (60 mg, 0.15 mmol, 1.0 eq) in DMSO (3 mL) was added K
2CO
3 (64 mg, 0.46 mmol, 3.0 eq) and water (0.5 mL) . H
2O
2 (30%aqueous solution, 52 mg, 0.46 mmol, 3.0 eq) was added dropwise to the mixture at 0 ℃. The mixture was stirred at 30 ℃ for 0.5 hour. The reaction mixture was added to EtOAc (50 mL) and washed twice with brine (20 mL) , dried over anhydrous sodium sulfate and concentrated. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mmx5um, gradient: 11-48%B (A= water, B = acetonitrile) ) to give 2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (C5) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.73 (s, 1H) , 8.69 (s, 1H) , 7.85 (t, J = 6.0 Hz, 1H) , 7.80 (d, J = 8.8 Hz, 1H) , 7.69 (d, J = 5.6 Hz, 1H) , 7.23 (br s, 1H) , 7.10 (d, J = 5.2 Hz, 1H) , 7.06 (d, J = 8.0 Hz, 1H) , 6.91 (d, J = 8.8 Hz, 1H) , 3.96 (s, 3H) , 3.89 (br s, 1H) , 3.24 (t, J = 6.4 Hz, 2H) , 2.05-2.02 (m, 2H) , 1.83-1.80 (m, 2H) , 1.58 (br s, 1H) , 1.23-1.06 (m, 4H) . MS: [M+H]
+ = 408.2.
Example 6
N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide (C6)
The title compound was prepared using a procedure similar to that in Step 1 of Example 2, with 1- (tert-butoxycarbonyl) azetidine-3-carboxylic acid being replaced with acetic acid and the product purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mmx5μm, gradient: 19-49%B (A= water, B = acetonitrile) ) to give N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide (C6) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.73 (s, 1H) , 8.36 (s, 2H) , 7.78 (d, J = 8.8 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.12-7.04 (m, 3H) , 6.90 (d, J = 8.8 Hz, 1H) , 3.94 (s, 3H) , 3.88 (br s, 1H) , 3.14 (t, J = 6.0 Hz, 2H) , 2.03-2.00 (m, 2H) , 1.99 (s, 3H) , 1.82-1.79 (m, 2H) , 1.55 (br s, 1H) , 1.21-1.02 (m, 4H) . MS: [M+H]
+ = 422.2.
Example 7
2-hydroxy-N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide (C7)
The title compound was prepared using a procedure similar to that in Step 1 of Example 2, with 1- (tert-butoxycarbonyl) azetidine-3-carboxylic acid replaced with 2-hydroxyacetic acid.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.59 (s, 1H) , 8.46 (s, 2H) , 7.79 (d, J = 8.8 Hz, 1H) , 7.68 (d, J = 5.2 Hz, 1H) , 7.13 (t, J = 6.0 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.06 (d, J = 8.0 Hz, 1H) , 6.90 (d, J = 8.8 Hz, 1H) , 5.75 (t, J = 6.0 Hz, 1H) , 3.97 (d, J = 5.6 Hz, 2H) , 3.95 (s, 3H) , 3.87 (br s, 1H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.03-2.01 (m, 2H) , 1.83-1.80 (m, 2H) , 1.55 (br s, 1H) , 1.22-1.03 (m, 4H) . MS: [M+H]
+ = 438.2.
Example 8
(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone (C8)
Step 1: Ethyl 2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxylate (8-1)
To a solution of (1-8) (2.2 g, 7.7 mmol, 1.0 eq) in DMF (30 mL) was added ethyl 2-chloropyrimidine-5-carboxylate (1.6 g, 8.4 mmol, 1.1 eq) and DIPEA (4.9 g, 38.5 mmol, 5.0 eq) and the mixture was stirred at 100 ℃ for 2.5 hours. The mixture was added to EtOAc (100 mL) , washed three times with brine (30 mL) , dried over anhydrous Na
2SO
4 and concentrated. The crude product was purified by column chromatography (petroleum ether/EtOAc from 2/1 to 1/1) to give ethyl 2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxylate (8-1) .
1H NMR (400 MHz, CDCl
3) : δ ppm 8.87 (s, 1H) , 8.78 (s, 1H) , 7.80-7.76 (m, 2H) , 7.01 (d, J = 5.6 Hz, 1H) , 6.82 (d, J = 9.2 Hz, 1H) , 5.81 (br s, 1H) , 5.07 (d, J = 7.6 Hz, 1H) , 4.33 (q, J = 6.8 Hz, 1H) , 4.13 (s, 3H) , 3.62 (br s, 1H) , 3.40 (t, J = 6.4 Hz, 2H) , 2.18-2.16 (m, 2H) , 1.92-1.90 (m, 2H) , 1.65 (br s, 1H) , 1.36 (t, J = 6.8 Hz, 3H) , 1.24-1.20 (m, 4H) . MS: [M+H]
+ = 437.2.
Step 2: 2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxylic acid (8-2)
To a solution of (8-1) (2.2 g, 5.0 mmol, 1.0 eq) in MeOH (20 mL) was added H
2O (4 mL) and KOH (1.12 g, 20 mmol, 4.0 eq) , the reaction mixture was stirred at 50 ℃ for 2.5 hours. The mixture was concentrated and adjusted to pH 5~6 with 1N HCl. The formed precipitate was collected by filtration to give 2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxylic acid (8-2) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 12.72 (br s, 1H) , 8.73 (d, J = 2.8 Hz, 1H) , 8.66 (d, J = 3.2 Hz, 1H) , 8.13 (t, J = 6.0 Hz, 1H) , 7.79 (d, J = 9.2 Hz, 1H) , 7.68 (d, J = 5.2 Hz, 1H) , 7.10-7.06 (m, 2H) , 6.90 (d, J = 9.2 Hz, 1H) , 3.94 (s, 3H) , 3.88 (br s, 1H) , 3.24 (t, J = 6.4 Hz, 2H) , 2.04-2.01 (m, 2H) , 1.82-1.79 (m, 2H) , 1.59 (br s, 1H) , 1.20-1.08 (m, 4H) .
Step 3: (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone (C8)
To a solution of compound (8-2) (2.5 g, 6.1 mmol, 1.0 eq) in DMF (20mL) was added piperazine (10 g, 123 mmol, 20.0 eq) , DIEA (2.4 g, 18.3 mmol, 3.0 eq) and HATU (7.0 g, 18.3 mmol, 3.0 eq) . The mixture was stirred at 15 ℃ for 0.5 hour. The mixture was quenched with H
2O (50 ml) and extracted with EtOAc (100 mL*4) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography (CH
2Cl
2/CH
3OH = 50/1) to give the crude product which was triturated with petroleum ether/EtOAc (5/1, 100 mL) , filtered, and dried to give (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone (C8) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.36 (s, 1H) , 8.32 (s, 1H) , 7.79 (d, J = 8.8 Hz, 1H) , 7.75 (t, J = 6.0 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.06 (d, J = 7.6 Hz, 1H) , 6.90 (d, J = 9.2 Hz, 1H) , 3.95 (s, 3H) , 3.88 (br s, 1H) , 3.49-3.40 (m, 4H) , 3.20 (t, J = 6.4 Hz, 2H) , 2.72-2.66 (m, 4H) , 2.04-2.01 (m, 2H) , 1.83-1.80 (m, 2H) , 1.58 (br s, 1H) , 1.22-1.04 (m, 4H) . MS: [M+H]
+ = 477.3.
Example 9
N- (2-hydroxypropyl) -2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (C9)
The title compound was prepared by using a procedure similar to that of Example 8, with piperazine being replaced with 1-aminopropan-2-ol.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.71 (s, 1H) , 8.68 (s, 1H) , 8.24 (t, J = 5.6 Hz, 1H) , 7.83-7.77 (m, 2H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.05 (d, J = 8.0 Hz, 1H) , 6.90 (d, J = 9.2 Hz, 1H) , 4.74 (d, J = 4.8 Hz, 1H) , 3.95 (s, 3H) , 3.87 (br s, 1H) , 3.76-3.71 (m, 1H) , 3.23 (t, J = 6.4 Hz, 2H) , 3.19-3.11 (m, 2H) , 2.04-2.01 (m, 2H) , 1.83-1.79 (m, 2H) , 1.58 (br s, 1H) , 1.19-1.08 (m, 4H) , 1.05 (d, J = 6.4 Hz, 3H) . MS: [M+H]
+ = 466.2.
Example 10
(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone (C10)
The title compound was prepared by using a procedure similar to that of Example 8, with piperazine being replaced with morpholine.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.40 (s, 1H) , 8.36 (s, 1H) , 7.81-7.77 (m, 2H) , 7.68 (d, J = 5.2 Hz, 1H) , 7.09 (d, J = 5.2 Hz, 1H) , 7.06 (d, J = 8.0 Hz, 1H) , 6.90 (d, J = 8.8 Hz, 1H) , 3.95 (s, 3H) , 3.89 (br s, 1H) , 3.68-3.58 (m, 4H) , 3.58-3.49 (m, 4H) , 3.21 (t, J = 6.4 Hz, 2H) , 2.04-2.02 (m, 2H) , 1.83-1.80 (m, 2H) , 1.58 (br s, 1H) , 1.22-1.05 (m, 4H) . MS: [M+H]
+ = 478.2.
Example 11
(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (4-methylpiperazin-1-yl) methanone (C11)
The title compound was prepared by using a procedure similar to that of Example 8, with piperazine being replaced with 1-methylpiperazine.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.37 (s, 1H) , 8.33 (s, 1H) , 7.80-7.76 (m, 2H) , 7.68 (d, J = 5.2 Hz, 1H) , 7.09 (d, J = 5.2 Hz, 1H) , 7.06 (d, J = 7.6 Hz, 1H) , 6.90 (d, J = 8.8 Hz, 1H) , 3.95 (s, 3H) , 3.86 (br s, 1H) , 3.59 (br s, 4H) , 3.21 (t, J = 6.4 Hz, 2H) , 2.38-2.29 (m, 4H) , 2.20 (s, 3H) , 2.05-2.02 (m, 2H) , 1.84-1.80 (m, 2H) , 1.58 (br s, 1H) , 1.22-1.04 (m, 4H) . MS: [M+H]
+ = 491.3.
Example 12
N- ( (1, 4-trans) -4- ( ( (5- (1H-1, 2, 4-triazol-5-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (C12)
Step 1: N- ( (E) - (dimethylamino) methylene) -2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (12-1)
To a solution of compound (C5) (55 mg, 0.13 mmol, 1.0 eq) in THF (5 mL) was added DMFDMA (0.3 mL) . The mixture was heated at 60 ℃ for 30 minutes. The mixture was concentrated under vacuum to give N- ( (E) - (dimethylamino) methylene) -2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (12-1) , which was used directly for next step. MS: [M+H]
+ = 463.2.
Step 2: N- ( (1, 4-trans) -4- ( ( (5- (1H-1, 2, 4-triazol-5-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (C12)
To a solution of (12-1) (50 mg, 0.11 mmol, 1.0 eq) in AcOH (5 mL) was added hydrazine hydrate (127 mg, 2.16 mmol, 20 eq) . The reaction was heated at 85 ℃ for 0.5 hour. Then AcOH was removed under vacuum and the residue was basified by addition of ammonia. The reaction mixture was extracted with EtOAc (30 mL*2) and the organic solvent was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Waters XSELECT C18 150mmx30mmx5μm, gradient: 22-37%B (A= 0.05%NH
3H
2O in water, B = acetonitrile) ) to give N- ( (1, 4-trans) -4- ( ( (5- (1H-1, 2, 4-triazol-5-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (C12) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.81 (s, 2H) , 8.39 (br s, 1H) , 7.79 (d, J = 8.8 Hz, 1H) , 7.70-7.60 (m, 2H) , 7.11-7.06 (m, 2H) , 6.90 (d, J = 8.4 Hz, 1H) , 3.95 (s, 3H) , 3.88 (br s, 1H) , 3.24 (t, J = 5.6 Hz, 2H) , 2.06-2.02 (m, 2H) , 1.86-1.82 (m, 2H) , 1.60 (br s, 1H) , 1.21-1.09 (m, 4H) . MS: [M+H]
+ = 432.2.
Example 13
2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (C13)
Step 1: N- ( (1, 4-trans) -4- ( ( (5-iodopyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (13-1)
The title compound was prepared using a procedure similar to that in Step 1 of Example 8, with ethyl 2-chloropyrimidine-5-carboxylate being replaced with 2-chloro-5-iodopyrimidine and the product purified by column chromatography on silica gel (petroleum ether/EtOAc from 5/1 to 1/1) to give N- ( (1, 4-trans) -4- ( ( (5-iodopyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (13-1) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.39 (s, 2H) , 7.78 (d, J = 9.2 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.50 (t, J = 6.0 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.05 (d, J = 8.0 Hz, 1H) , 6.89 (d, J = 8.8 Hz, 1H) , 3.95 (s, 3H) , 3.88 (br s, 1H) , 3.13 (t, J = 6.0 Hz, 2H) , 2.03-2.00 (m, 2H) , 1.81-1.77 (m, 2H) , 1.54 (br s, 1H) , 1.15-1.05 (m, 4H) . MS: [M+H]
+ = 491.1.
Step 2: tert-butyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (13-2)
To a mixture of zinc powder (346.7 mg, 5.30 mmol, 20 eq) in THF (8 mL) was added TMSCl (0.1 mL) , and the mixture was stirred at 17 ℃ for 0.5 hour under N
2 protection, followed by the dropwise addition of tert-butyl 2-bromoacetate (930.8 mg, 4.77 mmol, 18 eq) over 10 minutes. The resulting mixture was stirred at 17 ℃ for another 1 hour under nitrogen. Then to the above mixture was added (13-1) (130 mg, 0.27 mmol, 1.0 eq) , X-phos (31.6 mg, 0.066 mmol, 0.25 eq) and Pd
2 (dba)
3 (48.6 mg, 0.053 mmol, 0.2 eq) . The reaction mixture was stirred at 60 ℃ for 12 hours under N
2. The mixture was quenched with saturated NH
4Cl solution (5 mL) , extracted three times with EtOAc (10 mL) . The combined organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated. The crude product was purified by column chromatography on silica gel (petroleum ether/EtOAc from 3/1 to 1/2) to give tert-butyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (13-2) ) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.13 (s, 2H) , 7.78 (d, J = 8.8 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.16 (d, J = 6.0 Hz, 1H) , 7.09 (d, J = 5.2 Hz, 1H) , 7.05 (d, J = 8.0 Hz, 1H) , 6.89 (d, J = 9.2 Hz, 1H) , 3.95 (s, 3H) , 3.88 (br s, 1H) , 3.38 (s, 2H) , 3.15 (t, J = 6.4 Hz, 2H) , 2.04-2.01 (m, 2H) , 1.83-1.80 (m, 2H) , 1.56 (br s, 1H) , 1.40 (s, 9H) , 1.19-1.06 (m, 4H) .
Step 3: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetic acid (13-3)
To a solution of (13-2) (100 mg, 0.21 mmol, 1.0 eq) in CH
2Cl
2 (4 mL) was added TFA (1.0 mL) in portions over 5 minutes. The reaction mixture was stirred at 19 ℃ for 1.5 hours. The mixture was concentrated to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetic acid (13-3) . MS: [M+H]
+ = 423.0.
Step 4: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (C13)
To a mixture of (13-3) (80 mg, 0.19 mmol, 1.0 eq) in DMF (4 mL) was added DIEA (97.89 mg, 0.76 mmol, 4.0 eq) , followed by the addition of oxetan-3-amine (27.68 mg, 0.38 mmol, 2.0 eq) and HATU (144.0 mg, 0.38 mmol, 2.0 eq) . The resulting mixture was stirred at 19 ℃ for 1.0 hour. The mixture was diluted with water (5 mL) , extracted three times with EtOAc (10 mL) . The combined organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated. The crude product was purified by preparative HPLC (column: DuraShell 150mmx25mmx5um: 22-52%B (A= 0.5%NH
4OH in water, B = acetonitrile) ) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (C13) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.80 (d, J = 6.4 Hz, 1H) , 8.12 (s, 2H) , 7.78 (d, J = 8.8 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.12 (d, J = 6.0 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.05 (d, J = 7.6 Hz, 1H) , 6.89 (d, J = 8.8 Hz, 1H) , 4.80-4.74 (m, 1H) , 4.70 (t, J = 6.0 Hz, 2H) , 4.41 (t, J = 6.4 Hz, 2H) , 3.95 (s, 3H) , 3.87 (br s, 1H) , 3.24 (s, 2H) , 3.15 (t, J = 6.4 Hz, 2H) , 2.04-2.01 (m, 2H) , 1.83-1.79 (m, 2H) , 1.55 (br s, 1H) , 1.22-1.02 (m, 4H) . MS: [M+H]
+ = 478.1.
Example 14
N
2- ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C14)
Step 1: 8-chloro-N- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (14-1)
A mixture of (1-9) (160 mg, 0.39 mmol, 1.0 eq) in POCl
3 (5 mL) was stirred at 110 ℃ for 1.5 hours. The solvent was removed and the residue was basified to pH 7~8 with saturated NaHCO
3 solution, extracted twice with EtOAc (50 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give 8-chloro-N- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (14-1) . MS: [M+H]
+ = 414.0.
Step 2: N
2- ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C14)
To a solution of (14-1) (100 mg, 0.24 mmol, 1.0 eq) in CH
3OH (4 mL) and CH
2Cl
2 (1.5 mL) was added NiCl
2
.6H
2O (114 mg, 0.48 mmol, 2.0 eq) and NaBH
4 (36 mg, 0.96 mmol, 4.0 eq) . The mixture was stirred at 25 ℃ for 10 minutes. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 250mmx21.2mmx5um, gradient: 32-47%B (A= water, B = acetonitrile) ) to give N
2- ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C14) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 7.95 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.79 (s, 2H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.50 (d, J = 7.2 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 6.24 (t, J = 5.6 Hz, 1H) , 4.37 (s, 2H) , 3.90 (br s, 1H) , 3.07 (t, J = 6.4 Hz, 2H) , 2.12-2.09 (m, 2H) , 1.84-1.80 (m, 2H) , 1.55 (br s, 1H) , 1.22-1.00 (m, 4H) . MS: [M+H]
+ = 384.1.
Example 15
Methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate (C15)
To a solution of (C14) (100 mg, 0.26 mmol, 1.0 eq) in CH
2Cl
2 (5 mL) was added CDI (carbonyl diimidazole, 168 mg, 1.04 mmol, 5.0 eq) and DIEA (134 mg, 1.04 mmol, 5.0 eq) . The mixture was stirred at 25 ℃ for 2 hours. Then CH
3OH (5 mL) was added and stirred at 25 ℃ for 20 minutes. The reaction mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150mmx30mmx5um, gradient: 31-61%B (A= 0.5%NH
4HCO
3 in water, B = acetonitrile) ) to give methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate (C15) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.27 (s, 1H) , 8.27 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56-7.52 (m. 2H) , 7.11 (br s, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 3.91 (br s, 1H) , 3.63 (s, 3H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.13-2.11 (m. 2H) , 1.85-1.82 (m. 2H) , 1.57 (br s, 1H) , 1.24-1.15 (m, 2H) , 1.14-1.03 (m, 2H) . MS: [M+H]
+ = 442.2.
Example 16
2-methoxyethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate (C16)
The title compound was prepared by using a procedure similar to that of Example 15, with methanol being replaced with 2-methoxyethan-1-ol.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.36 (s, 1H) , 8.27 (s, 2H) , 7.95 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.50 (d, J = 7.2 Hz, 1H) , 7.08 (br s, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 4.17 (t, J = 4.8 Hz, 2H) , 3.90 (br s, 1H) , 3.54 (t, J = 4.8 Hz, 2H) , 3.27 (s, 3H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.25-1.03 (m, 4H) . MS: [M+H]
+ = 486.2.
Example 17
2-hydroxyethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate (C17)
The title compound was prepared by using a procedure similar to that of Example 15, with methanol being replaced with ethane-1, 2-diol.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.31 (s, 1H) , 8.27 (s, 2H) , 7.96 (d, J = 4.8 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.08 (d, J = 5.6 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.83 (t, J = 5.2 Hz, 1H) , 4.07 (t, J = 5.2 Hz, 2H) , 3.90 (br s, 1H) , 3.61-3.58 (m, 2H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.13-2.10 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.29-1.15 (m, 2H) , 1.13-1.03 (m, 2H) . MS: [M+H]
+ = 472.1.
Example 18
Oxetan-3-ylmethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate (C18)
The title compound was prepared by using a procedure similar to that of Example 15, with methanol being replaced with oxetan-3-ylmethanol.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.35 (s, 1H) , 8.28 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.10 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 8.4 Hz, 1H) , 4.66 (t, J = 6.0 Hz, 2H) , 4.38 (t, J = 6.0 Hz, 2H) , 4.27 (d, J = 6.4 Hz, 2H) , 3.91 (br s, 1H) , 3.29-3.24 (m, 1H) , 3.14 (t, J = 6.0 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.25-1.19 (m, 2H) , 1.16-1.06 (m, 2H) . MS: [M+H]
+ = 498.2.
Example 19
N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxyacetamide (C19)
The title compound was prepared using a procedure similar to that in Step 1 of Example 2, with (C1) being replaced with (C14) and 1- (tert-butoxycarbonyl) azetidine-3-carboxylic acid being replaced with 2-hydroxyacetic acid. The product was purified by preparative HPLC (column: Phenomenex Gemini C18 250mmx21.2mmx5um, gradient: 20-50%B (A= 0.5%NH
4HCO
3 in water, B = acetonitrile) ) to give N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxyacetamide (C19) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.59 (s, 1H) , 8.45 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56-7.51 (m, 2H) , 7.13 (t, J = 6.0 Hz, 1H) , 7.00 (d, J = 8.4 Hz, 1H) , 5.74 (t, J = 6.4 Hz, 1H) , 3.96 (d, J = 6.0 Hz, 2H) , 3.90 (br s, 1H) , 3.15 (t, J = 6.4 Hz, 2H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.58 (br s, 1H) , 1.25-1.03 (m, 4H) . MS: [M+H]
+ = 442.1.
Example 20
N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -4-morpholino-4-oxobutanamide (C20)
Step 1: 4- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) amino) -4-oxobutanoic acid (20-1)
To a solution of (C14) (20 mg, 0.05 mmol, 1.0 eq) in toluene (4 mL) was added dihydrofuran-2, 5-dione (11 mg, 0.1 mmol, 2.0 eq) . The mixture was stirred at 110 ℃ for 30 minutes. The reaction mixture was concentrated under reduced pressure to give 4- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) amino) -4-oxobutanoic acid (20-1) . MS: [M+H]
+ = 484.2.
Step 2: N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -4-morpholino-4-oxobutanamide (C20)
The title compound was prepared by using a procedure similar to that in Step 4 of Example 13, with (13-3) being replaced with (20-1) and oxetan-3-amine being replaced with morpholine. The product was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150mmx30mmx5um, gradient: 25-55%B (A= 0.5%NH
4HCO
3 in water, B = acetonitrile) ) to give N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -4-morpholino-4-oxobutanamide (C20) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.76 (s, 1H) , 8.39 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1Hz) , 7.51 (d, J = 7.6 Hz, 1Hz) , 7.08 (t, J = 5.6 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 3.91 (br s, 1H) , 3.59-3.52 (m, 4H) , 3.47-3.42 (m, 4H) , 3.15 (t, J = 6.0 Hz, 2H) , 2.61 (t, J = 6.0 Hz, 2H) , 2.53 (t, J = 6.0 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.23-1.16 (m, 2H) , 1.13-1.07 (m, 2H) . MS: [M+H]
+ = 553.1.
Example 21
2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C21)
Step 1: 2- ( ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) amino) -1, 7-naphthyridin-8-ol (21-1)
To a solution of (1-7) (350 mg, 0.90 mmol, 1.0 eq) in EtOAc (5 mL) was added HCl/EtOAc (5 mL, 4N) and the mixture was stirred at 25 ℃ for 1 hour. The mixture was concentrated to give 2- ( ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) amino) -1, 7-naphthyridin-8-ol (21-1) , which was used in the next step without further purification. MS: [M+H]
+ = 273.3.
Step 2: 2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (21-2)
The title compound was prepared by using a procedure similar to that in Step 9 of Example 1, with (1-8) being replaced with (21-1) and 2-chloro-5-nitropyrimidine being replaced with 2-chloropyrimidine-5-carbonitrile. The product was purified by column chromatography (petroleum ether/EtOAc from 1/1 to 0/100, then CH
2Cl
2/CH
3OH 20/1) to give 2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (21-2) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 11.17 (d, J = 4.4 Hz, 1H) , 8.71 (d, J = 2.8 Hz, 1H) , 8.63 (d, J = 3.2 Hz, 1H) , 8.42 (t, J = 6.0 Hz, 1H) , 7.62 (d, J = 8.8 Hz, 1H) , 6.87 (t, J = 6.4 Hz, 1H) , 6.82 (d, J = 8.0 Hz, 1H) , 6.79 (d, J = 8.8 Hz, 1H) , 6.29 (d, J = 6.4 Hz, 1H) , 3.86 (br s, 1H) , 3.22 (t, J = 6.4 Hz, 2H) , 2.01-1.98 (m, 2H) , 1.88-1.70 (m, 2H) , 1.57 (br s, 1H) , 1.18-1.03 (m, 4H) . MS: [M+H]
+ = 376.0.
Step 3: 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C21)
A mixture of (21-2) (350 mg, 0.93 mmol, 1.0 eq) in POCl
3 (5 mL) was stirred at 110 ℃ for 2 hours. The solvent was removed and the residue was basified to pH 7~8 with saturated NaHCO
3 solution, extracted twice with EtOAc (50 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give the crude product (280 mg) . The crude product (40 mg) was purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx21.2mmx5um, gradient: 40-70%B (A= water, B = acetonitrile) ) to give 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C21) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.71 (d, J = 2.8 Hz, 1H) , 8.63 (d, J = 3.2 Hz, 1H) , 8.42 (t, J = 6.0 Hz, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.52 (d, J = 7.2 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 3.90 (br s, 1H) , 3.24 (t, J = 6.4 Hz, 2H) , 2.14-2.11 (m, 2H) , 1.83-1.80 (m, 2H) , 1.59 (br s, 1H) , 1.25-1.06 (m, 4H) . MS: [M+H]
+ = 394.1.
Example 22
(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone (C22)
Step 1: 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonyl chloride (22-1)
A solution of (8-2) (140 mg, 0.34 mmol, 1.0 eq) in POCl
3 (3 mL) was stirred at 110 ℃ for 2 hours. The mixture was concentrated to give 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonyl chloride (22-1) , which was used in the next step without further purification.
Step 2: (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone (C22)
To a solution of morpholine (2 mL) in THF (10 mL) was added dropwise a suspension of (22-1) (70 mg, 0.16 mmol, 1.0 eq) in THF (10 mL) for 10 minutes. The reaction mixture was stirred at 15 ℃ for 10 minutes. Then the mixture was concentrated to give the crude product which was purified by preparative HPLC (column: Phenomenex Gemini C18 250mmx21.2mmx5um: 29-59%B (A= 0.5%NH
4HCO
3 in water, B = acetonitrile) ) to give (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone (C22) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.40 (s, 1H) , 8.36 (s, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.80 (t, J = 6.0 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.52 (d, J = 7.2 Hz, 1H) , 7.00 (d, J = 8.4 Hz, 1H) , 3.91 (br s, 1H) , 3.60-3.59 (m, 4H) , 3.53-3.52 (m, 4H) , 3.21 (t, J = 6.4 Hz, 2H) , 2.14-2.12 (m, 2H) , 1.86-1.83 (m, 2H) , 1.59 (br s, 1H) , 1.26-1.06 (m, 4H) . MS: [M+H]
+ = 482.1.
Example 23
(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (4-methylpiperazin-1-yl) methanone (C23)
The title compound was prepared by using a procedure similar to that in Step 2 of Example 22, with morpholine being replaced with 1-methylpiperazine.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.37 (s, 1H) , 8.33 (s, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.78 (t, J = 6.0 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.52 (d, J = 7.2 Hz, 1H) , 7.00 (d, J = 8.8 Hz, 1H) , 3.91 (br s, 1H) , 3.60-3.46 (m, 4H) , 3.21 (t, J = 6.4 Hz, 2H) , 2.35-2.30 (m, 4H) , 2.19 (s, 3H) , 2.15-2.12 (m, 2H) , 1.86-1.83 (m, 2H) , 1.60 (br s, 1H) , 1.26-1.06 (m, 4H) . MS: [M+H]
+ = 495.1. IC50 value in the EZH2 (a) LC-Qualified was > 100 μM.
Example 24
(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone (C24)
The title compound was prepared by using a procedure similar to that in Step 2 of Example 22, with morpholine being replaced with piperazine.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.36 (s, 1H) , 8.32 (s, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.76 (t, J = 5.6 Hz, 1H) , 7.56-7.52 (m, 2H) , 7.00 (d, J = 8.8 Hz, 1H) , 3.90 (br s, 1H) , 3.43 (br s, 4H) , 3.21 (t, J = 6.4 Hz, 2H) , 2.75-2.65 (m, 4H) , 2.14-2.12 (m, 2H) , 1.86-1.83 (m, 2H) , 1.61 (br s, 1H) , 1.28-1.05 (m, 4H) . MS: [M+H]
+ = 481.1.
Example 25
2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) -N- (oxetan-3-yl) pyrimidine-5-carboxamide (C25)
The title compound was prepared by using a procedure similar to that in Step 2 of Example 22, with morpholine being replaced with oxetan-3-amine.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.88 (d, J = 6.8 Hz, 1H) , 8.71 (d, J = 9.2 Hz, 2H) , 7.97-7.90 (m, 3H) , 7.56-7.51 (m, 2H) , 6.99 (d, J = 9.2 Hz, 1H) , 5.00-4.95 (m, 1H) , 4.76 (t, J = 6.4 Hz, 2H) , 4.55 (t, J = 6.4 Hz, 2H) , 3.90 (br s, 1H) , 3.24 (t, J = 6.4 Hz, 2H) , 2.14-2.12 (m, 2H) , 1.85-1.82 (m, 2H) , 1.60 (br s, 1H) , 1.26-1.07 (m, 4H) . MS: [M+H]
+ = 468.0.
Example 26
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C26)
Step 1: N- ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine (26-1)
A solution of (21-1) (290 mg, 1.081 mmol, 1.0 eq) in POCl
3 (8 mL) was stirred at 110 ℃ for 5 hours. Then the mixture was concentrated and the residue was basified with NH
3-H
2O to pH 7~8. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 250mmx21.2mmx5um: 45-75%B (A= 0.5%NH
4OH in water, B = methanol) ) to give N- ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine (26-1) . MS: [M+H]
+ = 290.9.
Step 2: Ethyl 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxylate (26-2)
The title compound was prepared by using a procedure similar to that of in Step 1 of Example 8, and purified by column chromatography on silica gel (petroleum ether/EtOAc from 3/1 to 3/2) to give ethyl 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxylate (26-2) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.75 (d, J = 2.8 Hz, 1H) , 8.69 (d, J = 2.8 Hz, 1H) , 8.20 (t, J = 6.0 Hz, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.25 (q, J = 7.2 Hz, 2H) , 3.91 (br s, 1H) , 3.26 (t, J = 6.4 Hz, 2H) , 2.14-2.11 (m, 2H) , 1.84-1.81 (m, 2H) , 1.60 (br s, 1H) , 1.28 (t, J = 7.2 Hz, 3H) , 1.22-1.15 (m, 2H) , 1.12-1.06 (m, 2H) . MS: [M+H]
+ = 441.1.
Step 3: (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methanol (26-3)
To a solution of (26-2) (40 mg, 0.09 mmol, 1.0 eq) in THF (5 mL) was added dropwise DIBAL-H (0.45 mL, 0.45 mmol, 5.0 eq) at -78 ℃. The reaction mixture was stirred at 20 ℃ for 2 hours. Then the mixture was quenched with aqueous NH
4Cl (10 mL) , filtered and the filtrate was extracted three times with EtOAc (20 mL) . The organic layer was washed with brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methanol (26-3) . MS: [M+H]
+ = 399.1.
Step 4: 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbaldehyde (26-4)
To a solution of (26-3) (33 mg, 0.08 mmol, 1.0 eq) in CH
2Cl
2 (5 mL) was added MnO
2 (72 mg, 0.8 mmol, 10.0 eq) . The reaction mixture was stirred at 45 ℃ for 2 hours. Then filtered, the filtrate was concentrated to give 2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbaldehyde (26-4) . MS: [M+H]
+ = 397.2.
Step 5: 8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C26)
To a solution of (26-4) (50 mg, 0.126 mmol, 1.0 eq) in MeOH (3 mL) was added 1- (methylsulfonyl) piperazine (41 mg, 0.252 mmol, 2.0 eq) and NaBH
3CN (40 mg, 0.63 mmol, 5.0 eq) . The mixture was stirred at 25 ℃ for 4 hours. The reaction mixture was quenched with aqueous NaHCO
3 (10 mL) , extracted three times with CH
2Cl
2 (20 mL) . The organic layer was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by preparative HPLC (column: DuraShell 150mmx25mmx5um: 33-63%B (A=0.05%ammonia hydroxide in water, B = acetonitrile) ) to give 8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C26) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.16 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.22 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 3.90 (br s, 1H) , 3.32 (s, 2H) , 3.16 (t, J = 6.4 Hz, 2H) , 3.11-3.08 (m, 4H) , 2.86 (s, 3H) , 2.44-2.42 (m, 4H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.58 (br s, 1H) , 1.25-1.16 (m, 2H) , 1.13-1.04 (m, 2H) . MS: [M+H]
+ = 545.3.
The following compounds, as identified in Table 1, were prepared using the general procedures as well as the procedures from the examples described above with the appropriate starting materials and reagents.
Table 1
Example 34
(2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1, 3-dioxan-5-yl) methanol (C34)
To a solution of (26-4) (50 mg, 0.126 mmol, 1.0 eq) and CSA (1 mg, 0.005 mmol, 0.05 eq) in CH
2Cl
2 (3 mL) was added 2- (hydroxymethyl) propane-1, 3-diol (11 mg, 0.106 mmol, 0.84 eq) . The mixture was stirred at 30℃ for 2 hours. The reaction mixture was concentrated to give the crude product which was purified by preparative HPLC (column: DuraShell 150mmx25mmx5um: 38-68%B (A= 10 mM NH
4OH, B = acetonitrile) to give (2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1, 3-dioxan-5-yl) methanol (C34) .
1H NMR (400 MHz, DMSO-d
6) , cis/trans mixture: δ ppm 8.23 (d, J = 5.6 Hz, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.39-7.35 (m, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 5.42 (s, 0.5H) , 5.33 (s, 0.5H) , 4.71 (t, J = 5.2 Hz, 0.5H) , 4.60 (t, J = 5.2 Hz, 0.5H) , 4.12 (dd, J = 4.4 Hz, 7.6 Hz, 1H) , 4.06-4.03 (m, 1H) , 3.96-4.00 (m, 1H) , 3.92-3.88 (m, 1H) , 3.71 (dd, J = 5.2 Hz, 7.6 Hz, 1H) , 3.60 (t, J = 11.6 Hz, 1H) , 3.26 (t, J = 5.6 Hz, 1H) , 3.18 (t, J = 6.4 Hz, 2H) , 2.13-2.07 (m, 2.5H) , 1.84-1.81 (m, 2H) , 1.58-1.48 (m, 1.5H) , 1.25-1.16 (m, 2H) , 1.13-1.04 (m, 2H) . MS: [M+H]
+ = 485.2.
Example 35
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-yloxy) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C35)
Step 1: Oxetan-3-yl 4-methylbenzenesulfonate (35-1)
To a solution of oxetan-3-ol (300 mg, 4 mmol, 1.0 eq) in CH
2Cl
2 (10 mL) was added Et
3N (1.62 g, 16 mmol, 4.0 eq) and TsCl (1.52 g, 2 mmol, 2.0 eq) , the reaction mixture was stirred at 23-31℃ for 16 hours. The mixture was quenched with aqueous NaHCO
3 solution (20 mL) , extracted three times with CH
2Cl
2 (20 mL) , the organic layer was dried over Na
2SO
4, filtered and concentrated to give the crude product, which was purified by column chromatography on silica gel (petroleum ether/EtOAc from 50/1 to 10/1) to give oxetan-3-yl 4-methylbenzenesulfonate (35-1) .
1H NMR (400 MHz, CDCl
3) : δ ppm 7.78 (d, J = 8.4 Hz, 2H) , 7.36 (d, J = 8.0 Hz, 2H) , 5.32-5.26 (m, 1H) , 4.73-4.64 (m, 4H) , 2.45 (s, 3H) .
Step 2: 8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-yloxy) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C35)
To a solution of (26-3) (50 mg, 0.126 mmol, 1.0 eq) and (35-1) (29 mg, 0.126 mmol, 1.0 eq) in DMF (2 mL) was added NaH (60%in mineral oil, 6 mg, 0.15 mmol, 1.2 eq) at 0 ℃ in portions. The mixture was stirred at 25 ℃ for 4 hours. The reaction mixture was quenched with H
2O (20 mL) , extracted with EtOAc (3*20 mL) , the organic layer was dried over Na
2SO
4, filtered and concentrated to give the crude product, which was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 100mmx19mmx5um: 30-45%B (A= 0.05%NH
4OH in water, B = acetonitrile) ) to give 8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-yloxy) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C35) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.25 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.50 (t, J = 8.0 Hz, 1H) , 7.33 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 4.67-4.59 (m, 3H) , 4.40-4.38 (m, 2H) , 4.21 (s, 2H) , 3.90 (br s, 1H) , 3.18 (t, J = 6.4 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.81 (m, 2H) , 1.58 (br s, 1H) , 1.22-1.16 (m, 2H) , 1.13-1.07 (m, 2H) . MS: [M+H]
+ = 455.2.
Example 36
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (C36)
Step 1: Ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (36-1)
To a solution of (13-2) (43 g, 89.8 mmol, 1.0 eq) in EtOAc (20 mL) was added dropwise 4 N HC in EtOAc solution (40 mL) . The reaction mixture was stirred at 40 ℃ for 20 hours. Then EtOH (40 mL) was added to the above solution, and the mixture was stirred at 90℃ for 20 hours. Then the solution was concentrated to give ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (36-1) , which was used in the next step without further purification. MS: [M+H]
+ = 437.2.
Step 2: Ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (36-2)
A solution of (36-1) (45 g, 103.09 mmol, 1.0 eq) in POCl
3 (390 mL) was stirred at 110℃ for 1.5 hour. Then the mixture was concentrated under reduced pressure, the residue was diluted with ethyl acetate (450 mL) , then basified with aq. NaHCO
3 to pH 8-9 at 0 ℃, the organic layer was separated and the aqueous layer was extracted twice with ethyl acetate (400 mL) , the combined organic layer was washed with brine (400 mL) , dried over Na
2SO
4, filtered and concentrated under reduce pressure to give ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (36-2) . MS: [M+H]
+ = 455.2.
Step 3: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetic acid (36-3)
To a solution of (36-2) (40 g, 88.1 mmol, 1.0 eq) in MeOH (300 mL) and THF (300 mL) was added NaOH (17.6 g, 441 mmol, 5.0 eq) in H
2O (200 mL) . The mixture was stirred at 20℃ for 2 hours. Then the mixture was acidified with 2N HCl to pH 6-7, and extracted with CH
2Cl
2 (200 mL x 3) . The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetic acid (36-3) , which was used in the next step without further purification. MS: [M+H]
+ = 427.2.
Step 4: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (C36)
To a solution of (36-3) (40.9 g, 0.096 mol, 1.0 eq) in DMF (200 mL) and CH
2Cl
2 (400 mL) was added oxetan-3-amine (8.4 g, 0.115 mol, 1.2 eq) , HATU (54.7 g, 0.144 mol, 1.5 eq) and DIEA (37 g, 0.288 mol, 2.0 eq) . The mixture was stirred at 15 ℃ for 3 hours. Then the mixture was diluted with H
2O (300 mL) , extracted three times with CH
2Cl
2 (300 mL) , the organic layer was dried over Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (CH
2Cl
2/MeOH from 100/1 to 40/1) to give the crude compound, which was triturated with EtOAc, filtered and dried to afford 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide (C36) .
1H NMR (400MHz, DMSO-d
6) : δ ppm 8.79 (d, J = 6.4 Hz, 1H) , 8.12 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.13 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.79-4.73 (m, 1H) , 4.69 (t, J = 6.4 Hz, 2H) , 4.41 (t, J = 6.0 Hz, 2H) , 3.90 (br s, 1H) , 3.24 (s, 2H) , 3.15 (t, J = 6.4 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.24-1.12 (m, 2H) , 1.09-1.03 (m, 2H) . MS: [M+H]
+ = 482.2.
The following compounds, as identified in Table 2, were prepared using the general procedures as well as the procedures from the examples described above with the appropriate starting materials and reagents.
Table 2
Example 46
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethan-1-ol (C46)
Step 1: Isopropyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (46-1)
The title compound was prepared by using a procedure similar to that in Step 2 of Example 13, Intermediate (13-2) , with tert-butyl 2-bromoacetate being replaced with isopropyl 2-bromoacetate and the product purified by column chromatography on silica gel (petroleum ether/EtOAc from 3/1 to 1/2) to give isopropyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (46-1) .
1H NMR (400MHz, DMSO-d
6) : δ 8.14 (s, 2H) , 7.78 (d, J = 8.8 Hz, 1H) , 7.68 (d, J = 5.6 Hz, 1H) , 7.17 (t, J = 6.0 Hz, 1H) , 7.09 (d, J = 5.6 Hz, 1H) , 7.05 (d, J = 7.6 Hz, 1H) , 6.89 (d, J = 9.2 Hz, 1H) , 4.93-4.86 (m, 1H) , 3.95 (s, 3H) , 3.87 (br s, 1H) , 3.45 (s, 2H) , 3.15 (t, J = 6.0 Hz, 2H) , 2.04-2.01 (m, 2H) , 1.83-1.80 (m, 2H) , 1.56 (br s, 1H) , 1.20-1.03 (m, 10H) . MS: [M+H]
+ = 465.2.
Step 2: Isopropyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2 yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (46-2)
To a solution of (46-1) (720 mg, 1.55 mmol, 1.0 eq) in EtOAc (5 mL) was added HCl/EtOAc (10 mL, 4N) . The reaction mixture was stirred at 35 ℃ for 3 hours. The reaction mixture was concentrated under reduced pressure to isopropyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2 yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (46-2) , which was used without further purification. MS: [M+H]
+ = 451.2.
Step 3: Isopropyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (46-3)
A solution of compound (46-2) (850 mg, 1.88 mmol, 1.0 eq) in POCl
3 (10 mL) was stirred at 110 ℃ for 1.5 hours. Then the mixture was concentrated under reduced pressure. The crude product was dissolved in EtOAc (100 mL) and the organic phase was washed with saturated aqueous NaHCO
3 solution (50 mL) and brine (50 mL) , dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give isopropyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7- naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetate (46-3) , which was used without further purification. MS: [M+H]
+ = 469.2.
Step 4: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethan-1-ol (C46)
To a solution of (46-3) (310 mg, 0.66 mmol, 1.0 eq) in anhydrous THF (10 mL) was added dropwise DIBAL-H (3.3 mL, 3.30 mmol, 5.0 eq, 1.0 M in toluene) over 10 minutes under N
2 protection at -78℃. After the addition was completed, the reaction mixture was stirred at 19-22 ℃ for 2 hours. Then the reaction mixture was diluted with EtOAc (50 mL) , quenched with saturated aqueous NH
4Cl (3.5 mL) . After stirred for 30 minutes at 19-22 ℃, the mixture was filtered and the filtrate was washed with brine (30 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethan-1-ol (C46) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.12 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.03-6.99 (m, 2H) , 4.65 (t, J = 5.2 Hz, 1H) , 3.90 (br s, 1H) , 3.51 (dd, J = 12.0, 6.8 Hz, 2H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.49-2.47 (m, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.25-1.16 (m, 2H) , 1.12-1.06 (m, 2H) . MS: [M+H]
+ = 413.2.
Example 47
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- ( (3-methyloxetan-3-yl) amino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C47)
Step 1: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethyl methanesulfonate (47-1)
To a solution of compound (C46) (50 mg, 0.12 mmol, 1.0 eq) in anhydrous CH
2Cl
2 (5 mL) was added DIPEA (46.5 mg, 0.36 mmol, 3.0 eq) and MsCl (20.6 mg, 0.18 mmol, 1.5 eq) . The resulting mixture was stirred at 28-38 ℃ for 4 hours. Then the mixture was poured into water (60 mL) , extracted with CH
2Cl
2 (30 mL x 2) . The combined organic phase was washed with brine (30 mL) , dried over anhydrous Na
2SO
4, filtered and concentrated under reduced pressure to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2- yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethyl methanesulfonate (47-1) , which was used without further purification. MS: [M+H]
+ = 491.1.
Step 2: 8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- ( (3-methyloxetan-3-yl) amino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C47)
To a solution of (47-1) (65 mg, 0.13 mmol, 1.0 eq) in DMF (5 mL) was added 3-methyloxetan-3-amine (23 mg, 0.26 mmol, 2.0 eq) , K
2CO
3 (90 mg, 0.65 mmol, 5.0 eq) and NaI (97.4 mg, 0.65 mmol, 5.0 eq) . The reaction mixture was heated at 80 ℃ for 18 hours. Then the reaction mixture was cooled to room temperature, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: DuraShell 150mmx25mmx5um: 24-54%B (A= 0.05%NH
4OH in water, B = acetonitrile) ) to give Synthesis of 8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- ( (3-methyloxetan-3-yl) amino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C47) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.15 (s, 2H) , 7.96 (d, J = 4.8 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.02-6.99 (m, 2H) , 4.41 (d, J = 5.2 Hz, 2H) , 4.16 (d, J = 5.6 Hz, 2H) , 3.91 (br s, 1H) , 3.15 (t, J = 6.4 Hz, 2H) , 2.64 (t, J = 7.2 Hz, 2H) , 2.46 (t, J = 7.2 Hz, 2H) , 2.24 (br s, 1H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.33 (s, 3H) , 1.25-1.19 (m, 2H) , 1.12-1.03 (m, 2H) . MS: [M+H]
+ = 482.3.
Example 48
8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- (oxetan-3-ylamino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (C48)
The title compound was prepared by using a procedure similar to that of in Step 2 of Example 47, with 3-methyloxetan-3-amine being replaced with oxetan-3-amine.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.12 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.03-6.98 (m, 2H) , 4.60 (t, J = 6.4 Hz, 2H) , 4.31 (t, J = 6.0 Hz, 2H) , 3.88-3.85 (m, 2H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.60 (t, J = 7.2 Hz, 2H) , 2.44 (t, J = 7.2 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.19-1.16 (m, 2H) , 1.12-1.06 (m, 2H) . MS: [M+H]
+ = 468.2.
Example 49
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N- (oxetan-3-yl) acetamide (C49)
Step 1: 3- (oxetan-3-ylamino) propanenitrile (49-1)
To a solution of 3-aminopropanenitrile (280 mg, 4.00 mmol, 1.0 eq) in DCE (25 mL) was added oxetan-3-one (432.4 mg, 6.00 mmol, 1.5 eq) and AcOH (720.6 mg, 12.00 mmol, 3.0 eq) . After stirred for 10 minutes, NaB (OAc)
3H (2.54 g, 12.00 mmol, 3.0 eq) was added to the reaction mixture. The resulting mixture was stirred at 23-31 ℃ for 18 hours. Then the reaction mixture was diluted with CH
2Cl
2 (100 mL) , and the organic phase was washed with saturated aqueous NaHCO
3 solution (100 mL) and brine (50 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to 3- (oxetan-3-ylamino) propanenitrile (49-1) , which was used directly for next step.
Step 2: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N- (oxetan-3-yl) acetamide (C49)
To a solution of (36-5) (50 mg, 0.12 mmol, 1.0 eq) in DMF (5 mL) was added (49-1) (23 mg, 0.18 mmol, 1.5 eq) , DIPEA (77.5 mg, 0.60 mmol, 5.0 eq) and HATU (91 mg, 0.24 mmol, 2.0 eq) . The resulting mixture was stirred at 25-32 ℃ for 2 hours. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: DuraShell 150mmx25mmx5um: 29-39%B (A= 0.05%NH
4OH in water, B = acetonitrile) ) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N- (oxetan-3-yl) acetamide (C49) .
1H NMR (400 MHz, DMSO-d
6) , existed of ratomers: δ ppm 8.06 (d, J = 9.6 Hz, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.12 (t, J = 6.4 Hz, 1H) , 7.00 (d, J = 8.8 Hz, 1H) , 5.33-5.29 (m, 0.5H) , 4.84-4.80 (m, 0.5H) , 4.73-4.70 (m, 2H) , 4.61-4.59 (m, 2H) , 3.91 (br s, 1H) , 3.81-3.74 (m, 2H) , 3.61 (s, 1H) , 3.49 (s, 1H) , 3.16 (t, J = 6.0 Hz, 2H) , 2.84-2.78 (m, 2H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.58 (br s, 1H) , 1.25-1.16 (m, 2H) , 1.13-1.04 (m, 2H) . MS: [M+H]
+ = 535.2.
Example 50
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N-ethylacetamide (C50)
The title compound was prepared by using a procedure similar to that in Step 2 of Example 49, with 3- (oxetan-3-ylamino) propanenitrile (49-1) being replaced with 3- (ethylamino) propanenitrile .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.08 (d, J = 8.4 Hz, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 4.8 Hz, 1H) , 7.52 (d, J = 7.2 Hz, 1H) , 7.12 (t, J = 5.6 Hz, 1H) , 7.00 (d, J = 8.8 Hz, 1H) , 3.91 (br s, 1H) , 3.69 (t, J = 6.8 Hz, 1H) , 3.56-3.44 (m, 5H) , 3.15 (t, J = 6.0 Hz, 2H) , 2.87 (t, J = 6.8 Hz, 1H) , 2.72 (t, J = 6.8 Hz, 1H) , 2.14-2.11 (m, 2H) , 1.86-1.83 (m, 2H) , 1.58 (br s, 1H) , 1.25-1.19 (m, 2H) , 1.17-1.00 (m, 5H) . MS: [M+H]
+ = 507.4.
Example 51
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-hydroxyethyl) -N- (oxetan-3-yl) acetamide (C51)
The title compound was prepared by using a procedure similar to that in Step 2 of Example 49 with 3- (oxetan-3-ylamino) propanenitrile (49-1) being replaced with 2- (oxetan-3-ylamino) ethan-1-ol.
1H NMR (400 MHz, DMSO-d
6, T = 80 ℃) : δ ppm 8.09 (s, 2H) , 7.95 (d, J = 5.6 Hz, 1H) , 7.88 (d, J = 9.2 Hz, 1H) , 7.52 (d, J = 4.8 Hz, 1H) , 7.18 (d, J = 7.2 Hz, 1H) , 7.02 (d, J = 9.2 Hz, 1H) , 6.66 (t, J = 5.6 Hz, 1H) , 4.98 (br s, 1H) , 4.65-4.63 (m, 4H) , 3.89 (br s, 1H) , 3.57-3.52 (m, 6H) , 3.22 (t, J = 6.0 Hz, 2H) , 2.17-2.14 (m, 2H) , 1.89-1.86 (m, 2H) , 1.63 (br s, 1H) , 1.33-1.23 (m, 2H) , 1.19-1.09 (m, 2H) . MS: [M+H]
+ = 526.2.
Example 52
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (C52)
The title compound was prepared by using a procedure similar to that of Example 36, except (13-2) was replaced with
which was prepared by using a procedure similar to that in Step 2 of Example 13, with tert-butyl 2-bromoacetate being replaced with tert-butyl 2-bromopropanoate. The product was purified by preparative HPLC (column: DuraShell 150mmx25mmx5μm: 35-65%B (A= 0.5%NH
4OH in water, B = acetonitrile) ) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (C52) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.73 (d, J = 6.8 Hz, 1H) , 8.17 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.50 (d, J = 6.8 Hz, 1H) , 7.15 (t, J = 6.0 Hz, 1H) , 7.00 (d, J = 8.8 Hz, 1H) , 4.76-4.65 (m, 3H) , 4.41 (t, J = 6.0 Hz, 1H) , 4.35 (t, J = 6.0 Hz, 1H) , 3.91 (br s, 1H) , 3.41 (q, J = 6.8 Hz, 1H) , 3.15 (t, J = 6.0 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.29 (d, J = 7.2 Hz, 3H) , 1.25-1.16 (m, 2H) , 1.13-1.03 (m, 2H) . MS: [M+H]
+ = 496.2.
Example 53 and Example 54
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (C53) and
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide (C54)
Compound (C52) (32 mg, 0.0645 mmol) was separated by SFC (Chiralpak AD-3 100×4.6mm I.D., 3um; 40%of ethanol (0.05%DEA) in CO
2, Flow rate: 2.8 mL/min) to give Peak 1 (t
R = 3.61 min) and Peak 2 (t
R = 4.22 min) .
Peak 1 (C53 or C54) :
1H NMR (400 MHz, DMSO-d6) : δ ppm 8.74 (d, J = 6.4 Hz, 1H) , 8.17 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.55 (d, J = 5.6 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.15 (t, J = 5.6 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.77-4.65 (m, 3H) , 4.41 (t, J = 5.6 Hz, 1H) , 4.35 (t, J = 6.0 Hz, 1H) , 3.90 (br s, 1H) , 3.41 (q, J = 7.2 Hz, 1H) , 3.15 (t, J = 6.0 Hz, 2H) , 2.13-2.10 (m, 2H) , 1.84-1.81 (m, 2H) , 1.57 (br s, 1H) , 1.30 (d, J = 7.2 Hz, 3H) , 1.22-1.16 (m, 2H) , 1.12-1.06 (m, 2H) . MS: [M+H]
+ = 496.2.
Peak 2 (C53 or C54) :
1H NMR (400 MHz, DMSO-d6) : δ ppm 8.74 (d, J = 5.6 Hz, 1H) , 8.17 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.6 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.15 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 4.77-4.65 (m, 3H) , 4.41 (t, J = 5.6 Hz, 1H) , 4.35 (t, J = 5.6 Hz, 1H) , 3.90 (br s, 1H) , 3.41 (q, J = 7.2 Hz, 1H) , 3.15 (t, J = 6.0 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.30 (d, J = 7.2 Hz, 3H) , 1.21-1.16 (m, 2H) , 1.11-1.05 (m, 2H) . MS: [M+H]
+ = 496.2.
Example 55
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide (C55)
The title compound was prepared by using a procedure similar to that of Example 52, except in Step 4 of Example 36 oxetan-3-amine is replaced with N-methyloxetan-3-amine. The product was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150mmx30mmx5um: 22-52%B (A= NH
4OH 0.5%, B = acetonitrile) ) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide (C55) .
1H NMR (400 MHz, DMSO-d
6, T = 80 ℃) : δ ppm 8.16 (s, 2H) , 7.95 (d, J = 5.2 Hz, 1H) , 7.88 (d, J = 9.2 Hz, 1H) , 7.51 (d, J = 5.2 Hz, 1H) , 7.18 (d, J = 6.8 Hz, 1H) , 7.02 (d, J = 9.2 Hz, 1H) , 6.73 (t, J = 6.0 Hz, 1H) , 5.21-5.18 (m, 1H) , 4.69-4.67 (m, 1H) , 4.60-4.55 (m, 3H) , 3.95-3.89 (m, 2H) , 3.21 (t, J = 6.4 Hz, 2H) , 3.05 (s, 3H) , 2.16-2.14 (m, 2H) , 1.88-1.85 (m, 2H) , 1.56 (br s, 1H) , 1.33-1.26 (m, 5H) , 1.16-1.12 (m, 2H) . MS: [M+H]
+ = 510.2.
Example 56 and Example 57
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide (C56) and
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide (C57)
Compound (C55) was separated by SFC (Chiralpak AD-3 100×4.6mm I.D., 3um; 40%of ethanol (0.05%DEA) in CO
2; Flow rate: 2.8mL/min) to give Peak 1 (t
R = 3.61 min) and Peak 2 (t
R = 4.22 min) .
Peak 1 (C56 or C57) :
1H NMR (400 MHz, DMSO-d
6) , existed as rotamers: δ ppm 8.16 (s, 1.2H) , 8.12 (s, 0.8H) , 7.96 (d, J = 5.1 Hz, 1H) , 7.91 (d, J = 8.9 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.53 (d, J = 7.0 Hz, 1H) , 7.24 -7.17 (m, 1H) , 6.99 (d, J = 8.6 Hz, 1H) , 5.38-5.15 (m, 1H) , 4.78 -4.33 (m, 4H) , 3.96-3.88 (m, 2H) , 3.14 (t, J = 6.3 Hz, 2H) , 3.03 (s, 1.5H) , 3.02 (s, 1.5H) , 2.13-2.10 (m, 2H) , 1.84-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.26-1.03 (m, 7H) . MS: [M+H]
+ = 510.0.
Peak 2 (C56 or C57) :
1H NMR (400 MHz, DMSO-d
6) , existed as rotamers: δ ppm 8.16 (s, 1.3H) , 8.12 (s, 0.8H) , 7.96 (d, J = 5.1 Hz, 1H) , 7.91 (d, J = 8.9 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.53 (d, J = 7.1 Hz, 1H) , 7.24 -7.14 (m, 1H) , 6.99 (d, J = 8.6 Hz, 1H) , 5.34-5.15 (m, 1H) , 4.78 -4.33 (m, 4H) , 3.94-3.90 (m, 2H) , 3.15 (t, J = 6.2 Hz, 2H) , 3.03 (s, 1.5H) , 3.02 (s, 1.5H) , 2.13-2.11 (m, 2H) , 1.84-1.82 (m, 2H) , 1.56 (br s, 1H) , 1.26 -1.03 (m, 7H) . MS: [M+H]
+ = 510.0.
Example 58
N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidine-2-carboxamide (C58)
Step 1: 2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) isoindoline-1, 3-dione (58-1)
To a solution of (26-1) (75 mg, 0.26 mmol, 1.0 eq) in NMP (3 mL) was added DIEA (168 mg, 1.3 mmol, 5.0 eq) and 2- ( (2-chloropyrimidin-5-yl) methyl) isoindoline-1, 3-dione (78 mg, 0.28 mmol, 1.1 eq) . The reaction mixture was heated at 100 ℃ for 4 hours. The mixture was diluted with EtOAc (10 mL) and washed three times with brine (20 mL) . The organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated. The crude product was purified by column chromatography on silica gel (petroleum ether/EtOAc = 1/1) to give 2- ( (2- ( ( ( (1, 4-trans) -4- ( (8- chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) isoindoline-1, 3-dione (58-1) . MS: [M+H]
+ = 528.3.
Step 2: N- ( (1, 4-trans) -4- ( ( (5- (aminomethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine (58-2)
To a solution of (58-1) (100 mg, 0.185 mmol, 1.0 eq) in EtOH (4 mL) was added N
2H
2-H
2O (1 mL, 85%) . The reaction mixture was stirred at 25 ℃ for 1 hour. The mixture was lyophilized to give N- ( (1, 4-trans) -4- ( ( (5- (aminomethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine (58-2) .
Step 3: N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidine-2-carboxamide (C58)
To a solution of (58-2) (37 mg, 0.09 mmol, 1.0 eq) in DMF (3 mL) was added 1- (tert-butoxycarbonyl) azetidine-2-carboxylic acid (20 mg, 0.09 mmol, 1.0 eq) , DIEA (35 mg, 0.27 mmol, 3.0 eq) and HATU (89 mg, 0.27 mmol, 3.0 eq) . The resulting mixture was stirred at 25 ℃ for 1 hour. The mixture was diluted with EtOAc (50 mL) and washed three times with brine (30 mL) . The organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated. The residue was dissolved in Cl
2CH
2 (2 mL) and TFA (0.4 mL) . The mixture was stirred at 25 ℃ for 1.5 hours. The mixture was concentrated to give the crude product which was purified by preparative HPLC (column: Waters Xbridge 150mmx25mmx5um: 20-50%B (A= 10 mM NH
4HCO
3 in water, B = acetonitrile) ) to give N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidine-2-carboxamide (C58) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.30 (t, J = 6.0 Hz, 1H) , 8.18 (s, 2H) , 7.95 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.50 (d, J = 7.2 Hz, 1H) , 7.17 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.12-4.09 (m, 3H) , 3.90 (br s, 1H) , 3.52 (q, J = 8.0 Hz, 2H) , 3.17-3.14 (m, 2H) , 2.42-2.39 (m, 1H) , 2.14-2.07 (m, 3H) , 1.84-1.81 (m, 2H) , 1.57 (br s, 1H) , 1.22-1.09 (m, 4H) . MS: [M+H]
+ = 481.3.
Example 59
N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) oxetane-3-carboxamide (C59)
The title compound was prepared by using a procedure similar to that in Step 3 of Example 58, with 1- (tert-butoxycarbonyl) azetidine-2-carboxylic acid being replaced with oxetane-3-carboxylic acid.
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.27 (t, J = 5.2 Hz, 1H) , 8.17 (s, 2H) , 7.95 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.50 (d, J = 7.2 Hz, 1H) , 7.20 (t, J = 5.6 Hz, 1H) , 6.99 (d, J = 8.0 Hz, 1H) , 4.63-4.57 (m, 4H) , 4.07 (d, J = 5.2 Hz, 2H) , 3.89 (br s, 1H) , 3.76-3.69 (m, 1H) , 3.16 (t, J = 6.4 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.84-1.81 (m, 2H) , 1.57 (br s, 1H) , 1.24-1.03 (m, 4H) . MS: [M+H]
+ = 482.2.
Example 60
2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C60)
To a solution of compound (C21) (140 mg, 0.36 mmol, 1.0 eq) in THF (2 mL) was added t-BuONa (48 mg, 0.5 mmol, 1.4 eq) and Pd
2 (dba)
3 (33 mg, 0.036 mmol, 0.1 eq) , t-BuXphos (15 mg, 0.036 mmol, 0.1 eq) and MeNH
2 (2 mL, 2 M in THF) under N
2 protection. The mixture was stirred at 70 ℃ for 12 hours. The mixture was filtered and the filtrate was added to H
2O (20 mL) , and extracted twice with EtOAc (50 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (petroleum ether/EtOAc from 3/1 to EtOAc) to give 2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile (C60) which was re-purified by preparative HPLC (column: YMC-Actus Triart C18 150mmx30mmx5um, gradient: 50-80%B (A= 0.05%NH
4OH in water, B = acetonitrile) ) to give (C60) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.71 (d, J = 2.8 Hz, 1H) , 8.63 (d, J = 2.8 Hz, 1H) , 8.42 (t, J = 6.0 Hz, 1H) , 7.64 (d, J = 8.8 Hz, 1H) , 7.58 (d, J = 5.6 Hz, 1H) , 6.89 (d, J = 8.0 Hz, 1H) , 6.80 (d, J = 9.2 Hz, 1H) , 6.70 (d, J = 4.8 Hz, 1H) , 6.61 (d, J = 5.6 Hz, 1H) , 3.98 (br s, 1H) , 3.24 (t, J = 6.4 Hz, 2H) , 2.97 (d, J = 5.2 Hz, 3H) , 2.04-2.01 (m, 2H) , 1.79-1.77 (m, 2H) , 1.57 (br s, 1H) , 1.23-1.09 (m, 4H) . MS: [M+H]
+ = 389.2.
Example 61
2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (C61)
The title compound was prepared by using a procedure similar to that of Example 5, except Compound (C4) was replaced with Compound (C60) and the product was purified by preparative HPLC (column: YMC-Actus Triart C18 150mmx30mmx5um, gradient: 38-68%B (A = 0.05%NH
4OH in water, B = acetonitrile) ) to give 2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide (C61) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.72 (s, 1H) , 8.68 (s, 1H) , 7.84 (t, J = 6.0 Hz, 1H) , 7.78 (br s, 1H) , 7.64 (d, J = 9.2 Hz, 1H) , 7.58 (d, J = 5.6 Hz, 1H) , 7.22 (br s, 1H) , 6.89 (d, J = 8.0 Hz, 1H) , 6.70 (q, J = 5.2 Hz, 1H) , 6.61 (d, J = 5.6 Hz, 1H) , 3.99 (br s, 1H) , 3.24 (t, J = 6.4 Hz, 2H) , 2.98 (d, J = 4.8 Hz, 3H) , 2.04-2.02 (m, 2H) , 1.81-1.78 (m, 2H) , 1.57 (br s, 1H) , 1.24-1.10 (m, 4H) . MS: [M+H]
+ = 407.2.
Example 62
N
2- ( (1, 4-trans) -4- ( ( (5-aminopyrimidin-2-yl) amino) methyl) cyclohexyl) -N
8-methyl-1, 7-naphthyridine-2, 8-diamine (C62)
Step 1: N
8-methyl-N
2- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridine-2, 8-diamine (62-1)
The title compound was prepared by using a procedure similar to that of Example 60, except Compound (C21) was replaced with (14-1) The product was purified by column chromatography (petroleum ether/EtOAc from 1/1 to 0/1) to give N
8-methyl-N
2- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridine-2, 8-diamine (62-1) .
1H NMR (400 MHz, CDCl
3) : δ ppm 9.11 (d, J = 3.2 Hz, 1H) , 9.03 (d, J = 3.2 Hz, 1H) , 7.78 (d, J = 6.0 Hz, 1H) , 7.65 (d, J = 8.8 Hz, 1H) , 6.69 (t, J = 6.0 Hz, 1H) , 6.55 (br s, 1H) , 6.09 (br s, 1H) , 4.60 (d, J = 6.0 Hz, 1H) , 3.88 (br s, 1H) , 3.49 (t, J = 6.4 Hz, 2H) , 3.24 (d, J = 4.8 Hz, 3H) , 2.23-2.21 (m, 2H) , 1.95-1.93 (m, 2H) , 1.26-1.23 (m, 5H) . MS: [M+H]
+ = 409.1.
Step 2: N
2- ( (1, 4-trans) -4- ( ( (5-aminopyrimidin-2-yl) amino) methyl) cyclohexyl) -N
8-methyl-1, 7-naphthyridine-2, 8-diamine (C62)
To a solution of (62-1) (50 mg, 0.12 mmol, 1.0 eq) in CH
3OH (10 mL) was added Pd/C (10%, 10 mg) . The suspension was degassed and then purged with H
2 several times. The mixture was stirred under H
2 balloon at 30 ℃ for 1 hour. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mm*x5um, gradient: 29-49%B (A= 0.05%NH
4HCO
3 in water, B = acetonitrile) ) to give N
2- ( (1, 4-trans) -4- ( ( (5-aminopyrimidin-2-yl) amino) methyl) cyclohexyl) -N
8-methyl-1, 7-naphthyridine-2, 8-diamine (C62) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 7.79 (s, 2H) , 7.64 (d, J = 8.8 Hz, 1H) , 7.58 (d, J = 5.6 Hz, 1H) , 6.88 (d, J = 8.0 Hz, 1H) , 6.80 (d, J = 9.2 Hz, 1H) , 6.68 (q, J = 4.8 Hz, 1H) , 6.61 (d, J = 5.6 Hz, 1H) , 6.22 (t, J = 6.4 Hz, 1H) , 4.36 (s, 2H) , 3.97 (br s, 1H) , 3.08 (t, J = 6.4 Hz, 2H) , 2.98 (d, J = 4.8 Hz, 3H) , 2.02 (br s, 2H) , 1.79 (br s, 2H) , 1.53 (br s, 1H) , 1.19-1.08 (m, 4H) . MS: [M+H]
+ = 379.2.
Example 63
N- (2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide (C63)
The title compound was prepared by using a procedure similar to that of intermediate (2-1) , except Compound (C1) was replaced with Compound (C62) and the product was purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mmx5um, gradient: 24-44%B (A= 0.05%NH
4CO
3 in water, B = acetonitrile) ) to give N- (2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide (C63) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.72 (s, 1H) , 8.36 (s, 2H) , 7.64 (d, J = 8.8 Hz, 1H) , 7.57 (d, J = 5.6 Hz, 1H) , 7.09 (t, J = 6.0 Hz, 1H) , 6.89 (d, J = 7.6 Hz, 1H) , 6.80 (d, J = 8.8 Hz, 1H) , 6.71 (d, J = 4.8 Hz, 1H) , 6.61 (d, J = 5.6 Hz, 1H) , 3.98 (br s, 1H) , 3.15 (t, J = 6.4 Hz, 2H) , 2.98 (d, J = 4.8 Hz, 3H) , 2.03-2.01 (m, 2H) , 2.00 (s, 3H) , 1.79 (br s, 2H) , 1.55 (br s, 1H) , 1.21-1.09 (m, 4H) . MS: [M+H]
+ = 421.2.
Example 64
3- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (C64)
Step 1: N- ( (1, 4-trans) -4- ( ( (5-bromopyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (64-1)
To a solution of (1-8) (518 mg, 1.81 mmol, 1.0 eq) in DMA (5 mL) was added 5-bromo-2-chloropyrimidine (454 mg, 2.35 mmol, 1.3 eq) and DIPEA (1167 mg, 9.05 mmol, 5.0 eq) and the mixture was stirred at 100 ℃ for 8 hour. The mixture was diluted with EtOAc (50 mL) and washed twice with brine (30 mL) . The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography on silica gel (petroleum ether/EtOAc from 2/1 to 1/1) to give N- ( (1, 4-trans) -4- ( ( (5-bromopyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine (64-1) . MS: [M+H]
+ = 443.1/445.1.
Step 2: 3- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (64-2)
To a solution of (64-1) (100 mg, 0.23 mmol, 1.0 eq) in dioxane (2.5 mL) was added oxazolidin-2-one (98 mg, 1.13 mmol, 5.0 eq) and (1S, 2S) -cyclohexane-1, 2-diamine (26 mg, 0.23 mmol, 1.0 eq) , CuI (13 mg, 0.07 mmol, 0.3 eq) and K
2CO
3 (63 mg, 0.46 mmol, 2.0 eq) . The reaction mixture was stirred at 120 ℃ for 2 hours under microwave irradiation. The mixture was filtered and the filtrate was concentrated. The crude product was purified by column chromatography on silica gel (petroleum ether/EtOAc from 1/1 to 0/100) to give 3- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (64-2) .
1H NMR (400 MHz, CDCl
3) : δ ppm 8.45 (s, 2H) , 7.81-7.78 (m, 2H) , 7.02 (d, J = 5.6 Hz, 1H) , 6.84 (d, J = 8.8 Hz, 1H) , 5.26 (t, J = 6.0 Hz, 1H) , 5.09 (br s, 1H) , 4.52 (t, J = 8.4 Hz, 2H) , 4.14 (s, 3H) , 3.98 (t, J = 8.0 Hz, 2H) , 3.69-3.56 (m, 1H) , 3.32 (t, J = 6.4 Hz, 2H) , 2.19-2.17 (m, 2H) , 1.94-1.92 (m, 2H) , 1.60 (br s, 1H) , 1.27-1.17 (m, 4H) . MS: [M+H]
+ = 450.1.
Step 3: 3- (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (64-3)
To a solution of (64-2) (80 mg, 0.178 mmol, 1.0 eq) in EtOAc (5 mL) was added HCl/EtOAc (10 mL, 4N) and the mixture was stirred at 35 ℃ for 2.5 hours, then concentrated to give 3- (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (64-3) . MS: [M+H]
+ = 436.3.
Step 4: 3- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (C64)
A solution of (64-3) (75 mg, 0.17 mmol, 1.0 eq) in POCl
3 (5 mL) was stirred at 110℃ for 1.5 hours. The reaction mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: DuraShell 150*25mm*5um, gradient: 34-64%B (A= 0.5%NH
4HCO
3 in water, B = acetonitrile) ) to give 3- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one (C64) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.42 (s, 2H) , 7.95 (d, J = 4.8 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.31 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.45-4.41 (m, 2H) , 3.97 (t, J = 8.0 Hz, 2H) , 3.91 (br s, 1H) , 3.17 (t, J = 6.4 Hz, 2H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.58 (br s, 1H) , 1.25-1.04 (m, 4H) . MS: [M+H]
+ = 454.1.
Example 65
Methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate (C65)
Step 1: N
2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) -N
5-methylpyrimidine-2, 5-diamine (65-1)
The title compound was prepared by using a procedure similar to that of Example 60, except Compound (C21) was replaced with (64-1) and the product was purified by column chromatography (petroleum ether/EtOAc from 1/1 to 0/100) to give N
2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) -N
5-methylpyrimidine-2, 5-diamine (65-1) .
1H NMR (400 MHz, CDCl
3) : δ ppm 7.87 (s, 2H) , 7.80-7.78 (m, 2H) , 7.02 (d, J = 5.6 Hz, 1H) , 6.84 (d, J = 9.2 Hz, 1H) , 5.11 (br s, 1H) , 4.76 (t, J = 5.6 Hz, 1H) , 4.14 (s, 3H) , 3.79-3.52 (m, 1H) , 3.27 (t, J = 6.4 Hz, 2H) , 2.81 (s, 3H) , 2.18-2.16 (m, 2H) , 1.96-1.93 (m, 2H) , 1.50 (br s, 1H) , 1.27-1.16 (m, 4H) . MS: [M+H]
+ = 394.1.
Step 2: Methyl (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate (65-2)
To a solution of (65-1) (130 mg, 0.33 mmol, 1.0 eq) in Cl
2CH
2 (5 mL) was added CDI (430 mg, 2.64 mmol, 8.0 eq) and DIPEA (426 mg, 2.64 mmol, 8.0 eq) . The mixture was stirred at 40 ℃ for 1.5 hours. Then CH
3OH (10 mL) was added and stirred at 50 ℃ for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was dissolved with EtOAc (50 mL) and washed three times with brine (30 mL) . The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography on silica gel (petroleum ether/EtOAc from 1/1 to 0/100) to give methyl (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate (65-2) .
1H NMR (400 MHz, CDCl
3) : δ ppm 8.15 (br s, 2H) , 7.81-7.78 (m, 2H) , 7.02 (d, J = 5.6 Hz, 1H) , 6.84 (d, J = 9.2 Hz, 1H) , 5.29 (br s, 1H) , 5.07 (br s, 1H) , 4.14 (s, 3H) , 3.82-3.52 (m, 4H) , 3.32 (t, J = 6.4 Hz, 2H) , 3.24 (s, 3H) , 2.20-2.17 (m, 2H) , 1.96-1.93 (m, 2H) , 1.66 (br s, 1H) , 1.27-1.21 (m, 4H) . MS: [M+H]
+ = 452.2.
Step 3: Methyl (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate (65-3)
The title compound was prepared by using a procedure similar to that of (64-3) , except (64-2) was replaced with (65-2) . MS: [M+H]
+ = 438.2.
Step 3: methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate (C65)
The title compound was prepared by using a procedure similar to that of in Step 4 of Example 64, except (64-3) was replaced with (65-3) . The product was purified by preparative HPLC (column: DuraShell 150mmx25mmx5μm, gradient: 35-65%B (A= 0.05%ammonia hydroxide in water, B = acetonitrile) ) to give methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate (C65) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.22 (s, 2H) , 7.95 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.38 (br s, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 3.91 (br s, 1H) , 3.56 (br s, 3H) , 3.17-3.14 (m, 5H) , 2.14-2.11 (m, 2H) , 1.86-1.83 (m, 2H) , 1.59 (br s, 1H) , 1.26-1.04 (m, 4H) . MS: [M+H]
+ = 456.2.
Example 66
N
2- ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C66)
Step 1: 2-chloro-8- (difluoromethoxy) -1, 7-naphthyridine (66-1)
To a solution of (1-6) (300 mg, 1.66 mmol, 1.0 eq) in CH
3CN (70 mL) was added ClCF
2COONa (303 mg, 1.99 mmol, 1.2 eq) . The mixture was stirred at 90 ℃ for 15 hours. The mixture was added saturated aqueous NH
4Cl solution (30 mL) and extracted twice with EtOAc (50 mL) . The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (petroleum ether/EtOAc = 3/1) to give 2-chloro-8- (difluoromethoxy) -1, 7-naphthyridine (66-1) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.55 (d, J = 8.8 Hz, 1H) , 8.24 (d, J = 5.6 Hz, 1H) , 7.96 (t, J = 72 Hz, 1H) , 7.94 (d, J = 4.0 Hz, 1H) , 7.81 (d, J = 5.6 Hz, 1H) . MS: [M+H]
+ = 230.8.
Step 2: tert-butyl ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) carbamate (66-2)
The title compound was prepared using a procedure similar to that in Step 7 of Example 1, (1-6) being replaced with (66-1) and the product was purified by column chromatography (petroleum ether/EtOAc from 5/1 to 3/1) to give tert-butyl ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) carbamate (66-2) . MS: [M+H]
+ = 423.1.
Step 3: N- ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) -8- (difluoromethoxy) -1, 7-naphthyridin-2-amine (66-3)
To a solution of (66-2) (160 mg, 0.38 mmol, 1.0 eq) in CH
2Cl
2 (5 mL) was added TFA (1 mL) and the mixture was stirred at 15 ℃ for 2 hours. The mixture was concentrated to give N- ( (1, 4-trans) -4- (aminomethyl) cyclohexyl) -8- (difluoromethoxy) -1, 7-naphthyridin-2-amine (66-3) , which was used without further purification. MS: [M+H]
+ = 323.1.
Step 4: 8- (difluoromethoxy) -N- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (66-4)
The title compound was prepared by using a procedure similar to that in Step 9 of Example 1, with (1-8) being replaced with (66-3) and the product was purified by column chromatography (petroleum ether/EtOAc from 3/1 to 1/1) to give 8- (difluoromethoxy) -N- ( (1, 4-trans) -4- ( ( (5-nitropyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine (66-4) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.10 (d, J = 3.2 Hz, 1H) , 9.02 (d, J = 3.2 Hz, 1H) , 8.91 (t, J = 5.6 Hz, 1H) , 7.89 (d, J = 8.8 Hz, 1H) , 7.79 (t, J = 73.2 Hz, 1H) , 7.76 (d, J = 4.8 Hz, 1H) , 7.41-7.36 (m, 2H) , 6.99 (d, J = 8.4 Hz, 1H) , 3.87 (br s, 1H) , 3.31 (t, J = 6.4 Hz, 2H) , 2.08-2.06 (m, 2H) , 1.83-1.80 (m, 2H) , 1.62 (br s, 1H) , 1.22-1.11 (m, 4H) . MS: [M+H]
+ = 446.2.
Step 4: N
2- ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C66)
To a solution of (66-4) (100 mg, 0.22 mmol, 1.0 eq) in CH
3OH (20 mL) and EtOAc (20 mL) was added Pd/C (10%, 80 mg) . The suspension was degassed under vacuum and purged with H
2 several times. The mixture was stirred under H
2 balloon at 15 ℃ for 1.5 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Phenomenex Gemini C18 200mmx25mmx5um, gradient: 29-39%B (A= 0.5%NH
4HCO
3 in water, B = acetonitrile) ) to give N
2- ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine (C66) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 7.89 (d, J = 8.8 Hz, 1H) , 7.80 (t, J = 73.6 Hz, 1H) , 7.79 (s, 2H) , 7.75 (d, J = 5.2 Hz, 1H) , 7.40 (d, J = 5.2 Hz, 1H) , 7.36 (d, J = 7.6 Hz, 1H) , 6.99 (d, J = 8.4 Hz, 1H) , 4.37 (s, 2H) , 3.86 (br s, 1H) , 3.06 (t, J = 6.4 Hz, 2H) , 2.06-2.04 (m, 2H) , 1.83-1.81 (m, 2H) , 1.52 (br s, 1H) , 1.22-1.00 (m, 4H) .
19F NMR (400 MHz, DMSO-d
6) : δ ppm -86.34, -86.50. MS: [M+H]
+ = 416.1.
Example 67
N- ( (1, 4-trans) -4- ( ( (5- (4H-1, 2, 4-triazol-3-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine (C67)
The solution of compound (C12) (100 mg, 0.23 mmol, 1.0 eq) in POCl
3 (10 g) was heated at 110 ℃ for 5 hours. Then POCl
3 was removed under vacuum and the residue was basified by addition of ammonia. The reaction mixture was extracted twice with EtOAc (50 mL) and the organic solvent was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Waters XSELECT C18 150mmx30mmx5μm, gradient: 22-37%B (A= 0.05%NH
3H
2O in water, B = acetonitrile) ) to give N- ( (1, 4-trans) -4- ( ( (5- (4H-1, 2, 4-triazol-3-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine (C67) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 13.91 (br s, 1H) , 8.81 (s, 2H) , 8.39 (br s, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.2 Hz, 1H) , 7.69-7.66 (m, 1H) , 7.56 (d, J = 5.6 Hz, 1H) , 7.52 (d, J = 7.6 Hz, 1H) , 7.00 (d, J = 9.2 Hz, 1H) , 3.91 (br s, 1H) , 3.24 (t, J = 6.0 Hz, 2H) , 2.15-2.13 (m, 2H) , 1.87-1.84 (m, 2H) , 1.58 (br s, 1H) , 1.24-1.10 (m, 4H) . MS: [M+H]
+ = 436.2.
Example 68
2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propan-1-ol (C68)
Step 1: Ethyl 2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-hydroxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propanoate (68-1)
The title compound was prepared by using a procedure similar to that of Step 9 in Example 1, by replacing 2-chloro-5-nitropyrimidine with ethyl 2- ( (2-chloropyrimidin-5-yl) oxy) propanoate. MS: [M+H]
+ = 467.0.
Step 2: Ethyl 2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propanoate (68-2)
The title compound was prepared by using a procedure similar to that of Example 67, except Compound (C12) was replaced with (68-1) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.09 (s, 2H) , 7.97 (d, J = 5.3 Hz, 1H) , 7.92 (d, J = 9.0 Hz, 1H) , 7.56 (d, J = 5.3 Hz, 1H) , 7.53 (d, J = 7.0 Hz, 1H) , 7.00 (d, J = 6.0 Hz, 2H) , 4.83 (q, J = 6.8 Hz, 1H) , 4.14 (qd, J = 7.1, 2.3 Hz, 2H) , 3.44-3.42 (m, 1H) , 3.12 (t, J = 6.3 Hz, 2H) , 2.12 (d, J = 11.0 Hz, 2H) , 1.83 (d, J = 11.8 Hz, 2H) , 1.61-1.53 (m, 1H) , 1.48 (d, J = 6.8 Hz, 3H) , 1.25-1.16 (m, 5H) , 1.13-1.02 (m, 2H) . MS: [M+H]
+ = 485.0.
Step 3: 2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propan-1-ol (C68)
To a solution of (68-2) (18 mg, 0.037 mmol) in EtOH (2 mL) was added NaBH
4 (42.1 mg, 1.113 mmol) . The mixture was stirred at 0 ℃ for 10 min, then at rt for 4 h. The mixture was purified by preparative HPLC to give 2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propan-1-ol (C68) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.09 (s, 2H) , 7.96 (d, J = 5.3 Hz, 1H) , 7.92 (d, J = 9.0 Hz, 1H) , 7.56 (d, J = 5.3 Hz, 1H) , 7.53 (d, J = 7.3 Hz, 1H) , 7.00 (d, J = 8.5 Hz, 1H) , 6.89 (t, J = 5.8 Hz, 1H) , 4.20-4.11 (m, 1H) , 3.95 (br s, 1H) , 3.57-3.25 (m, 2H) , 3.12 (t, J = 6.4 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.25-1.06 (m, 7H) . MS: [M+H]
+ = 443.0.
Example 69
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one (C69)
The title compound was prepared by using a procedure similar to that of Example 52, with oxetan-3-amine being replaced with azetidin-3-ol.
1H NMR (400 MHz, DMSO-d
6) , existed of ratomer: δ ppm 8.17 (s, 1H) , 8.16 (s, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 9.1 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.0 Hz, 1H) , 7.21-7.13 (m, 1H) , 7.00 (d, J = 9.2 Hz, 1H) , 5.71 (d, J = 6.2 Hz, 0.5H) , 5.67 (d, J = 6.3 Hz, 0.5H) , 4.49-4.33 (m, 1.5H) , 4.24 (t, J = 7.6 Hz, 0.5H) , 4.07-3.82 (m, 2.5H) , 3.74 (d, J = 5.1 Hz, 0.5H) , 3.62-3.55 (m, 0.5H) , 3.50 (q, J = 7.1 Hz, 1.5) , 3.15 (br s, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.26-1.07 (m, 7H) . MS: [M+H]
+ = 496.2.
Example 70 and Example 71
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one (C70) and
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one (C71)
Racemic compound (C69) was separated by SFC (Chiralpak AD-3 50*4.6mm I.D., 3um; 40% of iso-propanol (0.05%DEA) in CO
2; Flow rate: 4mL/min; 40 ℃) to give Peak 1 (t
R = 0.57 min) and Peak 2 (t
R = 1.04 min) .
Peak 1 (C70 or C71) :
1H NMR (400 MHz, DMSO-d
6) , existed as rotamers: δ ppm 8.17 (s, 1H) , 8.16 (s, 1H) , 7.96 (d, J = 5.1 Hz, 1H) , 7.91 (d, J = 8.9 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.1 Hz, 1H) , 7.19 (q, J = 6.7 Hz, 1H) , 7.00 (d, J = 8.7 Hz, 1H) , 5.68 (br s, 1H) , 4.50-4.34 (m, 1.5H) , 4.24 (t, J = 7.8 Hz, 0.5H) , 4.08-3.82 (m, 2.5H) , 3.75 (d, J = 4.9 Hz, 0.5H) , 3.63-3.56 (m, 0.5H) , 3.50 (q, J = 6.9 Hz, 1.5H) , 3.15 (br s, 2H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.58 (br s, 1H) , 1.26-1.04 (m, 7H) . MS: [M+H]
+ = 496.2.
Peak 2 (C70 or C71) : 1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.19 (s, 1H) , 8.18 (s, 1H) , 7.96 (d, J = 5.1 Hz, 1H) , 7.91 (d, J = 8.9 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.52 (d, J = 7.1 Hz, 1H) , 7.29-7.19 (m, 1H) , 7.00 (d, J = 9.0 Hz, 1H) , 5.71 (br s, 1H) , 4.48-4.35 (m, 1.5H) , 4.25 (t, J = 7.9 Hz, 0.5H) , 4.08-3.93 (m, 2.5H) , 3.78-3.72 (m, 0.5H) , 3.58 (dd, J = 10.1, 4.4 Hz, 0.5H) , 3.55-3.47 (m, 1.5H) , 3.16 (br s, 2H) , 2.14-2.11 (m, 2H) , 1.85-1.82 (m, 2H) , 1.57 (br s, 1H) , 1.28-1.04 (m, 7H) . MS: [M+H]
+ = 496.2.
Example 72
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide (C72)
To a solution of Compound (C36) (200 mg, 0.207 mmol, 1.0 eq) in DMF (5 mL) was added K
2CO
3 (172 mg, 0.621 mmol, 3.0 eq) and paraformaldehyde (24 mg, 0.414 mmol, 2.0 eq) . The mixture was stirred at 30 ℃ for 4 hours, then diluted with H
2O (20 mL) , extracted three times with CH
2Cl
2 (20 mL) , the organic layer was dried over Na
2SO
4, filtered and concentrated to give the residue which was purified by column chromatography on silica gel (CH
2Cl
2/MeOH from 100/1 to 20/1) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide (C72) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.80 (d, J = 6.4 Hz, 1H) , 8.15 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.16 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 4.88 (t, J = 5.2 Hz, 1H) , 4.79-4.65 (m, 3H) , 4.41 (t, J = 6.0 Hz, 1H) , 4.34 (t, J = 6.0 Hz, 1H) , 3.90-3.89 (m, 1H) , 3.86-3.80 (m, 1H) , 3.53-3.47 (m, 1H) , 3.41-3.37 (m, 1H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.13-2.10 (m, 2H) , 1.84-1.81 (m, 2H) , 1.56 (br s, 1H) , 1.24-1.16 (m, 2H) , 1.12-1.03 (m, 2H) . MS: [M+H]
+ = 512.1.
Example 73 and Example 74
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide (C73) and
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide (C74)
Racemic compound Example 72 was separated by SFC (Chiralpak AS-H, 150*4.6mm I.D., 5um; Mobile phase: A: CO
2 B: ethanol (0.05%DEA) ; Gradient: hold 5%for 0.5 min, then from 5%to 40%of B in 3.5 min and hold 40%for 2.5 min, then 5%of B for 1.5 min; Flow rate: 3mL/min Column temp: 40 ℃) to give Peak 1 (t
R = 4.56 min) and Peak 2 (t
R = 5.05 min) .
Peak 1 (C73 or C74) :
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.80 (d, J = 6.4 Hz, 1H) , 8.15 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.17 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.88 (t, J = 5.2 Hz, 1H) , 4.77-4.65 (m, 3H) , 4.41 (t, J = 6.0 Hz, 1H) , 4.34 (t, J = 6.0 Hz, 1H) , 3.90-3.89 (m, 1H) , 3.86-3.82 (m, 1H) , 3.51-3.47 (m, 1H) , 3.41-3.33 (m, 1H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.13-2.10 (m, 2H) , 1.84-1.81 (m, 2H) , 1.56 (br s, 1H) , 1.22-1.16 (m, 2H) , 1.12-1.03 (m, 2H) . MS: [M+H]
+ = 512.1.
Peak 2 (C73 or C74) :
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.80 (d, J = 6.4 Hz, 1H) , 8.15 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.55 (d, J = 4.8 Hz, 1H) , 7.51 (d, J = 7.2 Hz, 1H) , 7.17 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 4.88 (t, J = 5.2 Hz, 1H) , 4.77-4.65 (m, 3H) , 4.41 (t, J = 6.0 Hz, 1H) , 4.34 (t, J = 6.0 Hz, 1H) , 3.90 (br s, 1H) , 3.86-3.80 (m, 1H) , 3.51-3.47 (m, 1H) , 3.41-3.37 (m, 1H) , 3.14 (t, J = 6.4 Hz, 2H) , 2.13-2.10 (m, 2H) , 1.84-1.81 (m, 2H) , 1.56 (br s, 1H) , 1.22-1.16 (m, 2H) , 1.12-1.03 (m, 2H) . MS: [M+H]
+ = 512.1.
Example 75 and Example 76
(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide (C75) and
(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide (C76)
Step 1: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-oxoacetic acid (75-1)
To a solution of compound (C36) (212 mg, 0.44 mmol, 1.0 eq) in anisole (15 mL) was added SeO
2 (195.3 mg, 1.76 mmol, 4.0 eq) . The reaction mixture was heated to 125 ℃ for 3 hours. Then the mixture was cooled to room temperature, filtered and washed with CH
2Cl
2/MeOH (100 mL, 10/1) . The filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC (column: Xtimate C18 150mmx25mmx5um, gradient: 21-51%B (A = 0.05%ammonia in water, B = acetonitrile) ) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-oxoacetic acid (75-1) . MS: [M+H]
+ = 441.0.
Step 2: Ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-oxoacetate (75-2)
To a solution of (75-1) (120 mg, 0.27 mmol) in anhydrous EtOH (10 mL) was added SOCl
2 (161 mg, 1.35 mmol) . The reaction mixture was stirred at 1-9 ℃ for 24 hours under N
2 protection. Then the reaction mixture was diluted with ice/H
2O (30 mL) , basified with saturated aqueous NaHCO
3 to pH 8-9, then extracted with CH
2Cl
2 (3*50 mL) . The combined organic layers were washed with brine (30 mL) , dried over anhydrous Na
2SO
4, filtered and concentrated under reduced pressure to give ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-oxoacetate (75-2) . MS: [M+H]
+ = 469.1.
Step 3: Ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxyacetate (75-3)
To a solution of (75-2) (132 mg, 0.28 mmol, 1.0 eq) in anhydrous MeOH (12 mL) was added NaBH
4 (10.6 mg, 0.28 mmol, 1.0 eq) at 0 ℃ under N
2 protection. The reaction mixture was stirred at this temperature for 10 minutes. Then the reaction mixture was quench with H
2O (5 mL) , diluted with brine (30 mL) , extracted three times with CH
2Cl
2 (50 mL) . The combined organic layers were dried over anhydrous Na
2SO
4, filtered and concentrated under reduced pressure to give the crude compound, which was purified by column chromatography on silica gel (CH
2Cl
2/MeOH from 50/1 to 20/1) to afford ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxyacetate (75-3) .
1H NMR (400 MHz, CDCl
3) : δ ppm 8.32 (s, 2H) , 8.05 (d, J = 5.2 Hz, 1H) , 7.77 (d, J = 9.2 Hz, 1H) , 7.34 (d, J = 5.2 Hz, 1H) , 6.81 (d, J = 8.8 Hz, 1H) , 5.41-5.40 (m, 1H) , 5.03 (s, 1H) , 4.32-4.20 (m, 2H) , 3.51-3.49 (m, 1H) , 3.35 (t, J = 6.4 Hz, 2H) , 2.27 (br s, 2H) , 1.96-1.94 (m, 2H) , 1.66-1.65 (m, 1H) , 1.30-1.27 (m, 3H) , 1.24-1.21 (m, 4H) . MS: [M+H]
+ = 471.2.
Step 4: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide (75-4)
A mixture of (75-3) (35 mg, 0.074 mmol, 1.0 eq) in oxetan-3-amine (0.5 mL) was heated to 65 ℃ for 16 hours. Then the mixture was cooled to room temperature and purified by prep-HPLC (column: Xtimate C18 150*25mm*5um, gradient: 24-54%B (A= water/0.05%ammonia hydroxide, B = acetonitrile) ) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide (75-4) . MS: [M+H]
+ = 498.1.
Step 4: (S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide (C75) and (R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) -amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide (C76)
(75-4) was purified by SFC separation (Chiralpak AD-3 50*4.6mm I.D., 3um; Mobile phase: 40%of ethanol (0.05%DEA) in CO
2; Flow rate: 4mL/min; Column temp: 40 ℃) to give Peak 1 (t
R = 1.40 min) and Peak 2 (t
R = 4.80 min) .
Peak 1 (C75 or C76) :
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.77 (d, J = 6.4 Hz, 1H) , 8.22 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.27 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 8.4 Hz, 1H) , 6.15 (d, J = 4.8 Hz, 1H) , 4.84-4.78 (m, 2H) , 4.67-4.65 (m, 2H) , 4.55-4.52 (m, 2H) , 3.90 (br s, 1H) , 3.16 (t, J = 6.0 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.85-1.81 (m, 2H) , 1.57 (br s, 1H) , 1.22-1.16 (m, 2H) , 1.13-1.04 (m, 2H) . MS: [M+H]
+ = 498.2.
Peak 2 (C75 or C76) :
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.77 (d, J = 6.8 Hz, 1H) , 8.22 (s, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 7.27 (t, J = 6.0 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 6.15 (d, J = 4.4 Hz, 1H) , 4.84-4.78 (m, 2H) , 4.68-4.65 (m, 2H) , 4.55-4.52 (m, 2H) , 3.90 (br s, 1H) , 3.16 (t, J = 6.0 Hz, 2H) , 2.13-2.11 (m, 2H) , 1.84-1.81 (m, 2H) , 1.57 (br s, 1H) , 1.22-1.16 (m, 2H) , 1.13-1.06 (m, 2H) . MS: [M+H]
+ = 498.1.
Example 77
2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoro-N- (oxetan-3-yl) acetamide (C77)
Step 1: Ethyl 2- (2-chloropyrimidin-5-yl) -2, 2-difluoroacetate (77-1)
A mixture of 2-chloro-5-iodopyrimidine (4.0 g, 16.64 mmol, 1.0 eq) , Cu (3.17 g, 49.91 mmol, 3.0 eq) and ethyl 2-bromo-2, 2-difluoroacetate (4.05 g, 19.96 mmol, 1.2 eq) in dried DMSO (40 mL, dried with MgSO
4) was heated at 75 ℃ for 2 hours under N
2 protection. The mixture was quenched with saturated NH
4Cl solution (20 mL) , extracted three times with EtOAc (40 mL) . The organic phase was washed with water (100 mL*3) , dried with anhydrous Na
2SO
4, filtered and concentrated. The crude was purified by column chromatography on silica gel (Petroleum Ether/EtOAc = 40: 1) to give ethyl 2- (2-chloropyrimidin-5-yl) -2, 2-difluoroacetate (77-1) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.08 (s, 2H) , 4.33 (q, J = 7.2 Hz, 2H) , 1.25 (t, J = 7.2 Hz, 3H) . MS: [M+H]
+ = 236.9.
Step 2: Ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoroacetate (77-2)
To a mixture of (26-1) (150 mg, 0.46 mmol, 1.0 eq) in DMF (5 mL) was added (77-1) (130 mg, 0.55 mmol, 1.2 eq) and DIEA (355 mg, 2.75 mmol, 6.0 eq) . The resulting solution was heated at 100 ℃ for 4 hours. Then diluted with water (6 mL) , extracted three times with EtOAc (10 mL) . The organic layers were washed three times with water (30 mL) , dried with anhydrous Na
2SO
4, filtered and concentrated. The crude product was purified by column chromatography on silica gel (Petroleum Ether/EtOAc from 10: 1 to 6: 1) to give ethyl 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoroacetate (77-2) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 8.48 (s, 1H) , 8.43 (s, 1H) , 8.03 (t, J = 5.6 Hz, 1H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.91 (d, J = 8.4 Hz, 1H) , 7.56 (d, J = 5.2 Hz, 1H) , 7.52 (d, J = 7.2 Hz, 1H) , 6.99 (d, J = 9.2 Hz, 1H) , 4.33 (q, J = 6.8 Hz, 2H) , 3.90 (br s, 1H) , 3.22 (t, J = 6.8 Hz, 2H) , 2.15-2.11 (m, 2H) , 1.85-1.81 (m, 2H) , 1.60 (br s, 1H) , 1.26 (t, J = 7.2 Hz, 3H) , 1.12-1.08 (m, 4H) . MS: [M+H]
+ = 491.2.
Step 3: 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoro-N- (oxetan-3-yl) acetamide (C77)
A mixture of (77-2) (50 mg, 0.10 mmol, 1.0 eq) and oxetan-3-amine (372.22 mg, 5.09 mmol, 50 eq) in a 50 mL of round-bottom flask was stirred at 15 ℃ for 2 hours. The mixture was diluted with water (3 mL) , extracted three times with EtOAc (5 mL) . The combined organic layers were concentrated and the crude product was purified by preparative HPLC (column: Xtimate C18 150mmx25mmx5um, gradient: 35-65%B (A= 0.05%ammonia in water, B = ACN) , flow rate: 25 mL/min) to give 2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoro-N- (oxetan-3-yl) acetamide (C77) .
1H NMR (400 MHz, DMSO-d
6) : δ ppm 9.65 (d, J = 6.4 Hz, 1H) , 8.44-8.40 (m, 2H) , 7.96 (d, J = 5.2 Hz, 1H) , 7.94-7.90 (m, 1H) , 7.55 (d, J = 5.2 Hz, 1H) , 7.51 (d, J = 6.8 Hz, 1H) , 6.99 (d, J = 8.8 Hz, 1H) , 4.90-4.82 (m, 1H) , 4.70 (t, J = 6.8 Hz, 2H) , 4.55 (t, J = 6.8 Hz, 2H) , 3.90 (br s, 1H) , 3.21 (t, J = 6.8 Hz, 2H) , 2.14-2.11 (m, 2H) , 1.84-1.81 (m, 2H) , 1.60 (br s, 1H) , 1.26-1.05 (m, 4H) .
19F NMR (400 MHz, DMSO-d
6) : δ ppm -100.00. MS: [M+H]
+ = 518.1.
Biological Assays
The compounds of the present invention may be evaluated for their ability to inhibit PRC2 using assays described below, as well as other assays known in the art.
EZH2 LC-MS Assay
Representative compounds of the invention were serially and separately diluted 3-fold in DMSO to obtain twelve concentrations. Then the test compounds at each concentration (120 nL of each) were transferred by Mosquito into a 384-well Perkin Elmer ProxiPlate 384 plus plates. Solutions (6 μL) of 80 nM wild type PRC2 (wtPRC2) complex and 60 μM SAM in reaction buffer (20 mM Tris, pH 8.0, 0.1%BSA, 0.01%Triton, 0.5 mM DTT) were added to the wells that were then incubated with the test compound for 20 min. A 6 μL solution of 3 μM of the substrate peptide H3K27me1 (histone H3 [21-44] -K27me1-biotin) and 6 μM regulatory peptide H3K27me3 (histone H3 [21-44] -K27me3) in reaction buffer was added to initiate each reaction. The final components in the reaction solution include 40 nM wtPRC2 complex, 30 μM SAM, 1.5 μM H3K27me1 and 3 μM H3K27me3 peptides with varying concentration of the compounds. A positive control consisted of the enzyme at 40 nM, 30 μM SAM, 1.5 μM H3K27me1 and 3 μM H3K27me3 in the absence of the test compound, and a negative control consisted of 30 μM SAM, 1.5 μM H3K27me1 and 3 μM H3K27me3 only. Each reaction was incubated at room temperature for 120 min, then stopped by addition of 3 μL per of quench solution (2.5%TFA with 320 nM d4-SAH) . The reaction mixture was centrifuged (Eppendorf centrifuge 5810, Rotor A-4-62) for 2 min at 2000 rpm and read on an API 4000 triple quadrupole mass spec with Turbulon Spray (Applied Biosystem) coupled with Prominence UFLC (Shimadzu) . The levels of SAH production were normalized based on the values coming from the positive and negative controls to give percent enzyme activities. The data were fit to a dose response equation using the program Helios to get the IC
50 values of the test compound.
ELISA (H3K27 methylation) assay
Representative compounds of the invention were serially and separately diluted 3-fold in DO to obtain a total of eight or twelve concentrations. Then the compounds were added to G401 cell cultured in 384-well plate at 1: 500 dilution to obtain the highest concentration of 20 μM. The cells were further cultured for 48 h before ELISA procedure.
Histone extraction: Cells, in 384-well plate, were washed with PBS (10 x PBS buffer (80 g NaCl (Sigma, S3014) , 2 g KCl (Sigma, 60128) , 14.4 g Na
2HPO
4 (Sigma, S5136) , 2.4 g KH
2PO
4 (Sigma, P9791) to 1 L water, pH to 7.4) and lysed with the addition of lysis buffer (0.4N HCl; 45 μL per well) . The plate was gently agitated at 4℃ for 30 min. The cell lysate was neutralized with neutralization buffer (0.5 M sodium phosphate dibasic, pH 12.5, 1 mM DTT; 36 μL per well) . The plate was agitated to ensure the lysates were well mixed prior to the ELISA protocol.
ELISA protocol: Cell lysates were transferred to the wells of a 384-well plate and the final volume was adjusted to 50 μL per well with PBS. The plate was sealed, centrifuged at 2,000 rpm for 2 min and incubated at 4℃ for about 16 h. The plate was washed with TBST buffer (1 x TBS (10x TBS: 24.2 g Tris (Sigma, T6066) , 80 g NaCl (Sigma, S3014) to 1 L of water and adjust pH to 7.6 with HCl) with 0.1%Tween-20) . Blocking buffer (TBST, 5%BSA; 50 μL per well) was added and the plate was incubated for 1 h at rt. The blocking buffer was removed and primary antibody was added (30 μL per well) . The following dilutions were performed with blocking buffer: for anti-H3K27me3 antibody (Cell Signaling Technology, #9733) , dilution was 1: 1000; for anti-H3K27me2 antibody (Cell Signaling Technology, #9288) , dilution was 1: 100; for anti-H3 antibody (Abcam, Cat#24834) , dilution was 1: 1000. The primary antibody was incubated in the plate at rt for 1 h. The wells were washed with TBST and incubated with secondary antibody for 1 h at rt. For secondary antibodies, the following dilutions were carried out with blocking buffer: anti-rabbit antibody (Jackson ImmunoResearch, #111-035-003) , dilution was 1: 2000; and anti-mouse antibody (Cell signaling technology, #7076) , dilution was 1: 1000.
After 1 h of incubation at rt, the wells were washed with TBST. ECL substrate (Pierce, #34080) was added at 30 μL per well and the plates were centrifuged at 2,000 rpm for 2 min. The signal was read using a PerkinElmer Envision Reader. The H3K27 methylation readouts were normalized using H3 signal and then percentage inhibition was calculated against the samples treated with DO. The data were fit to a dose response curve using the program Helios to get the IC
50 values of the test compound.
Analysis of Cell Proliferation
B cell lymphoma cell KARPAS422 was cultured using standard cell culture conditions in RPMI-1640 (Invitrogen, cat #11875) supplemented with 15%FBS (Invitrogen, cat #10099-141) in humidified incubator at 37℃, 5%CO
2. To assess the effect of PRC2 inhibition on cell proliferation, exponentially growing cells were seeded at a density of 1 × 10
5 cells/mL in 12-well plate (Corning, cat #CLS3513) . After cell seeding, a compound of the invention was added to the cell media (in concentrations ranging from 0 to 100 μM, 3x dilution series) . Viable cell numbers were determined every 3–4 days for up to 14 days using Vi-CELL (Beckman Coulter) . On days of cell counting, fresh growth media and compound were replenished and cells split back to a density of 1 × 10
5 cells/mL. Total cell number is expressed as split-adjusted viable cells per mL. The dose response curves and IC
50 values were generated using Prism.
The exemplified Examples disclosed below were tested in the EZH2 LC-and/or EZH2 ELISA assays described above and found having EZH2 inhibitory activity.
Table 3 below lists IC
50 values in the EZH2 (a) LC-Qualified and/or (b) ELISA Qualified assays measured for the following examples.
Table 3
n.d. = not determined
Table 4 below lists antiproliferative activities (IC
50 values) in B cell lymphoma cell KARPAS422 after 14 days of treatment for the following examples.
Table 4
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.
Claims (23)
- A compound of Formula (I) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;wherein:Y is N or CR 4;R 1, R 3 and R 4 are independently H, halogen or -C 1-C 4 alkyl;R 2 is -CN, -C 1-C 6 alkyl, -hydroxyC 1-C 4 alkylene, -C 1-C 6 alkyl substituted with -N (C 1-C 4 alkyl) 2; -C 1-C 4 alkoxy, -C 2-C 4 alkoxy substituted with 1-2 hydroxyl or cyano; -NH 2, -NR 11C (=O) R 15, -C (=O) NH 2, - (CH 2) nR 15, -R 15, -NHC (=O) R 11, -NR 12C (=O) OR 11, -C (=O) NR 11R 12, - (CH 2) nC (=O) NR 11R 12, - (CH 2) nNR 11R 15, - (CH 2) nC (=O) NR 11R 15, -C (=O) NR 11R 15, -CR 13R 14C (=O) NR 11R 15, -OCR 11R 12R 13, - (CH 2) nC (=O) R 15, -C (=O) R 15, -CR 13R 14C (=O) R 15, - (CH 2) nNR 11C (=O) R 15, - (CH 2) nNR 11 (CH 2) 2C (=O) R 15, -NR 12C (=O) (CH 2) 2C (=O) R 15, - (CH 2) nOR 15, - (CH 2) nNR 11C (=O) OCH 2R 15, -NR 11C (=O) OCH 2R 15, - (CH 2) nNR 11 (CH 2) nR 15, or a 5-to 6-membered heteroaryl having 1 to 4 ring members independently selected from O, S, N and -NR c;R 5a, R 5b, R 5c, R 5d and R c are independently H or -C 1-C 4 alkyl;R 6, R 7, R 8 and R 9 are independently H, halogen or -C 1-C 4 alkyl;R 10 is H, halogen, -C 1-C 4 alkyl, -C 1-C 4 alkoxy, -C 1-C 4 haloalkoxy or -NH (C 1-C 4 alkyl) ;R 11 is H, -C 1-C 4 alkyl, -SO 2 (C 1-C 4 alkyl) , -hydroxyC 1-C 4 alkylene, -cyanoC 1-C 4 alkylene or -C 1-C 4 alkyl substituted with -C 1-C 4 alkoxy;R 12 is H or -C 1-C 4 alkyl;R 13 is H, halogen, -CN, -OH, -C 1-C 4 alkyl or –hydroxyC 1-C 4 alkylene;R 14 is H, halogen or -C 1-C 4 alkyl;R 15 is -C 3-C 6cycloalkyl, or a 4-to 6-membered heterocycoalkyl having 1-2 ring members independently selected from O, S, S (=O) 2, N and -NR 11; wherein said -C 3-C 6cycloalkyl and 4-to 6-membered heterocycloalkyl are independently unsubstituted or substituted with 1-2 substituents selected from -OH, -C 1-C 4 alkyl, -hydroxyC 1-C 4 alkylene, -C 1-C 4 alkoxy and -N (C 1-C 4 alkyl) 2;R 16, if present, is halogen, -CN, -OH, -C 1-C 4 alkyl or -hydroxyC 1-C 4 alkylene;m is 0, 1 or 2;each n is independently selected from 1 and 2; andprovided that the compound of Formula (I) is not (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (4-methylpiperazin-1-yl) methanone.
- The compound of claim 1, wherein said compound is of Formula (I-4) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
- The compound of claim 1 or claim 2, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;wherein R 2 is -CN, -NH 2, -C (=O) NH 2, -NHC (=O) R 11, -NR 12C (=O) OR 11, -C (=O) NR 11R 12, - (CH 2) nC (=O) NR 11R 12, - (CH 2) nNR 11R 15, - (CH 2) nC (=O) NR 11R 15, -C (=O) NR 11R 15, -CR 13R 14C (=O) NR 11R 15, -OCR 11R 12R 13, - (CH 2) nR 15, -NR 12C (=O) (CH 2) 2C (=O) R 15, - (CH 2) nNR 11C (=O) OCH 2R 15, -NR 11C (=O) OCH 2R 15, - (CH 2) nNR 11 (CH 2) nR 15, - (CH 2) nC (=O) R 15, -CR 13R 14C (=O) R 15, - (CH 2) nNR 11C (=O) R 15, -NR 11C (=O) R 15, - (CH 2) nNR 11 (CH 2) 2C (=O) R 15, - (CH 2) nOR 15, -C 1-C 6 alkyl substituted with one R a, -C 1-C 4 alkoxy substituted with one R b, or a 5-to 6-membered heteroaryl having 1 to 4 heteroatoms independently selected from N and -NR c wherein R c is H or -C 1-C 4 alkyl;R a is -OH, -CH 2OH, C 1-C 4 alkyl, C 1-C 4 alkoxy, or -N (C 1-C 4 alkyl) 2; andR b is independently selected from -CN, -OH and C 1-C 4 alkoxy.
- The compound of claim 1 or claim 2, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;wherein R 2 is -CN, -NH 2, -C (=O) NH 2, -NHC (=O) R 11, -NR 12C (=O) OR 11, -C (=O) NR 11R 12, -CH 2C (=O) NR 11R 12, triazolyl, a C 1-C 6 alkyl substituted with one R a group, or a C 1-C 4 alkoxy substituted with one R b group;R a is -OH, -CH 2OH, C 1-C 4 alkyl, C 1-C 4 alkoxy, or -N (C 1-C 4 alkyl) 2; andR b is independently selected from -CN, -OH and C 1-C 4 alkoxy.
- The compound of claim 1 or claim 2, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;wherein R 2 is -CH 2C (=O) NR 11R 12, or a C 1-C 6 alkyl substituted with one R a; andR a is -OH, -CH 2OH, C 1-C 4 alkyl, C 1-C 4 alkoxy, or -N (C 1-C 4 alkyl) 2.
- The compound of claim 1 or claim 2, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;wherein R 2 is andR a is -OH, -CH 2OH, C 1-C 4 alkyl, C 1-C 4 alkoxy, or -N (C 1-C 4 alkyl) 2.
- The compound of any one of claims 1-6, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 2 is -CN, -NH 2, -C (=O) NH 2, triazolyl,
- The compound of any one of claims 1-6, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 2 is
- The compound of claim 1, wherein said compound is of Formula (II) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;wherein:Y is CH or N;R 1, R 3, R 5a, R 5b, R 5c and R 5d are independently H or -C 1-C 4 alkyl;R 6, R 7, R 8 and R 9 are independently is H, halogen or -C 1-C 4 alkyl;R 10 is halogen or –C 1-C 4 alkoxy;R 11 is H, C 1-C 4 alkyl, -hydroxyC 1-C 4 alkylene or -cyanoC 1-C 4 alkylene;R 13 is H, halogen, -OH, -C 1-C 4 alkyl or –hydroxyC 1-C 4 alkylene;R 14 is H, halogen or -C 1-C 4 alkyl;R 15 is a 4-to 6-membered heterocycloalkyl having 1-2 heteroatoms independently selected from O, S and N; and wherein said 4-to 6-membered heterocycloalkyl is unsubstituted or substituted with 1-2 substituents selected from -OH, -C 1-C 4 alkyl, -hydroxyC 1-C 4 alkylene, -C 1-C 4 alkoxy and -N (C 1-C 4 alkyl) 2.
- The compound of claim 6, wherein said compound is of Formula (II-2) , or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof;
- The compound of any one of claims 1, 3-6 and 9-10, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 11 is H, -C 1-C 4 alkyl or -C 1-C 4 alkyl substituted with one R b; and R b is -CN, -OH or -OCH 3.
- The compound of any one of claims 1, 3-6 and 9-11, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 13 is H, F, -CN, -OH, -CH 3 or -CH 2OH.
- The compound of any one of claims 1, 3-6 and 9-12, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 14 is H, F or -CH 3.
- The compound of any one of claims 9-13, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 15 is azetidinyl or oxetanyl, each of which is unsubstituted or substituted with -OH, -C 1-C 4 alkyl or -hydroxyC 1-C 4 alkylene.
- The compound of claim 14, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 15 isR 16, if present, is -C 1-C 4 alkyl; and m is 0-1.
- The compound of claim 14, or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein R 15 is
- The compound of claim 1, wherein said compound is selected from:N 2- ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine;N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) azetidine-3-carboxamide;N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1-methylazetidine-3-carboxamide;2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile;2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide;N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide;2-hydroxy-N- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide;(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone;N- (2-hydroxypropyl) -2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide;(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone;(2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (4-methylpiperazin-1-yl) methanone;N- ( (1, 4-trans) -4- ( ( (5- (1H-1, 2, 4-triazol-5-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-methoxy-1, 7-naphthyridin-2-amine;2- (2- ( ( ( (1, 4-trans) -4- ( (8-methoxy-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide;N 2- ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine;methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;2-methoxyethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;2-hydroxyethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;oxetan-3-ylmethyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) carbamate;N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxyacetamide;N- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -4-morpholino-4-oxobutanamide;2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile;(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (morpholino) methanone;(2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (piperazin-1-yl) methanone;2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) -N- (oxetan-3-yl) pyrimidine-5-carboxamide;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-ylamino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( ( (3-methyloxetan-3-yl) amino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;1- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidin-3-ol;4- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) thiomorpholine 1, 1-dioxide;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( ( (oxetan-3-ylmethyl) amino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( ( (3-methoxycyclobutyl) amino) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;3- ( ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) amino) cyclobutan-1-ol;(2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1, 3-dioxan-5-yl) methanol;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- ( (oxetan-3-yloxy) methyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) acetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) acetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) ethan-1-one;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3- (dimethylamino) pyrrolidin-1-yl) ethan-1-one;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (4- (2-hydroxyethyl) piperazin-1-yl) ethan-1-one;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (piperazin-1-yl) ethan-1-one;2- (6- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyridin-3-yl) -N- (oxetan-3-yl) acetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (4-methylpiperazin-1-yl) ethan-1-one;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-cyclobutylacetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (4- (2-methoxyethyl) piperazin-1-yl) ethan-1-one;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) ethan-1-ol;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- ( (3-methyloxetan-3-yl) amino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;8-chloro-N- ( (1, 4-trans) -4- ( ( (5- (2- (oxetan-3-ylamino) ethyl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -1, 7-naphthyridin-2-amine;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N- (oxetan-3-yl) acetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-cyanoethyl) -N-ethylacetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (2-hydroxyethyl) -N- (oxetan-3-yl) acetamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide;(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide;(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N- (oxetan-3-yl) propanamide;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide;(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide;(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -N-methyl-N- (oxetan-3-yl) propanamide;N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) azetidine-2-carboxamide;N- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) methyl) oxetane-3-carboxamide;2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carbonitrile;2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidine-5-carboxamide;N 2- ( (1, 4-trans) -4- ( ( (5-aminopyrimidin-2-yl) amino) methyl) cyclohexyl) -N 8-methyl-1, 7-naphthyridine-2, 8-diamine;N- (2- ( ( ( (1, 4-trans) -4- ( (8- (methylamino) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) acetamide;3- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxazolidin-2-one;methyl (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) (methyl) carbamate;N 2- ( ( (1, 4-trans) -4- ( (8- (difluoromethoxy) -1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) pyrimidine-2, 5-diamine;N- ( (1, 4-trans) -4- ( ( (5- (4H-1, 2, 4-triazol-3-yl) pyrimidin-2-yl) amino) methyl) cyclohexyl) -8-chloro-1, 7-naphthyridin-2-amine;2- ( (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) oxy) propan-1-ol;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one;(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one;(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -1- (3-hydroxyazetidin-1-yl) propan-1-one;2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide;(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide;(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -3-hydroxy-N- (oxetan-3-yl) propanamide;(S) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide ;(R) -2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2-hydroxy-N- (oxetan-3-yl) acetamide; and2- (2- ( ( ( (1, 4-trans) -4- ( (8-chloro-1, 7-naphthyridin-2-yl) amino) cyclohexyl) methyl) amino) pyrimidin-5-yl) -2, 2-difluoro-N- (oxetan-3-yl) acetamide;or a pharmaceutically acceptable salt thereof.
- A pharmaceutical composition comprising a compound of any one of claims 1-17 and a pharmaceutically acceptable carrier.
- A combination comprising a compound according to any one of claims 1-17, and one or more therapeutically active agent.
- The combination of claim 19, wherein said one or more therapeutically active agent is selected from an anti-cancer agent, immunomodulator, anti-allergic agent, anti-nausea agent, pain reliever, and a cytoprotective agent.
- A method for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2) , Polycomb Repressive Complex 2 (PRC2) , or a combination of Enhancer of Zeste Homolog 2 (EZH2) and Polycomb Repressive Complex 2 (PRC2) , comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any of claims 1-17.
- The method of claim 21, wherein said disease or condition is diffuse large B cell lymphoma (DLBCL) , follicular lymphoma, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, rhabdomyosarcoma, Kaposi sarcoma, synovial sarcoma, osteosarcoma or Ewing’s sarcoma.
- Use of a compound according to any one of claims 1-17 and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for a disease or condition that is mediated by Enhancer of Zeste Homolog 2 (EZH2) , Polycomb Repressive Complex 2 (PRC2) , or a combination of Enhancer of Zeste Homolog 2 (EZH2) and Polycomb Repressive Complex 2 (PRC2) .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2019/108296 | 2019-09-26 | ||
CN2019108296 | 2019-09-26 | ||
PCT/CN2020/117487 WO2021057853A1 (en) | 2019-09-26 | 2020-09-24 | Aza-quinoline compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020355837A1 true AU2020355837A1 (en) | 2022-02-24 |
Family
ID=75166744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020355837A Pending AU2020355837A1 (en) | 2019-09-26 | 2020-09-24 | AZA-quinoline compounds and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220280509A1 (en) |
EP (1) | EP4034535A4 (en) |
JP (1) | JP2022550353A (en) |
KR (1) | KR20220070229A (en) |
CN (1) | CN114746414A (en) |
AU (1) | AU2020355837A1 (en) |
CA (1) | CA3150284A1 (en) |
IL (1) | IL291499A (en) |
WO (1) | WO2021057853A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR123185A1 (en) * | 2020-08-10 | 2022-11-09 | Novartis Ag | COMPOUNDS AND COMPOSITIONS TO INHIBIT EZH2 |
AR128015A1 (en) * | 2021-12-16 | 2024-03-20 | Transthera Sciences Nanjing Inc | CDK9 INHIBITOR AND USE THEREOF |
CN117384153A (en) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | Methyltransferase inhibitors and uses thereof |
CN118515653A (en) * | 2024-07-23 | 2024-08-20 | 西湖制药(杭州)有限公司 | EZH2 specific inhibitor and preparation method and application thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
AU776788C (en) | 1998-12-16 | 2005-10-27 | Warner-Lambert Company | Treatment of arthritis with MEK inhibitors |
EP1301472B1 (en) | 2000-07-19 | 2014-03-26 | Warner-Lambert Company LLC | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
US7799827B2 (en) | 2002-03-08 | 2010-09-21 | Eisai Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
EP3000810B1 (en) | 2002-03-13 | 2017-07-19 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivative as mek inhibitor |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
DK1912636T3 (en) | 2005-07-21 | 2014-07-21 | Ardea Biosciences Inc | N- (ARYLAMINO) -SULPHONAMIDE INHIBITORS OF MEK |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
TWI471134B (en) | 2007-09-12 | 2015-02-01 | Genentech Inc | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
CN107108637B (en) * | 2014-12-23 | 2019-10-29 | 诺华股份有限公司 | Triazolopyrimidine compound and application thereof |
UY36758A (en) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR |
EP3472161B1 (en) * | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
US10676479B2 (en) * | 2016-06-20 | 2020-06-09 | Novartis Ag | Imidazolepyridine compounds and uses thereof |
-
2020
- 2020-09-24 US US17/632,990 patent/US20220280509A1/en active Pending
- 2020-09-24 CA CA3150284A patent/CA3150284A1/en active Pending
- 2020-09-24 EP EP20868772.3A patent/EP4034535A4/en active Pending
- 2020-09-24 AU AU2020355837A patent/AU2020355837A1/en active Pending
- 2020-09-24 CN CN202080067448.9A patent/CN114746414A/en active Pending
- 2020-09-24 WO PCT/CN2020/117487 patent/WO2021057853A1/en unknown
- 2020-09-24 JP JP2022519331A patent/JP2022550353A/en active Pending
- 2020-09-24 KR KR1020227011716A patent/KR20220070229A/en unknown
-
2022
- 2022-03-20 IL IL291499A patent/IL291499A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL291499A (en) | 2022-05-01 |
US20220280509A1 (en) | 2022-09-08 |
CA3150284A1 (en) | 2021-04-01 |
CN114746414A (en) | 2022-07-12 |
EP4034535A4 (en) | 2023-11-22 |
KR20220070229A (en) | 2022-05-30 |
EP4034535A1 (en) | 2022-08-03 |
JP2022550353A (en) | 2022-12-01 |
WO2021057853A1 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
AU2020355837A1 (en) | AZA-quinoline compounds and uses thereof | |
US10604502B2 (en) | Substituted 5-cyanoindole compounds and uses thereof | |
EP3472161B1 (en) | Triazolopyridine compounds and uses thereof | |
TW202023559A (en) | Pyrazine compounds and uses thereof | |
US10501466B2 (en) | WDR5 inhibitors and modulators | |
CN111132967B (en) | Cycloolefin substituted heteroaromatic ring compound and application thereof | |
CA3145864A1 (en) | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof | |
CN110546145A (en) | Azaaryl derivative, preparation method and pharmaceutical application thereof | |
AU2021323828A1 (en) | Quinoline compounds and compositions for inhibiting EZH2 | |
WO2022095909A1 (en) | Compound used as ntrk inhibitor and application thereof | |
WO2022117012A1 (en) | Spirocyclic jak inhibitor, pharmaceutical composition containing same, and application thereof | |
CN118139846A (en) | EGFR small molecule inhibitor, pharmaceutical composition containing same and application of EGFR small molecule inhibitor | |
US20220242849A1 (en) | Wdr5 inhibitors and modulators | |
EA044101B1 (en) | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION |